Modeling Rare Protein-Coding Variation to Identify Mutation-Intolerant Genes With Application to Disease by Samocha, Kaitlin E.
Modeling Rare Protein-Coding Variation
to Identify Mutation-Intolerant
Genes With Application to Disease
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Samocha, Kaitlin E. 2016. Modeling Rare Protein-Coding Variation
to Identify Mutation-Intolerant Genes With Application to Disease.
Doctoral dissertation, Harvard University, Graduate School of Arts &
Sciences.
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33493508
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Modeling rare protein-coding variation to identify mutation-intolerant genes with 
application to disease 
 
 
A dissertation presented 
by 
Kaitlin Elisabeth Samocha 
to 
The Division of Medical Sciences 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of 
Genetics and Genomics 
 
 
 
 
 
 
Harvard University 
Cambridge, Massachusetts 
April 2016
 © 2016 Kaitlin Elisabeth Samocha 
All rights reserved.
! iii 
Dissertation Advisor: Professor Mark J. Daly Kaitlin Elisabeth Samocha 
 
Modeling rare protein-coding variation to identify mutation-intolerant genes with 
application to disease 
 
Abstract 
Sequencing exomes—the 1% of the genome that codes for proteins—has 
increased the rate at which the genetic basis of a patient’s disease is determined. 
Unfortunately, when a patient does not carry a well-established pathogenic variant, it is 
extremely challenging to establish which of the tens of thousands of variants identified 
in that individual is contributing to their disease. In these situations, variants must be 
prioritized to make further investigation more manageable. In this thesis, we have 
focused on creating statistical frameworks and models to aid in the interpretation of rare 
variants and towards establishing gene-level metrics for variant prioritization. 
We developed a sensitive and specific workflow to detect newly arising (de novo) 
variants from exome sequencing data of parent-child trios, and created a sequence-
context based mutational. This mutational model was the basis of a rigorous statistical 
framework to evaluate the significance of de novo variant burden not only globally, but 
also per gene. When we applied this framework to de novo variants identified in patients 
with an autism spectrum disorder, we found a global excess of de novo loss-of-function 
variants as well as two genes that harbored significantly more de novo loss-of-function 
variants than expected. 
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We also used the mutational model to predict the expected number of rare (minor 
allele frequency < 0.1%) variants in exome sequencing datasets of reference 
individuals. We found a significant depletion of missense and loss-of-function variants in 
a subset of genes, indicating that these genes are under strong evolutionary constraint. 
Specifically, we identified 3,230 genes that are intolerant of loss-of-function variation 
and that set of genes is enriched for established dominant and haploinsufficient disease 
genes. Similarly, we searched for regions within genes that were intolerant of missense 
variation. The most missense depleted 15% of the exome contains 83% of reported 
pathogenic variants found in haploinsufficient disease genes that cause severe disease. 
Additionally, both gene-level and region-level constraint metrics highlight a set of de 
novo variants from patients with a neurodevelopmental disorder that are more likely to 
be pathogenic, supporting the utility of these metrics when interpreting rare variants 
within the context of disease. 
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Chapter 1 
Introduction 
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Overview 
A primary goal of medical genetics is to associate genetic variants with risk of 
disease. This goal is impeded by a variety of complicating factors, such as the vast 
amount of genetic variation found in each individual1 and the fact that such variation can 
impact as much sequence as whole chromosomes to as little as single bases. 
Additionally, the genetic basis of human diseases varies in the complexity of its 
architecture: some diseases are monogenic and caused by high impact variants. These 
disorders are for the most part rare, and the one-to-one relationship between disease 
and disruption of a single gene often allows for identification of the risk locus in a small 
number of families. When the relevant gene has been identified, then specific variants 
can be established as pathogenic and screened for in new patients. 
Common diseases, however, have a far more complex genetic architecture and 
typically involve variants spread across the genome, each of which has a small effect on 
the phenotype (polygenicity). The polygenicity of common diseases makes it much 
more challenging to identify specific genetic risk factors; association analyses often 
require tens of thousands of affected and unaffected individuals (e.g. >36,000 cases 
with schizophrenia and >113,000 controls)2. The small average effect size of any 
identified risk-contributing variant does not typically permit the nomination of a primary 
causal event. 
Even when studying a disease that may be influenced by stronger acting 
variants, determining the specific variant or set of variants that are contributing to a 
patient’s disease is challenging, particularly when the patient does not carry a well-
established genetic risk factor. Unfortunately for these types of activities, each individual 
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harbors tens of thousands of variants (single base to larger structural changes). 
Focusing in on those variants that alter the coding sequence leaves thousands to 
examine, even if only considering alleles that are rare in the general population. 
Therefore, it is critical to be able to prioritize variants that are more likely to be 
contributing to disease. A primary focus on this thesis has been to establish methods to 
aid such prioritization. 
 
Tying genetic variation to disease 
It has long been observed that the frequency of some diseases in families is 
associated with the family members’ degree of relatedness, which suggests that the 
disease has a genetic component. A measure of the degree to which inherited genetic 
variation is contributing to disease is referred to as heritability3. More specifically, 
heritability is the amount of phenotypic variability that can be explained by inherited 
genetic variation. Estimates of heritability can come from many sources, but one of the 
classical approaches is to compare the concordance of the disease in monozygotic 
twins versus the concordance seen in dizygotic twins4. Since monozygotic twins share 
nearly 100% of their genetic material and dizygotic twins only ~50%, a highly heritable 
trait would be expected to have a much higher concordance rate in monozygotic twins. 
Of note, most traits are influenced by both genetic and environmental factors; 
comparing concordance in twins is designed to control for most of the environmental 
influence. 
Heritability, however, does not provide information about specific loci that are 
contributing to disease etiology. In order to find risk loci, researchers have taken a 
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variety of approaches, limited partially by available technology. One of the earliest 
approaches that could be used to identify risk loci was linkage mapping5-8. Linkage 
mapping relied on collecting families with many affected and unaffected members. To 
map, sites across the genome were used as marks of all variation nearby and the 
segregation of these markers in the family were compared to the segregation of the 
disease. Markers near areas of the genome that contribute to disease should therefore 
follow the inheritance of the disease. Linkage mapping is best suited to diseases that 
are caused by large effect variants that occur in a small number of genes, which makes 
the technology poorly suited for complex trait association. 
For diseases caused by many loci of small effect, genome-wide association 
studies (GWAS)6,9,10 are performed to find the contributing variants. In GWAS, sites of a 
common variation in the population are treated as markers of nearby variation, much 
like linkage mapping. However, instead of using families, GWAS use large numbers of 
unrelated affected and unaffected individuals and search for variants that are seen more 
often in the affected than unaffected individuals. Given that these loci individually have a 
small impact on risk, they are still seen commonly in unaffected individuals. GWAS are 
also affected by the polygenicity of a disease; for those diseases with many contributing 
loci, very large cohorts of affected and unaffected individuals are needed to identify 
specific risk variants. 
There are diseases that have a strong genetic component, but whose 
contributing variants would be difficult to find in either linkage or association studies. 
These are disorders that are not often passed on because they are extremely severe 
and affected individuals either do not survive to maturity or do not have children of their 
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own. These diseases are therefore often influenced by newly arising (de novo) alleles. 
An example of such a disease is Hutchinson-Gilford progeria syndrome, a rare disorder 
in which affected individuals show signs of early aging, such as hair loss and 
scleroderma11. It is caused by de novo missense variants in LMNA with the most 
common risk allele leading to the activation of a cryptic splice site and creation of a 
truncated protein product of the impacted gene copy12. These alleles are never passed 
on from an affected individual to their child because individuals with progeria die at an 
average age of 1311. 
 
De novo variation and disease 
Beyond examples like Hutchinson-Gilford progeria, de novo variation can also 
contribute to diseases that are not always lethal in childhood. Achondroplasia, a form of 
dwarfism, is caused by heterozygous (only one copy of the gene being affected) 
disruptions of FGFR313,14. While the disease and risk allele can be inherited from an 
affected parent, most cases are caused by a de novo event15. 
It was noted in the early 1900s that sporadic cases of achondroplasia occurred 
more often in the last-born child16 and it was later shown that a higher rate of 
achondroplasia is specifically associated with advanced paternal age15,17; a similar trend 
has been seen for other disorders as well18. Overwhelmingly, the causal allele was 
paternal in origin; in the case of achondroplasia, all 40 cases tested by Wilkin and 
colleagues were on the paternally inherited chromosome19. These results indicated not 
only that there is a higher mutation rate in males, but suggested that the number of 
mutations increases as the father ages. Germline mutations are introduced during DNA 
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replication in mitosis and the first half of meiosis. The female germline has 22 rounds of 
mitosis and 1 round of meiosis during development to produce an egg18,20. The male 
germline, however, undergoes far more mitotic divisions owing to lifelong sperm 
production, thereby having more opportunities to mutate. Additionally, the number of 
replication cycles affecting a particular sperm is higher for older males. It has been 
estimated that a 20-year old male has had approximately 150 rounds of replication 
where a 40-year old has had 61018,20. The increased number of mitotic divisions in the 
male germline, however, does not fully explain the increased rate of sporadic 
achondroplasia among the children of older fathers21. 
De novo variation also contributes to more complex disorders, such as 
schizophrenia and autism spectrum disorder, where no single de novo allele is likely to 
lead to a patient’s disease. As these disorders involve a large number of contributing 
loci, it is more challenging to define the role de novo variation plays. In particular, 
determining which de novo variants, if any, are contributing is complicated by non-
disease associated de novo variants: every individual is expected to carry 70-100 de 
novo variants across their genome22-26. Since the de novo variant signal is likely to be 
spread across many genes, studying de novo variation in these disorders requires 
careful consideration of the mutation rate. 
 
The role of sequencing technology 
Linkage and association studies rely on the ability to determine the allele at a 
specific locus, but historically a relatively limited number of loci were measured because 
sequencing and genotyping were slow and expensive. The advent of massively parallel 
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sequencing technologies opened the door to quickly and affordably interrogate variation 
at many locations and as small as single base changes. 
Whole genome sequencing within families successfully identified risk loci for 
Charcot-Marie-Tooth27 and severe hypercholesterolemia28, but in both cases the risk 
loci resided in the exome – the 1% of the genome that codes for proteins. Since 
understanding the effects of non-coding variation remains a major challenge to the field, 
much of the sequence data produced in these studies is considered uninterpretable. 
The creation of exome-capture kits allowed researchers to sequence only coding 
segments, which is faster and cheaper than sequencing the whole genome, thereby 
accelerating the discovery of protein-coding disease-associated variation29,30. 
Early successes of exome sequencing studies came from rare, severe, and likely 
monogenic disorders, such as Kabuki syndrome31, Schinzel-Giedion syndrome32, and 
Miller syndrome33. In the case of Kabuki syndrome, the nonsynonymous variants in 
KMT2B (previously known as MLL2) that were considered causal were often de novo in 
the affected individual31. These early studies proved that sequencing technology is 
especially critical for identifying de novo variation. 
 
Using evolutionary conservation to prioritize variants 
When analyzing the thousands of protein-coding variants within a patient, it is 
critical to prioritize variants for further investigation. One way to do so is to focus on 
variants that occur in genes that have been buffered against mutation across 
evolutionary time. The Human34 and Mouse35 Genome Projects – whose aims were to 
create reference genomes for the species – allowed large-scale comparisons of genetic 
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sequence in between species. The similarity (conservation) of sequence between 
humans and mice was first used to aid in the annotation of the genomes: highly 
conserved sequences were considered likely to be functional elements. Sequence 
homology, therefore, helped define coding and regulatory sequences within both 
species34,35. The level of conservation of sequence between species has become a 
common metric to indicate the importance of the sequence. Particularly, once gene 
annotations were defined, a plethora of tools were built to leverage sequence homology 
to predict the likely deleteriousness of specific variants (e.g. SIFT36, GERP37, 
Polyphen238). 
Additionally, reference sequences of various species, and the identification of 
polymorphisms within the species, allowed estimation of evolutionary selection 
pressures on genes (both positive and negative). The classical approaches rely on 
comparing the rates of nonsynonymous and synonymous substitutions (e.g. dN/dS, 
Ka/Ks)39-43. These methods were also used to measure the strength of the selection, 
often given as a selective coefficient (s) where s = 0 indicates neutrality and s = 1 
lethality44-46. 
While successful at identifying genes under the influence of weak negative 
selection (selective coefficient [s] < 10-3), these methods rely on the observation of 
variation within the population. Severely deleterious alleles (s > 10-2), however, will 
never become polymorphisms within a population. As modeled by Zuk et al47, when s ! 
10-2) the combined allele frequency of variants with that selective coefficient is 
approximately 0.0001, independent of the demographic history of the population studied 
(Figure 1.1, reproduced from the paper). These simulations reinforce that alleles that 
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contribute to traits which greatly reduce fecundity (reproductive rate) will never become 
common enough in the population to be included in conservation-based metrics. 
 
 
 
Figure 1.1. The relationship between combined allele frequency and selective 
coefficient (s) for various demographic models. As s increases, indicating stronger 
negative selection against those allele, the combined allele frequency of all variants with 
that s becomes smaller. This is supplementary Figure 1 from Zuk et al47.  
 
In order to determine how likely a variant, especially a de novo variant, seen in a 
patient is likely to be, we needed a measure of deleteriousness that captured larger 
values of s. In this thesis, we propose using the depletion of nonsynonymous variation 
within the human population as a reflection of the deleteriousness of variants that arise 
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within the gene. We are aided by recent large-scale sequencing efforts of reference 
populations, which provide power to determine significant depletion of variation. 
 
Genetic basis of autism spectrum disorder 
Autism spectrum disorders (ASDs) are a set of severe neurodevelopmental 
disorders that arise early in childhood and are characterized by impaired social 
interactions and communication, as well as restricted interests and repetitive behaviors. 
It has been recently estimated that the prevalence of ASDs in the United States is over 
1%, with a notable excess of male cases48. The biological bases of ASDs are currently 
unknown. 
ASDs are a class of disorders unlikely to show a strong evolutionary signature 
due to the strength of selection against the disorder. One way to measure how strongly 
selection is acting on a particular disease is to investigate the reproductive rate 
(fecundity) of affected individuals. In a study of a birth cohort in Sweden, Power and 
colleagues found that patients with ASD had dramatically reduced fecundity: male 
patients had 75% fewer children than their unaffected relatives, indicating very strong 
selective constraint (high s). Females showed a similar, but less severe, pattern 
(fecundity ratio 0.48)49. 
Various studies have established that there is a substantial genetic component to 
ASD risk. Estimates of the heritability of ASD are typically between 60 and 80%, 
indicating a large genetic component50. Unfortunately, research to find the genetic basis 
of ASDs has not been particularly successful. 
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Early linkage mapping efforts in ASD identified a very limited set of risk loci due 
to the highly polygenic and heterogeneous nature of ASD risk. Since linkage mapping 
works best for disorders caused by large-effect variants that fall into a small number of 
genes, linkage mapping successfully identified the causal loci for syndromic forms of 
ASDs, such as Fragile X syndrome51 and Rett syndrome52. While linkage also identified 
a few universally accepted risk loci (NLGN353, NLGN4X53, NRXN154, and SHANK355), it 
mostly lead to long lists of candidate genes, whose association to ASD did not replicate 
in subsequent studies. Similarly, multiple GWAS of ASD did not report significant 
results, or found loci that never replicated56-58. The association studies were limited 
small sample size in conjunction with the fact that each risk variant has a very small 
effect on phenotype. This limitation will be overcome when large enough samples are 
aggregated and jointly analyzed. 
The most successful early studies of the genetic basis of ASD were those that 
found associated copy number variants (CNVs)59-64. Researchers identified several 
CNVs that were strongly associated with risk for ASD (listed in Table 1.1), such as 
duplications and deletions in the 16p11.2 region59,60,64,65. These CNVs had larger effect 
sizes than are typically found for variants identified via GWAS and were often de novo 
in the affected individual59,60,62-64. Given the reduced fecundity of individuals with ASDs, 
it is not surprising that large effect variants are often de novo: these variants cannot be 
maintained in the population for multiple generations. 
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Table 1.1. Recurrent de novo copy number variants associated with autism spectrum 
disorder (ASD). The “Del vs Dup” column lists whether duplications, deletions, or both in 
the locus are associated with ASD. Size is given in megabase pairs (Mbp). Both the 
size of the region and the number of genes are approximate. 
 
 
Region Size (Mbp) Genes Del vs Dup References 
1q21.1 1.3 14 Both Sanders 201162 
7q11.23 1.4 22 Duplication Levy 201159; Sanders 201162 
15q11.2-13.1 4.9 12 Duplication 
Levy 201159; Marshall 200860; 
Pinto 201061; Sanders 201162; 
Sebat 200763 
15q13.2-13.3 1.5 6 Both Marshall 2008
60; Sanders 
201162; Sebat 200763 
16p11.2 0.6 25 Both 
Levy 201159; Marshall 200860; 
Pinto 201061; Sanders 201162; 
Sebat 200763; Weiss 200864 
22q11.2 2.5 56 Both Marshall 2008
60; Pinto 201061; 
Sanders 201162 
 
 
In light of these successes and the availability of exome sequencing data, our 
group began to study de novo single nucleotide (SNV) and insertions and deletions 
(indels) in ASD cases. A previous publication had sequenced 20 parent-child trios, but 
could not implicate any specific gene or pathway in ASD etiology66, an unsurprising 
result given the high polygenicity and locus heterogeneity of ASDs. As described in 
Chapter 3 and many subsequent publications67-73, it took analyzing many more trios to 
identify a significant, but minor50, role of de novo variation in ASD. 
 
Summary 
The ability to sequence patient genomes has allowed researchers to study 
variation with base-pair resolution. Sequencing, however, identifies thousands upon 
thousands of variants that need to be filtered in order to find those that may be 
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contributing to a patient’s disease. For this thesis, we wanted to create methods and 
tools that could be used to aid in such prioritization of variants. 
We first determined a way to sensitively and specifically identify de novo variants 
from family sequencing studies (Chapter 2). In order to properly analyze these results, 
we created a mutational model and statistical framework to rigorously evaluate 
excesses of such variation that may be observed in a patient population (Chapter 3). In 
particular, we established an important, but modest, role for de novo loss-of-function—
and to a lesser extent missense—variation in ASD. 
Given the modest enrichment of de novo variation in ASD cases, we needed a 
way to identify those variants that were more likely to be contributing. We used the 
mutational model we created to identify genes that are intolerant of nonsynonymous 
variation. In particular, using a large exome sequencing data set, we found 3,230 genes 
that appear to be extremely loss-of-function intolerant to the point of near 
haploinsufficiency – meaning that heterozygous loss-of-function variants in these genes 
should cause disease (Chapter 4). These highly loss-of-function intolerant genes 
contain the majority of the signal for de novo loss-of-function variants found in ASD 
cases as well as cases with other neurodevelopmental disorders. 
We also hoped to explain the modest excess of missense variation in ASD cases 
by searching for specifically missense constrained regions within genes. Using the 
intolerance to missense variation, as well as variant level predictors of deleteriousness, 
we created a score to predict how likely a missense variant is to be deleterious and 
show that is separates signal from noise in the de novo missense variant results from 
ASD cases (Chapter 5). 
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In summary, we have developed tools and metrics to better interrogate exome 
sequencing data and applied them to substantially clarify the role of rare variation in 
ASD risk. These approaches have been adopted by the broader community to both 
inform rare variant discovery and patient exome interpretation. 
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Chapter 2 
Identifying and characterizing de novo variation 
 
 
 
 
 
 
 
 
 
This chapter is based on methods reported in: 
Neale, B.M. et al. Patterns and rates of exonic de novo mutations in autism 
spectrum disorders. Nature 485, 242-245 (2012). 
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in 
autism. Nature 515, 209-15 (2014). 
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Motivation 
A natural property of DNA is that it spontaneously mutates, which leads to the 
creation of new alleles. The mutation rate of single nucleotides is quite low, but still 
large enough to expect that any individual will carry 70-100 newly arising (de novo) 
single nucleotide alleles not present in the somatic genome of either parent, with 
roughly one of these de novo alleles falling into exomic sequence (the 1% of the 
genome that encodes protein)1-5. 
While it has been established that there is a large genetic component to autism 
spectrum disorder (ASD), both linkage and association studies had limited success 
identifying risk loci. Some of the most fruitful studies came from examining large copy 
number variants (CNVs)6-11. Researchers identified several CNVs that were strongly 
associated with risk for ASD, many of which were de novo in the affected child. 
Unfortunately, these CNVs are large and contain many genes, complicating studies to 
decipher the underlying biology. As an example, the most-reported CNVs tied to ASD 
are deletions in the 16p11.2 region, which span roughly 500-600 kilobases and contain 
25 genes7,8,10,12. Understanding how these ASD-associated CNVs contribute to disease 
is further complicated by both incomplete penetrance and associations to other 
neurodevelopmental disorders8,10,11,13. All together, these CNVs account for less than 
3% of the heritability of ASD, indicating that there is much more to find14. 
The development of exome-capture kits, in combination with the falling costs of 
sequencing DNA, allowed the study of de novo single nucleotide variants (SNVs) and 
small insertions and deletions (indels) found in coding sequence15. De novo SNVs in 
single genes have been tied to a number of rare, severe, and likely monogenic 
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disorders16,17. There were also a few studies of de novo variation in more complex traits, 
such as schizophrenia, with less success implicating specific risk genes18,19. 
Subsequently, our group and others began to sequence parent-child families 
(known as trios) to define the role of de novo variation in ASD and discover genes or 
pathways associated with disease risk. While in theory identifying de novo variation 
should be straight forward—finding alleles in the child that neither parent has—it is 
complicated by such occurrences being rare and looking like genotyping or sample 
tracking errors. We therefore needed to establish specific and sensitive quality 
thresholds to determine trustworthy candidate de novo events. 
 
Data generation 
Identifying de novo variation requires genetic information, specifically sequencing 
data, from both parents and their child (a trio). Our earliest work was with the Autism 
Consortium, a Boston-based group of collaborators, which collected whole blood or cell 
lines from 96 trios. DNA was extracted and sheared into 200-300 base long fragments, 
which were then end-repaired, adenylated, and had adaptor oligonucleotides ligated in 
preparation for sequencing. PCR amplification with primers specific to the adaptor 
oligonucleotides was performed to enrich for fragments with attached adaptors. Exons 
were captured using Agilent 38Mb SureSelect v2. After capture, a round of ligation-
mediated PCR was performed to increase the quantity of DNA available for sequencing. 
All libraries were sequenced using an Illumina HiSeq 2000 instrument. The data were 
processed with the Picard software, which uses base quality score recalibration and 
local realignment at known indels20 and Burrows-Wheeler Aligner (BWA)21 to map reads 
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to hg19. Variants were called using the Genome Analysis Toolkit (GATK) software for 
all trios jointly20,22. The resulting output was a standard Variant Call Format (VCF) file 
containing genotypes for sequenced members of the trios at positions where at least 
one individual in the data set had a non-reference allele. All sequencing was performed 
at the Broad Institute. 
 
Key parameters to identify de novo variants 
We created a Python script to identify candidate de novo variants from 
sequencing data with two required inputs: a GATK-generated VCF file that contains the 
variant information and a family relation file—often referred to as a pedigree file—that 
describes sample relatedness. Our first requirement was that variants passed all of the 
standard quality filters of the genotyper (here, the GATK Unified Genotyper), which was 
indicated by a PASS in the FILTER field of the VCF. Of the high quality sites, we 
focused on those where a child had a heterozygous genotype and both parents were 
homozygous reference. Given the small size of the original data set (n = 96 trios), we 
assumed that any site where the alternative allele was seen in another individual in the 
data set was likely to not be a true de novo and therefore removed such sites from 
further consideration23. This assumption was later dropped (discussed below). 
We then sought to remove miscalled genotypes by imposing a threshold on the 
observed allele balance (the percentage of non-reference, or alternative, reads). Since 
the child should be heterozygous for the alternative allele, roughly 50% of all 
sequencing reads at the site in the child should have the alternative allele. There is a 
slight reference bias—it is easier to capture sequences with the reference allele than 
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the alternative—as well as normal sampling error. Given these two properties, we 
allowed the child’s allele balance to be as low as 30%. Additionally, we wanted to avoid 
the possibility of a missed heterozygous genotype in the parents and required that their 
allele balance be no greater than 5%. Instances where genotypes that appear to 
indicate a de novo event, but fail these expected allele balances, can arise from poor 
read mapping or biases in data generation but may still lead to confident genotyping 
calls if the site has high sequencing depth. We also removed sites where the child’s 
read depth was < 10% of the total depth of reads in both parents, which was meant to 
remove instances where the child may have been poorly sequenced or, less likely, had 
a deletion at the site. 
We next explored filtering variants based on the Phred-scaled likelihood (PL) of 
the data conditional on the genotype calls. The PL represents !!" ! !"#!"!!!, where p 
is the likelihood ratio of each genotype. In the case of a site with a single alternative 
allele, a PL is provided for each genotype: PL(AA) for the homozygous reference, 
PL(AB) for the heterozygote, and PL(BB) for homozygous alternative. The most likely 
genotype is assigned a PL score of 0 and all others are scaled relative to the most likely 
genotype. Therefore, a PL of 30 corresponds to the genotype in question being a 
thousand times less likely to be the true genotype than the reported most likely 
genotype. To determine an appropriate PL filter, we set a threshold of T and required 
sites to have a PL ! T for the child’s homozygous reference genotype—PL(AA)—and 
for the parents’ heterozygous genotypes—PL(AB). The relationship between T and the 
number of retained de novo events is depicted in Figure 2.1. As the genotypes become 
increasingly confident (greater PLs), the number of de novo events drops until 
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plateauing at a PL of ~20-3023. We therefore set 30 as our required threshold, T, when 
evaluating de novo events. 
 
 
 
Figure 2.1. The relationship between the genotype likelihood threshold (Phred Score) 
used and the number of de novo variants found in 96 trios. 
 
We sought to validate some of the identified de novo variants to support our 
choice of thresholds. Overall, nearly 95% of variants were confirmed to be de novo 
using an alternative sequencing technology, indicating high specificity23. To insure 
sensitivity of the PL threshold, we also attempted to validate variants that had a PL in 
between 20 and 30: all four of these variants failed to validate. Further investigation 
indicated that the most likely culprit for a falsely identified de novo event was missing a 
heterozygous genotype in one of the parents due to under-sampling the alternative 
allele, often because of low depth of sequencing. 
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After settling on the filtering parameters, we found 161 coding de novo variants in 
175 ASD trios (the additional 78 were sequenced at other centers)23. The number of de 
novo variants per trio matched a Poisson distribution (Table 2.1). We also observed the 
expected relationship between variant deleteriousness and the number of alternative 
alleles observed in the data set (Table 2.2). More common alternative alleles, as a 
class, have a lower percentage of nonsynonymous variants. In addition, these more 
common alternative alleles have lower percentages of missense variants that are 
predicted to be damaging by Polyphen224, a program that estimates variant deleterious 
using conservation of the amino acid across species and whether the change is 
predicted to destroy important structural features of the protein, among other features. 
 
Table 2.1. The number of de novo single nucleotide events per trio compared to the 
expected number of such events. We are including only single nucleotide variants 
(SNVs) and not insertions and deletions. The expected number of trios with a given 
number of de novo variants was determined by the Poisson with a lambda of 0.92, the 
median number of de novo events per trio. 
 
Events per trio Observed de novo SNVs Expected de novo SNVs 
0 71 69.7 
1 62 64.2 
2 28 29.5 
3 10 9.1 
4 2 2.1 
5 1 0.4 
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Table 2.2. The percentage of variants by mutation type for ASD cases and their 
parents. Only single nucleotide variants are included. Singletons (alternative allele seen 
once in the data set), doubletons (alternative allele seen twice in the data set), and 
variants where the alternative allele was seen ! 3 times in the data set were only those 
variants found in the 192 parents of the original 96 trios. 
 
Type of mutation De novo Singletons Doubletons ! 3 
Synonymous 31.1% 39.3% 43.8% 50.8% 
Missense 62.7 59.5 55.4 48.8 
Nonsense 6.2 1.2 0.8 0.4 
PolyPhen-2 missense classification 
Benign 35.0% 46.6% 51.3% 63.4% 
Possibly damaging 21.0 18.8 17.7 15.1 
Probably damaging 44.0 34.7 31.0 21.4 
 
Population frequency aware de novo identification 
Our early work only considered de novo variants that were singletons, where the 
alternative allele is seen only once in the data set. Of course, it is possible for a true de 
novo event to arise at a site that has been mutated in another individual, an occurrence 
that becomes increasingly likely as the sample size of the data set increases. The logic 
behind our original choice to only consider singletons was that a de novo variant should 
be a private event and unlikely to be seen in another individual, especially given the 
limited sample size at the beginning of the study. 
When we dropped the requirement that any de novo variant had to be a 
singleton, we found that many of the additional events identified had low read depth in 
all three members of the trio or borderline allele balances, indicating that there was 
likely under-calling of a heterozygous genotype in one of the parents. 
We therefore had to refine our filters and thresholds to have strong confidence in 
variants that were seen in another individual in the dataset, or as a standing variant in 
the population, but appeared de novo in a trio. As before, we first identified candidate de 
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novo variants at the highest quality (PASSing) sites as defined by a standard GATK 
pipeline where the child is called heterozygous and the parents both reference 
homozygotes. We maintained our requirement that the proportion of alternate allele 
reads was no more than 5% in each parent, but allowed the child to have as few as 
20% alternate allele reads. We also removed variants where the depth of sequence 
coverage in the child was less than 10% of the total depth of the two parents. However, 
we dropped the PL requirement from 30 to 20 since we were adding other filters to 
produce confident de novo variant calls (discussed below). 
The major error mode of falsely called de novo events is when one parent is truly 
heterozygous, but has been incorrectly called homozygous reference due to under-
sampling of the alternative allele. We therefore implemented a novel algorithm that uses 
population and sample allele frequency information to provide a Bayesian probability 
estimate that an apparent de novo variant constitutes a true de novo, as opposed to a 
missed heterozygous call in the parent. 
While the PL information from the parents provides an accurate picture of the 
probability of the data given the genotype, the prior probability of a heterozygous 
genotype must be derived from population data. To calculate this, we conservatively 
take the maximum allele frequency from two sources: the extensively curated National 
Heart, Lung, and Blood Institute’s Exome Sequence Project reference database and the 
sequenced population sample from which the trio is drawn. Including both data sets 
permits use of both the accuracy that comes from the size of well-curated reference but 
insures against false low frequency estimates should there be an occasional variant 
missed in the reference resource but present in many copies in the current data. The 
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probability of a site being present in a parent but absent from the reference data and all 
other samples in our data is simply the average number of singleton sites unique to an 
individual (~100) divided by the exome target size in base pairs, whereas the prior 
probability of a de novo mutation is the mean number of de novo variants (~1) divided 
by the same exome size in base pairs. 
The probabilities of the two hypotheses are then calculated using Bayes’ theorem 
and the relative probability, 
 ! !"!!"#" ! ! ! !"#$!!"!!"#"! !!"#"!! !"#$!!"!!"#"! !!"#"!!! !"##$%!!!"!!"!!"#$%!! !!"#"! , 
is reported as the probability of de novo variant. Sites for which !"#$%&'(') was 
estimated to be greater than 0.99 were considered high quality sites and constitute the 
set of variants included in all analyses. We also combined !"#$%&'(') with the allele 
balance of the variant and its allele count in the data set to assign it to one of three 
categories: high, medium, and low likelihood of validating as a true de novo event. 
We applied the improved version of the de novo identification script to the exome 
sequencing data from 1,474 trios where the child was diagnosed with ASD as part of 
the Autism Sequencing Consortium25. Extensive validation of sites via Sanger 
sequencing was performed and found that only three out of 200 high quality sites (both 
SNVs and indels) were inherited, confirming the validity of the !"#$%&'(') > 0.99 
estimate (Table 2.3). Additionally, we tested 56 sites that were considered to have a 
medium likelihood of validating: 30 (53.6%) of these were confirmed to be de novo. 
These results further supported the validity of the probability estimate. As these variants 
constituted a small but significantly real category (estimated to add ~2% true events), 
they were included in all analysis of the de novo variants. 
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Table 2.3. Validation of de novo variants by their likelihood of validating. No validation 
was attempted for variants that fell into the low likelihood of validating category. 
 
Likelihood of 
validating 
Number of 
variants tested 
Variants 
validated (%) 
Confirmed de 
novo variants (%) 
High 200 196 (98.0%) 193 (97.5%) 
Medium 56 36 (64.3%) 30 (53.6%) 
 
Author contributions 
Kaitlin Samocha: method design, data analyses (exceptions below), writing 
Mark Daly: method design, writing, overall guidance 
Benjamin Neale: Poisson analysis in Table 2.1 (“Expected de novo SNVs” column), 
extracted and analyzed singleton, doubleton, and variants with ! 3 alternative 
alleles in Table 2.2, guidance, writing 
Silvia De Rubeis: molecular validation listed in Table 2.3 
Samples were provided by the Autism Consortium and Autism Sequencing Consortium 
Principal investigators: Eric Boerwinkle, Joseph Buxbaum, Edwin Cook Jr, Mark 
Daly, Bernie Devlin, Richard Gibbs, Michael Gill, Kathryn Roeder, Gerard 
Schellenberg, Matthew State, James Sutcliffe, Michael Zwick 
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Chapter 3 
Using a mutational model to evaluate de novo findings and identify genes 
intolerant of missense variation 
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Abstract 
Spontaneously arising (de novo) variants play an important role in medical 
genetics. For diseases with extensive locus heterogeneity – such as autism spectrum 
disorders (ASDs) – the signal from de novo variants is distributed across many genes, 
making it difficult to distinguish disease-relevant variants from background variation. We 
provide a statistical framework for the analysis of de novo variant excesses per gene 
and gene set by calibrating a model of de novo mutation. We applied this framework to 
de novo variants collected from 1,078 ASD trios and – while affirming a significant role 
for loss-of-function variants – found no excess of de novo loss-of-function variants in 
cases with IQ above 100, suggesting that the role of de novo variants in ASD may 
reside in fundamental neurodevelopmental processes. We also used our model to 
identify ~1,000 genes that are significantly lacking functional coding variation in non-
ASD samples and are enriched for de novo loss-of-function variants identified in ASD 
cases. 
 
Introduction 
Exome sequencing has allowed for the identification of de novo (newly arising) 
events and has already been effectively put to use in identifying causal variants in rare, 
mendelian diseases. In the case of Kabuki syndrome, the observation of a de novo 
variant in KMT2D (previously MLL2) in 9 out of the10 patients strongly implicated the 
loss of KMT2D function as causal1. The conclusion that KMT2D is important in Kabuki 
syndrome etiology based on the de novo variant findings relies upon the unlikely 
accumulation of independent and infrequently occurring events in the vast majority of 
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these unrelated cases. By contrast, de novo variants (DNVs) play a smaller role in the 
pathogenesis of heritable complex traits, such as autism spectrum disorders (ASDs), 
and associated DNVs are spread across multiple genes. These differences in the 
etiologic architecture of complex traits make the task of identifying “causal” genes 
considerably more challenging. For example, recent exome sequencing studies 
demonstrated a significant excess of de novo loss-of-function (LoF) variants in ASD 
cases, but lacked the ability to directly implicate more than a very few genes2-6. 
The main complicating factor for interpreting the number of observed DNVs for a 
particular gene is the background rate of de novo mutation, which can vary greatly 
between genes. As more individuals are sequenced, multiple DNVs will inevitably be 
observed in the same gene by chance. However, if de novo variation plays a role in a 
given disease, then we would expect to find that genes associated to disease should 
contain more DNVs than expected by chance. 
Here, we develop a statistical model of de novo mutation in order to evaluate the 
findings from exome sequencing data. With this model, we establish a statistical 
framework to evaluate the rate of DNVs not only on a per-gene basis (in a frequentist 
manner analogous to common genome-wide association analysis), but also globally and 
by gene set. We further use this model to predict the expected amount of rare standing 
variation per gene and to detect those genes that are significantly and specifically 
deficient in functional variation, likely reflecting processes of selective constraint. 
Consequently, since selection has reduced standing functional variation in these genes, 
it is reasonable to hypothesize that mutations in these genes are more likely to be 
deleterious.  
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We used the mutational model along with our list of highly constrained genes to 
evaluate the relationship between de novo variation and ASDs. Most of the families 
employed in these analyses were included in a set of previous studies of de novo 
variation, which reported an overall excess of de novo LoF variants in ASD cases, as 
well as multiple DNVs in specific genes2-5. We build on those studies to examine the 
aggregate rates of DNVs, the excess of multiply mutated genes, and the overlap of 
DNVs with gene sets, which highlights the complex relationship between intellectual 
functioning and the genetic architecture of ASD. 
 
Results 
Basis of the mutational model 
Accurate estimation of the expected rate of de novo mutation in a gene requires 
a precise estimate of each gene’s mutability. While gene length is an obvious factor in a 
gene’s mutability, local sequence context is also a well-known source of mutation rate 
differences7. Accordingly, we extended a previous model of de novo mutation based on 
sequence context and developed gene-specific probabilities for different types of 
mutation: synonymous, missense, nonsense, essential splice site, and frameshift (see 
Materials and Methods; Figure 3.1)3. Underscoring the importance of the sequence 
context factors in the model, this genome-wide rate yields an expected mutation rate of 
1.67x10-8 per base per generation for the exome alone. Using counts of rare (minor 
allele frequency < 0.001) synonymous variants identified in the National Heart, Lung, 
and Blood Institute’s (NHLBI’s) Exome Sequencing Project (ESP), we found that our 
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per-gene probabilities of mutation were significantly more correlated (r = 0.940) with 
these counts than gene length alone p < 10-16; Materials and Methods). 
Having established accurate per-gene probabilities of mutation, we could then 
investigate the rates and distribution of DNVs found in sequencing studies. Specifically, 
we wished to systematically assess a) whether cases had genome-wide excesses of 
certain functional categories of de novo variation; b) whether individual genes could be 
associated via de novo variation with genome-wide statistical significance; c) whether 
specific sets of genes collectively showed significant enrichment of de novo variants 
and d) whether there were genome-wide excesses of genes with multiple de novo 
variants. Below we demonstrate the utility of the statistical framework in addressing all 
of these questions with respect to recently generated family exome sequencing for 
autism and intellectual disability. 
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Figure 3.1. An outline of the steps used in the model of de novo mutation probability. A 
graphic illustration of the steps taken to determine the per-gene probabilities of 
mutation. A mutation rate table was created from intergenic single nucleotide 
polymorphisms (SNPs) from the 1000 Genomes Project. This mutation rate table was 
then applied to every coding base and the bases of conserved splice site to create a 
gene specific probability of mutation, split by mutation type. 
 
 
  
1.! Create a mutation rate table from intergenic SNPs for all possible trinucleotide to trinucleotide 
changes"
"
"
"
2.! Use the sequence context to determine the probability of each base changing to each other base 
for all bases in the coding region and those in the conserved splice site"
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4.! Add up the probabilities for each outcome across a gene to create a probability per gene for 
different types of mutations"
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Identifying genes under selective constraint 
There has been a long standing interest in identifying genes in the human 
genome that are sensitive to mutational changes, as these genes would be the most 
likely to contribute to disease. Recent work made use of the ESP data to create a metric 
evaluating the proportion of common functional variation in each gene, thereby 
identifying genes that appeared to be intolerant of mutation8. Along these lines, we 
correlated our calculated per-gene probabilities of mutation with the observed counts of 
rare missense variants in the ESP data set. In contrast to the high consistency between 
predicted synonymous mutation rates and observed synonymous counts (expected if 
the category is under no specific selection), we observed a significant number of genes 
with severe deficit of missense variants compared to the expectation generated from 
predicted mutation rates (p < 10-16). Such a deficit is consistent with strong evolutionary 
constraint: when damaging mutations arise, they are quickly removed from the 
population by purifying selection. To avoid erroneously identified constrained genes, we 
removed 134 genes with either significantly elevated or depressed synonymous and 
nonsynonymous rates (both p < 0.001; Materials and Methods). 
Comparing both the synonymous and missense predictions of our model to the 
ESP data set, we identified a list of excessively constrained genes (missense Z score > 
3.09; corresponding to p < 0.001) that represented roughly 5% of all genes. A high 
proportion of the most significantly constrained genes (missense constraint p < 10-6) 
were associated with autosomal or X-linked dominant, largely sporadic, mendelian 
disease entries listed in the Online Mendelian Inheritance in Man database (OMIM; n = 
27/86). By contrast, a set of genes for which the missense constraint was very close to 
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expectation (n = 111, -0.01 < Z < 0.01) had only two de novo or dominant disease 
inheritance entries in OMIM, a number significantly different from that for the highly 
constrained set (p < 10-8). For the 86 most highly constrained genes, no autosomal 
recessive mendelian disorders have been documented. However, 11 of the 111 genes 
with average levels of constraint have been identified as causal in autosomal recessive 
mendelian disorders. The significant excess of recessive disease-causing genes in the 
middle part of the distribution in comparison to the constrained set (p < 0.003) 
underscores the idea that recessive inheritance models do not induce strong constraint. 
 
Mutation rates for ASD and intellectual disability 
We applied the model to two primary data sets: published results from ASD 
sequencing studies2-6 with a collection of additional unpublished ASD trios, and 
published results from patients with severe intellectual disability9,10. Table 3.1a shows 
the comparison between the predicted number of variants per exome and the observed 
data from the 1,078 ASD cases as well as 343 sequenced unaffected siblings2-6. The 
model’s predictions match the observed data for the unaffected siblings well, but the 
cases show a significant excess of de novo LoF variants consistent with the findings of 
the individual sequencing studies (p = 2.05x10-7). Using our model to simulate null DNV 
sets, we found that there are significantly more genes with two or more de novo LoF 
variants than would be expected by chance (p < 0.001, 6 observed when less than one 
was expected; Table 3.1b. Importantly, while we do not observe a global excess of de 
novo missense variants, we do observe an excess of genes with two or more functional 
(LoF or missense) de novo variants (observed 48 such genes when the average 
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expected is 27; p < 0.001) and genes with two or more de novo missense variants alone 
(observed 33 such genes when average expectation was 21, p = 0.007 for missense, 
Table 3.1b). No such excess of genes containing multiple DNVs was seen in the 
unaffected siblings (Table 3.1b). Of note, our framework also supports the assessment 
of many other weightings and combinations of alleles – such as missense variants only 
(optimal for pure gain-of-function disease models), predicted damaging missense 
variants only, and exact probability estimates for specific combinations of LoF and 
missense variants - than those shown above.  
 
Table 3.1. Evaluation of the rates of de novo variants in ASD cases and unaffected 
siblings. The observed and expected rate of variants by type per exome for unaffected 
siblings2 and ASD cases2-6 (a). (b) The number of genes with multiple de novo variants 
in unaffected siblings and ASD cases across studies. The average number of expected 
genes with multiple de novo variants was determined by simulation. LoF = Loss-of-
function. DNVs = de novo variants. For (a), a two-tailed test was performed for 
synonymous and missense; a one-tailed test for loss-of-function. 
 
a) Genome-wide excesses of mutational events 
 Unaffected Siblings 
Mutation Type Observed events per exome 
Expected events 
per exome p-value 
Synonymous 0.21 0.27 0.0218 
Missense 0.61 0.62 0.8189 
Loss-of-Function 0.09 0.09 0.4508 
n = 343      
 
 ASD Cases 
Mutation Type 
Observed 
events 
per exome 
Expected events 
per exome p-value 
Synonymous 0.25 0.27 0.1065 
Missense 0.64 0.62 0.5721 
Loss-of-Function 0.13 0.09 2.05x10-7 
n = 1,078      
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Table 3.1 (Continued) 
b) Genome-wide excesses of multiply hit genes 
 Unaffected Siblings 
Mutation Type Observed genes with 2+ DNVs 
Average expected 
genes with 2+ DNVs p-value 
Synonymous 0 0.5 1.0 
Missense 5 2.5 0.1049 
Loss-of-Function 0 0.04 1.0 
LoF+missense 6 3 0.0779 
n = 343  
 ASD Cases 
Mutation Type Observed genes with 2+ DNVs 
Average expected 
genes with 2+ DNVs p-value 
Synonymous 4 3.8 0.5186 
Missense 33 21.4 0.0070 
Loss-of-Function 6 0.5 < 0.001 
LoF+missense 48 27.2 < 0.001 
n = 1,078 
 
Table 3.2 lists all of the genes that have two or more de novo missense or LoF 
variants across the 1,078 ASD subjects. A conservative significance threshold of 1x10-6 
was used, correcting for 18,271 genes and two tests. Considering this set of 1,078 trios 
as a single experiment, two genes (DYRK1A and SCN2A) exceeded this conservative 
genome-wide significance threshold for more de novo LoF variants than predicted. 
SCN2A also had significantly more functional de novo variants than expected. CHD8, 
with three de novo LoF variants and one missense, was very close to the significance 
threshold in these studies (p = 1.76x10-6 for LoF; p = 3.20x10-5 for functional). However, 
a recent targeted sequencing study found 7 additional CHD8 de novo LoF variants in 
ASD cases11. This brought the total number of de novo LoF variants in CHD8 to 10, 
which was highly significant (p = 8.38x10-20 when accounting for the total number of 
trios – 2,750 – examined in the combination of the targeted and exome-wide study). 
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These results offer the encouraging point that, as with genome-wide association studies 
(GWAS), larger collaborative exome efforts for trios will define unambiguous risk 
factors. It is important to note, however, that not all genes with a large number of de 
novo variants in them had significant p-values. For example, TTN had four missense 
DNVs in ASD cases, but a p-value that is not even nominally significant due to the 
enormous size of the gene (p = 0.18). Even having two de novo LoF variants was on 
occasion not enough to provide compelling significance (POGZ, two frameshifts, p = 
8.93x10-5). In comparison, none of the genes found to contain multiple DNVs in the 
unaffected siblings crossed the significance threshold (Table 3.3). 
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Table 3.2. Significance of genes with multiple de novo variants (DNVs) in autism 
spectrum disorder (ASD) cases. Loss-of-function (LoF) mutations include nonsense, 
frameshift, and splice site-disrupting mutations. “# LoF Expected” refers to the expected 
number of de novo LoF variants based on the probability of mutation for the gene as 
determined by our model. The genome-wide significance threshold is 1x10-6. “.” = no 
data available. 
 
Gene # LoF # Missense # DNVs Expected p-value Test 
DYRK1A 3 0 0.0072 6.15x10-8 LoF 
SCN2A 3 2 0.0177 9.20x10-7 LoF 
CHD8 3 1 0.0221 1.76x10-6 LoF 
KATNAL2 2 0 0.0049 1.19x10-5 LoF 
POGZ 2 0 0.0134 8.93x10-5 LoF 
ARID1B 2 0 0.0178 1.57x10-4 LoF 
SCN2A 3 2 0.1334 3.15x10-7 LoF+mis 
CHD8 3 1 0.1724 3.20x10-5 LoF+mis 
SUV420H1 1 2 0.0602 3.48x10-5 LoF+mis 
PLEKHA8 0 2 0.0302 4.46x10-4 LoF+mis 
TUBA1A 0 2 0.0338 5.59x10-4 LoF+mis 
SLCO1C1 0 2 0.0394 7.55x10-4 LoF+mis 
NTNG1 0 2 0.0413 8.29x10-4 LoF+mis 
TSNARE1 0 2 0.0498 1.20x10-3 LoF+mis 
TBR1 1 1 0.0541 1.41x10-3 LoF+mis 
MEGF11 0 2 0.0552 1.47x10-3 LoF+mis 
KRBA1 0 2 0.0642 1.98x10-3 LoF+mis 
SRBD1 0 2 0.0645 1.99x10-3 LoF+mis 
KIRREL3 0 2 0.0652 2.03x10-3 LoF+mis 
NR3C2 1 1 0.0655 2.05x10-3 LoF+mis 
UBE3C 0 2 0.0775 2.85x10-3 LoF+mis 
AGAP2 0 2 0.0825 3.22x10-3 LoF+mis 
ABCA13 0 3 0.2890 3.24x10-3 LoF+mis 
ADCY5 0 2 0.1098 5.61x10-3 LoF+mis 
KIAA0182 0 2 0.1114 5.76x10-3 LoF+mis 
ZNF423 0 2 0.1131 5.94x10-3 LoF+mis 
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Table 3.2 (Continued) 
 
Gene # LoF # Missense # DNVs Expected p-value Test 
ZNF638 1 1 0.1212 6.78x10-3 LoF+mis 
SCN1A 0 2 0.1352 8.36x10-3 LoF+mis 
LAMB2 0 2 0.1604 1.16x10-2 LoF+mis 
MYO7B 0 2 0.1616 1.17x10-2 LoF+mis 
KIAA0100 1 1 0.1619 1.18x10-2 LoF+mis 
PLXNB1 1 1 0.1718 1.32x10-2 LoF+mis 
CACNA1D 0 2 0.1732 1.34x10-2 LoF+mis 
ZFYVE26 1 1 0.1753 1.37x10-2 LoF+mis 
SBF1 0 2 0.1808 1.45x10-2 LoF+mis 
BRCA2 0 2 0.1928 1.64x10-2 LoF+mis 
TRIO 0 2 0.2374 2.41x10-2 LoF+mis 
ALMS1 0 2 0.2422 2.50x10-2 LoF+mis 
RELN 1 1 0.2429 2.51x10-2 LoF+mis 
ANK2 1 1 0.2591 2.83x10-2 LoF+mis 
MLL3 1 1 0.3159 4.05x10-2 LoF+mis 
DNAH5 1 1 0.3219 4.19x10-2 LoF+mis 
FAT1 0 2 0.3343 4.49x10-2 LoF+mis 
GPR98 0 2 0.3761 5.53x10-2 LoF+mis 
AHNAK2 0 2 0.4172 6.62x10-2 LoF+mis 
SYNE1 0 2 0.5931 1.20x10-1 LoF+mis 
TTN 0 4 2.1947 1.80x10-1 LoF+mis 
MUC5AC 0 2 . . LoF+mis 
RFX8 0 2 . . LoF+mis 
EFCAB8 0 2 . . LoF+mis 
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Table 3.3. Significance of specific genes with multiple de novo variants (DNVs) in 
unaffected siblings. Loss-of-function (LoF) mutations include nonsense, frameshift, and 
splice site-disrupting mutations. “# LoF Expected” refers to the expected number of de 
novo LoF variants based on the probability of mutation for the gene as determined by 
our model. The genome-wide significance threshold is 1x10-6. “.” = no data available. 
 
Gene # LoF # Missense # DNVs Expected p-value Test 
CSNK1G3 1 1 0.0098 4.78x10-5 LoF+mis 
UGT2B4 0 2 0.0102 5.12x10-5 LoF+mis 
USP34 0 2 0.0717 2.45x10-3 LoF+mis 
AHNAK2 0 2 0.1327 8.07x10-3 LoF+mis 
SYNE2 0 2 0.1369 8.56x10-3 LoF+mis 
TTN 0 2 0.6983 1.55x10-1 LoF+mis 
 
These analyses were also applied to the results from the sequencing studies of 
moderate to severe (IQ < 60) intellectual disability9,10 (n = 151). Intellectual disability, 
like ASD, showed a significant excess of LoF DNVs (p = 6.49x10-7; Table 3.4a). Even 
with a much smaller sample size there were genes with significantly more LoF and 
functional DNVs than predicted by the model (Table 3.4c). The intellectual disability 
data also have significantly more genes with multiple de novo missense, LoF, and 
functional variants than predicted (p = 0.009 for missense, p < 0.001 for LoF and 
functional; Table 3.4b). 
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Table 3.4. Evaluation of the rates of de novo variants in cases with intellectual disability. 
(a) The observed and expected rate of variants by type per exome for cases of 
intellectual disability (ID, n = 151 families)9,10. A two-tailed test was performed for 
synonymous and missense; a one-tailed test for loss-of-function. (b) The number of 
genes with multiple de novo variants in intellectual disability cases across studies. The 
average number of expected genes with multiple de novo variants was determined by 
simulation. (c) Genes with multiple functional de novo variants in the ID cases9,10. LoF 
variants include nonsense, frameshift, and splice site-disrupting events. The genome-
wide significance threshold is 1x10-6. The number of variants is either compared to the 
expected number for LoF only or for both LoF and missense, as indicated by the “# 
DNVs Expected” and “Test” columns. LoF = Loss-of-function. DNVs = de novo variants. 
 
a) Genome-wide excesses of mutational events 
 
Mutation Type Observed events per exome 
Expected events 
per exome p-value 
Synonymous 0.19 0.27 0.0267 
Missense 0.70 0.62 0.2380 
Loss-of-Function 0.24 0.09 6.49x10-7 
 
b) Genome-wide excesses of multiply hit genes 
 
Mutation Type Observed genes with 2+ DNVs 
Average expected 
genes with 2+ DNVs p-value 
Synonymous 1 0.09 0.0879 
Missense 3 0.5 0.0090 
LoF 2 0.01 < 0.001 
LoF+missense 6 0.6 < 0.001 
 
c) Genes with multiple de novo missense and loss-of-function variants 
 
Gene # LoF #Missense # DNVs Expected p-value Test 
SYNGAP1 3 0 0.0017 8.15x10-10 LoF 
SCN2A 3 1 0.0025 2.56x10-9 LoF 
SCN2A 3 1 0.0187 5.01x10-9 LoF+mis 
STXBP1 1 2 0.0071 5.87x10-8 LoF+mis 
TCF4 0 2 0.0069 2.39x10-5 LoF+mis 
GRIN2A 0 2 0.0162 1.34x10-4 LoF+mis 
TRIO 0 2 0.0333 5.60x10-4 LoF+mis 
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In our ASD sample, we then investigated the rate of de novo events as a function 
of IQ; roughly 80% of this sample had an IQ assessment attempted. We found that the 
rate of de novo LoF mutation in ASD cases with a measured IQ above average was no 
different than expectation (IQ ! 100; n = 229; 0.08 de novo LoF variants per exome 
compared to expected 0.09, p = 0.59). By contrast, the rate in the rest of the sample 
was substantially higher than expectation (n = 572; rate of 0.17 de novo LoF variants 
per exome, p = 1.17x10-10). Furthermore, when directly compared (rather than to our 
expectation), these two groups were significantly different from each other, confirming a 
difference in genetic architecture among ASDs as a function of IQ (Table 3.5a-b, p < 
0.001). These conclusions are unchanged in separate analyses of nonverbal and verbal 
IQ as well as full scale IQ (Table 3.5c). 
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Table 3.5. Investigating the rate of de novo mutation as a function of IQ. (a) The 
observed and expected rate of de novo variants by mutation class for the autism 
spectrum disorder cases with full scale IQ ! 100. (b) The observed and expected rate of 
de novo variants by mutation class for the autism spectrum disorder cases that did not 
have a full scale IQ above 100. (c) The observed rate of de novo loss-of-function (LoF) 
mutations split by verbal IQ and nonverbal IQ. For (a) and (b), a two-tailed test was 
performed for synonymous and missense; a one-tailed test for loss-of-function. 
 
a) Full Scale IQ scored above 100 (n = 229) 
 
Mutation Type Observed events 
per exome 
Expected events 
per exome 
p-value 
Synonymous 0.24 0.27 0.2346 
Missense 0.66 0.62 0.4736 
Loss-of-Function 0.08 0.09 0.5867 
 
b) Full Scale IQ not scored above 100 (n = 572) 
 
Mutation Type Observed events 
per exome 
Expected events 
per exome 
p-value 
Synonymous 0.22 0.27 0.0123 
Missense 0.62 0.62 0.9946 
Loss-of-Function 0.17 0.09 1.17x10-10 
 
c) IQ comparisons split between verbal and nonverbal IQ 
 
Phenotypic Group Number of samples 
Observed de novo LoF 
events per exome p-value 
Verbal IQ ! 100 242 0.10 0.1903 
Verbal IQ not scored 
above 100 712 0.15 2.43x10
-8 
Nonverbal IQ ! 100 276 0.09 0.4829 
Nonverbal IQ not scored 
above 100 678 0.16 1.09x10
-9 
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Gene set enrichment 
Given the significant global excess of de novo LoF variants in ASD cases, we 
wanted to evaluate whether the set of genes harboring de novo LoF variants had 
significant overlap with several sets of genes proposed as relevant to autism or 
describing biochemical pathways. We used the probabilities of mutation to determine 
the fraction of LoF variants expected to fall into the given gene set. We then used the 
binomial distribution to evaluate the number of observed LoF variants overlapping the 
set compared to the established expectation. When we applied this analysis to a set of 
112 genes reported as disrupted in individuals with ASD or autistic features, we 
observed no enrichment of de novo LoF variants (Figure 3.2, “Betancur”)12. By contrast, 
we applied this analysis to a recent study of 842 genes found to interact with the Fragile 
X mental retardation protein (FMRP) in vivo and found a highly significant overlap (2.3-
fold enrichment, p < 0.0001, Figure 3.2)2,13. This enrichment with the targets of FMRP 
held even when we removed the de novo variants identified in the Iossifov et al study 
that initially reported an enrichment of de novo variants in ASD cases with FMRP-
associated genes (2.5-fold enrichment, p < 0.0001)2. 
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Figure 3.2. The expected and observed fraction of genes with a de novo variant in 
cases and controls for four gene sets of interest. ASD cases (n = 1,078), unaffected 
controls (n = 647), and intellectual disability (ID; n = 151) cases were sequenced across 
various studies2-6,9,10. “Betancur” refers to a set of genes reported as disrupted in 
individuals with ASD or autistic features; of the 112 on the list, we could evaluate 11112. 
“FMRP” refers to the genes whose mRNAs are bound and regulated by the Fragile X 
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Figure 3.2 (Continued) Mental Retardation Protein (FMRP), as identified by Darnell 
and colleagues13. The “constrained” category is a set of 1,003 genes that we defined as 
significantly lacking rare missense variation, indicating intolerance to mutation. The 
targets of FMRP that are also considered constrained by our metric make up the 
“Constrained FMRP” category. Loss-of-function variants are presented in (a); missense 
in (b) and synonymous in (c). * indicates p < 0.01; ** indicates p < 10-4. 
 
We then evaluated the group of individuals from the ASD studies who had a de 
novo LoF variant in one of the targets of FMRP. On average, these cases were 
enriched for having a measured IQ < 100 (Fisher’s exact p = 4.01x10-4; Table 3.6 as 
well as significantly reduced male:female ratio (p = 0.02; Table 3.7) as compared to the 
remaining sequenced cases (Materials and Methods). These individuals represent 
about 3% of the total sample, when at most a 1% overlap would be expected. The 
estimated odds ratio (OR) of de novo LoF variants in the set of FMRP target genes was 
around 6, very similar to the OR estimated for large CNVs that disrupt multiple genes14. 
In addition, the OR for the published cases of moderate to severe intellectual disability 
noted above (IQ < 60; not ascertained for ASDs) having a de novo LoF event in the set 
of FMRP targets was roughly 10. 
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Table 3.6. The number (and percentage) of individuals that have an IQ ! 100 or an IQ 
not scored above 100 split by whether they contain a de novo loss-of-function variant in 
a target of FMRP (FMRP-I) or not (“Rest of Cases”). In (a), individuals who started an 
IQ test but were not given an IQ score are included. Only individuals with IQ scores are 
included in (b). 
 
a) IQ Attempted but unscored individuals included 
 
 FMRP-I Rest of Cases 
IQ ! 100 1 (3%) 254 (31%) 
IQ not above100  29 (97%) 575 (69%) 
 
Fisher’s exact p-value = 4.01x10-4 
 
b) Only scored individuals 
 
 FMRP-I Rest of Cases 
IQ ! 100 1 (5%) 254 (35%) 
IQ not above100  20 (95%) 469 (65%) 
 
Fisher’s exact p-value = 0.0021 
 
Table 3.7. The number (and percentage) of individuals that are male and female split by 
containing a de novo loss-of-function mutation in a target of FMRP (FMRP-I) or not 
(“Rest of Cases”). 
 
 FMRP-I Rest of Cases 
Male 19 (63%) 658 (80%) 
Female 11 (37%) 163 (20%) 
 
Chi-square p-value = 0.02 
 
The same analysis was applied to the list of de novo LoF variants from 
unaffected siblings of ASD cases and additional control individuals (n = 647)2,4,5,15. 
There was a significant enrichment when evaluating the overlap with the set of autism 
related genes (p = 0.0095, Figure 3.2). However, no significance was observed for the 
overlap with the in vivo targets of FMRP. The de novo LoF variants from the intellectual 
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disability individuals, on the other hand, were significant for both sets (p < 10-4 for both 
sets; Figure 3.2). Even the de novo missense variants found in the intellectual disability 
cases showed significant overlap with both sets under study (p = 0.02 for autism-related 
genes, p < 0.0001 for the targets of FMRP, Figure 3.2). 
 
Evaluating constrained genes 
We further applied the enrichment analysis to our set of constrained genes and 
found that they contained more de novo LoF variants than expected by chance (2.3-fold 
enrichment, p < 0.0001, Figure 3.2). A greater fold enrichment was observed when 
focusing on the subset of constrained genes that were also identified in the FMRP study 
(3.0-fold enrichment, p < 0.0001, Figure 3.2)13. We note that the FMRP targets have a 
significant overlap with the constrained set of genes (odds ratio = 1.29, p < 0.0001), 
which is consistent with the report that the targets of FMRP are under greater purifying 
selection than expected2. All enrichments were demonstrated to be independent of 
gene size (Materials and Methods). 
The genes that contained a de novo missense or LoF variant in the cases of 
intellectual disability also showed a significant enrichment for both the constrained gene 
set and the set of constrained targets of FMRP (p < 0.0001 for all lists). In comparison, 
no enrichment was found with either set and the list of genes that had a de novo LoF 
variant in unaffected siblings and control individuals. 
In addition to treating constraint as a dichotomous trait, we also evaluated the 
missense Z score for each of the genes with a de novo LoF variant. We found that the 
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distribution of missense Z scores for genes with a de novo LoF variant in unaffected 
individuals was no different from the overall distribution of scores (Wilcoxon p = 0.8325; 
Figure 3.3). By contrast, both the genes with a de novo LoF variant in ASD and 
intellectual disability cases had values significantly shifted towards high constraint 
(Wilcoxon p < 10-6 for both). Furthermore, we compared the distribution of Z scores 
among each of the three groups. Both the ASD and intellectual disability distributions 
were significantly different from the distribution of missense Z scores for unaffected 
individuals (p = 0.0148 and 0.0012, respectively). The intellectual disability missense Z 
scores were also significantly higher than the ASD values (p = 0.0319). 
 
 
Figure 3.3. The distribution of missense Z scores and Z scores of genes containing de 
novo loss-of-function variants identified in unaffected individuals, autism spectrum 
disorder (ASD) cases, and intellectual disability cases. (a) The distribution of missense 
Z scores. The red line indicates a Z score of 3.09, or the threshold for inclusion into the 
set of 1,003 constrained genes. (b) The missense Z scores for genes containing de 
novo LoF in unaffected individuals, ASD cases, and intellectual disability cases2-6,9,10,15. 
Black bars indicate the mean Z score of each group: 0.94, 1.68, and 2.46 for unaffected 
Figure 2!
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Figure 3.3 (Continued) individuals, ASD cases, and intellectual disability cases, 
respectively. While the missense Z scores of the de novo LoF variants found in 
unaffected siblings matched the overall distribution (Wilcoxon p = 0.8325, n.s. = not 
significant), de novo LoF variants found in both ASD and intellectual disability cases 
were significantly shifted towards more extreme constraint values (p < 10-6 for both). All 
p-values for deviation from the overall distribution are listed on the right side of the 
figure. In addition, the distribution of missense Z scores fore each of the three de novo 
lists were all individually significant at p < 0.05. 
 
When evaluating the ASD cases split by IQ group, we found no enrichment of de 
novo LoF-containing genes with either constrained genes and targets of FMRP in the 
group with IQ ! 100 (p > 0.5 for both sets of genes) but very strong enrichment in the 
set with IQ < 100 (p < 0.0001 for both sets of genes). These results underscore that 
phenotypically distinct subsets of ASD cases may have significantly different 
contributions from de novo variation. 
 
Comparison of constraint metric with existing methods 
Identifying constrained genes by comparing observed nonsynonymous sites to 
expectation is conceptually similar to the traditional approach of detecting selective 
pressure by comparing observed nonsynonymous sites to observed synonymous sites 
(e.g. dN/dS) that has been used extensively. Our approach should in principle achieve 
greater statistical power to detect constrained genes; comparison of an observation to 
expectation is statistically more powerful than contrasting that observation with a 
generally smaller second observation – the number of observed synonymous variants. 
In order to investigate this claim, we identified genes that had significant evidence for 
selective constraint using the dN/dS metric (i.e. their ratio of synonymous and 
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nonsynonymous sites deviated from the genome-wide average at p < 0.001, Materials 
and Methods). There were only 377 of these genes, over half of which overlapped with 
the constrained gene list defined by our method (n = 1,003; overlap 237 genes). The 
genes identified as significantly constrained by only our metric (the top 10 of which 
include RYR2, KMT2A (MLL), KMT2D (MLL2), and SYNGAP1) are still significantly 
enriched for known causes of autosomal and X-linked dominant forms of mendelian 
disease (p = 5x10-4). We therefore conclude that the model-based approach to 
identifying constrained genes adds substantial power to traditional approaches. The 
importance of this increased power to detect constraint in further articulated in the ASD 
and intellectual disability analyses below. 
Several groups have previously published approaches, and specific gene sets 
from them, that are also aimed at identifying genes under excessive purifying selection 
or generally intolerant of functional mutation. Bustamante et al16 expanded on the 
McDonald-Kreitman framework17 contrasting fixed differences in the primate lineage to 
polymorphic differences in humans to identify a set of genes under weak negative 
selection, while more recently Petrovski et al8 utilized the excess of rare versus 
common missense variation within humans to flag genes intolerant of functional 
variation. We found a reasonable correlation between our metric of constraint and 
Petrovski’s Residual Variation Intolerance Score (RVIS8; Figure 3.4). A comparison of 
these approaches as applied to prioritization of known haploinsufficient genes as well as 
the autism de novo LoF variants described here are provided in the Materials and 
Methods and demonstrates that the two human-only approaches (constraint and RVIS) 
perform better on these tasks of identifying medical genetic lesions of severe effect in 
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modern humans (Table 3.8). Intriguingly, both of these other approaches utilize 
independent information from each other and from our approach (which uses the 
absence of rare functional variation versus expectation within humans), raising the 
potential that composite scores employing all three sources of information pointing to 
which genes are most sensitive to heterozygous mutation could add further value. 
 
 
Figure 3.4. Correlation between the constraint score and RVIS. The constraint scores 
(missense Z scores) determined by our method and residual variation intolerance score 
from Petrovski et al 8 have a Pearson correlation of -0.35. The black line shows the 
linear regression between the two metrics. 
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Table 3.8. Comparison of the predictive ability of different sets of constrained genes for 
known haploinsufficient genes and those disrupted by a de novo LoF mutation in ASD 
patients. In (a), the ability of both constraint scores and lists of constrained genes were 
tested for their ability to predict known haploinsufficient genes, as listed in OMIM. The 
quantitative scores (constraint and RVIS8) were used in a linear regression with gene 
size added as a covariate. The gene lists (constrained, top 5.5% most intolerant genes 
using RVIS8, and the genes identified in Bustamante et al16) were evaluated with a 
logistic regression with gene size as a covariate. In (b), the three gene lists were 
evaluated for their enrichment of de novo LoF mutations identified in ASD patients. To 
do this, the expected fraction of constrained genes to contain one of these de novo 
mutations was determined and then used to establish the fold enrichment and 
significance of the observed fraction. 
 
a) Linear and logistic regressions 
 
  Quantitative Scores   
List-Based 
 
  Constraint score RVIS  
Top 
Constrained 
Top 
RVIS Bustamante 
OMIM 
Haplo-
insufficiency 
t-
value 10.011 -9.561 OR 4.909 5.490 1.307 
p-
value < 10
-16 < 10-16 p-value < 10
-16 < 10-16 0.191 
 
b) Enrichment of genes with those containing a de novo LoF in ASD patients 
 
  Top Constrained Top RVIS Bustamante 
ASD de novo 
LoF 
Fold enrichment 2.282 1.904 0.836 
p-value 3.58x10-6 5.36x10-5 0.718 
 
Discussion 
We have developed a framework for evaluating excesses of de novo variants 
identified through exome sequencing. Even though this framework can be leveraged to 
evaluate excesses of variants study-wide and in gene sets, the key focus is to evaluate 
the significance for individual genes. Given the small number of observed de novo 
events per gene, simple case-control comparisons cannot achieve any meaningful level 
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of significance. For example, observing three de novo loss-of-function variants in a 
small gene in 1,000 case trios is perhaps quite compelling, especially if no such variants 
were identified in 1,000 control trios. However, a simple three to zero case/control 
comparison in this situation would yield no compelling statistical evidence (one-tailed p 
= 0.125). Incidence of such extremely rare events, however, can be evaluated if the 
expected rate of such events is known. Sequencing large numbers of control trios to 
gather empirical rate estimates on a per-gene basis that are accurate is infeasible and 
inefficient. The calibrated model and statistical approach described here can achieve a 
close approximation of this ideal. Our method, therefore, offers the ability to evaluate 
the rate of rare variation in individual genes in situations where burden tests would fail. 
Other groups have developed similar statistical frameworks11,18 – notably, the 
Epi4k consortium18 used the same base model we begin with3 to interpret event rates. 
Our model, however, has two primary strengths. First, our model of de novo mutation 
incorporates additional factors beyond sequence context that affect mutation rate. Both 
the depth of coverage – how many sequence reads were present on average – for each 
base and the regional divergence around the gene between humans and macaques 
independently and significantly improve the predictive value of our model (Materials and 
Methods). Second, given the high correlation between the number of rare synonymous 
variants in ESP and the probability of a synonymous mutation determined by our full 
model, we have a metric to evaluate the extent to which genes in the human genome 
show evidence of selective constraint. The list of 1,003 genes that we define as 
constrained contains an enrichment of genes known to cause severe human disease – 
an observation analogous to that recently made in using empirical comparison of 
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common and rare rates of functional variation to evaluate intolerance8. In fact, site count 
deficits and site frequency shifts each contribute independent information to the 
definition of constraint and can in principle be combined in a composite test. 
The results of our metric were compared to both the scores created by Petrovski 
and colleagues8 and loci identified as under negative selection by Bustamante et al 16 . 
Overall, our metric and the residual variation intolerance scores defined by the Petrovski 
worked similarly well, reinforcing the benefits that could come from combining the two 
approaches. It is unsurprising that these methods outperform the evolutionary ones on 
the specific matter of genes intolerant to heterozygous mutation. Evolutionary methods 
examining differences between polymorphism and fixed differences, which are more 
sensitive to weaker negative selection, require that mutations be tolerated well enough 
to become polymorphic in the first place. By contrast, approaches measuring the 
complete absence of variation will pick up the most strongly intolerant genes. 
Ideally, we can conceptualize defining two metrics of genic constraint, one based 
on missense variants and the other based on LoF variants. With only 6,503 individuals 
in ESP, we are underpowered to determine significant deviations for most genes with 
respect to loss-of-function variants. As sample size increases, our ability to calculate 
constraint improves. For example, if the sample size were to increase by an order of 
magnitude, we would be able to evaluate approximately 66% of genes using LoF 
variants. We therefore view the constrained gene list as a work in progress, to be 
updated when larger exome sequencing data sets become available. 
Applying our statistical framework to de novo variants from 1,078 ASD cases 
reveals that, while there is no global excess in de novo missense variants, there are 
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significantly more genes that contained multiple de novo missense variants than 
expected. We also see significant overlap between the list of genes with a de novo LoF 
in ASD cases and the set of constrained genes that we defined. In addition, there is a 
significant overlap between the genes with a de novo LoF variant and the targets of 
FMRP, as reported in Iossifov et al2. All of the significant signals in ASD – the global 
excess of de novo LoF variants, the excess of genes with multiple functional de novo 
variants, the overlap between the de novo LoF genes and both constrained genes and 
the targets of FMRP – are not found in the subset of ASD cases with IQ ! 100. The lack 
of signal in the IQ ! 100 indicates that genetic architecture among ASDs varies as a 
function of IQ. Overall, the probabilities of mutation defined by our full model and list of 
constrained genes can be used to critically evaluate the observed DNVs from 
sequencing studies and aid in the identification of variants and genes that play a 
significant role in disease. 
 
Materials and Methods 
De novo variant information 
Published de novo variants were collected for both autism spectrum disorders 
(ASD)2-6 and severe intellectual disability9,10. Updated de novo calls were provided from 
two of the ASD studies3,5. Details about sample collection, sequencing, and variant 
processing can be found in the separate studies. 
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Additional sequencing 
Exome sequencing of the additional families (n = 129) was performed at the 
Broad Institute. Exons were captured using the Agilent 38Mb SureSelect v2. After 
capture, a round of ligation-mediated PCR was performed to increase the quantity of 
DNA available for sequencing. All libraries were sequenced using an 
IlluminaHiSeq2000. Data were processed with Picard (http://picard. sourceforge.net/), 
which uses base quality-score recalibration and local realignment at known indels19 and 
BWA20 for mapping reads to hg19. SNPs were called using GATK for all trios jointly19,21. 
The variable sites that we have considered in analysis are restricted to those that pass 
GATK standard filters. From this set of variants, we identified putative de novo variants 
and validated them as previously described3. Autism Consortium samples (n = 78 trios) 
were collected in Boston under IRB approval from Harvard Medical School, 
Massachusetts General Hospital, Children’s Hospital Boston, Tufts-NEMC, Boston 
University Medical Center with ADI and ADOS assessment. Finnish autism samples (n 
= 51 trios) were collected under IRB approval at University of Helsinki with ADI and 
ADOS assessment and consented for autism research only. In both studies, all 
participants gave written informed consent, though as autism is classified as a 
childhood disorder, many subjects are children with informed consent provided by 
parents or guardians. 
 
Mutational model 
We wanted to create an accurate model of de novo mutation for each gene. The 
steps involved in the creation of the model are outlined in Figure 3.1. Briefly, we 
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determined the probability of a given base mutating into one of the three other possible 
bases as well as the coding impact of each possible mutation. We added probabilities 
across a gene to create per-gene probabilities of all mutation types under study: 
synonymous, missense, nonsense, and splice site. 
The first, and most important, step of making a model based on sequence 
context is to establish the mutability of a given base. Krawczak and colleagues 
determined that the best context for determining the mutability of a single base is to 
include both the 5’ and 3’ bases22. Following the lead of other groups, we took this 
trinucleotide context as sufficient for determining mutability23. We used 1000 Genomes 
intergenic regions that are orthologous between humans and chimps as the basis for 
our mutation rate table. Across the sequence, we tallied the number of observations for 
each of the 64 possible trinucleotides and, for each SNP, considered the chimp allele to 
be ancestral and determined the trinucleotide (XY1Z) to trinucleotide (XY2Z) change that 
occurred. To determine the probability of a given trinucleotide mutating, we divided the 
number of mutations in that trinucleotide context by the number of occurrences of the 
trinucleotide. This probability is adjusted by a proportionality constant, ", that gives the 
mutation rate of that trinucleotide for a single generation. The mutation rate for the given 
nucleotide is then proportionally divided between the three possible trinucleotides to 
which it could mutate. In the end, we have a mutation rate table that contains the 
probability of any of the 192 possible mutations. 
We then use the mutation rate table and the sequence context to determine the 
per-gene probability of mutation based on the sequence of the gene. For a given base 
in the gene, the trinucleotide sequence context is determined. The probability of the 
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middle base mutating to one of the three other bases is queried in the mutation rate 
table and the type of change it would create is determined. The probability of mutation is 
added to a running total for the type of mutation it would cause. This is repeated for the 
two other possible mutations for every coding base in the gene as well as the bases in 
the conserved splice sites for all genes in the genome. In the end, there is a per-gene 
probability of each type of mutation under study: synonymous, missense, nonsense, 
and splice site. We determine the probability of a frameshift mutation by multiplying the 
probability of a nonsense mutation by 1.25, the relative rate of singleton frameshift to 
singleton nonsense mutations found in exome sequencing data from roughly 2,000 ASD 
cases and controls. 
 
Adjustments to the model 
In order to evaluate the predictive value of the model of de novo mutation 
probability, we extracted the number of synonymous singletons – seen only once in the 
data set – found in each gene from the National Heart, Lung and Blood Institute’s 
Exome Sequencing Project (ESP). The number of these singletons in each gene was 
correlated to both gene length and the probability of synonymous mutation determined 
by our model. While gene length alone showed a high correlation with the number of 
synonymous singletons (0.835), the probability of a synonymous mutation was 
significantly higher (0.854, p < 10-16) 
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Depth adjustment 
We first investigated the role that depth of coverage could have on the 
predictions of mutation rates. The ability to call a de novo event is dependent on how 
well sequenced the location of the event is. Therefore, bases that are not covered at all 
should not contribute to the overall probability of mutation for the gene. In order to 
account for differences in sequencing coverage, we created a way to determine what 
fraction of a base’s mutation probabilities should be added to the total for the gene 
based on the coverage. For each base, we looked up the number of trios in which all 
members had 10x coverage or greater and used that number to determine the 
appropriate discount. For bases with almost all trios having 10x coverage, the 
probability of mutation was not adjusted. However, as the number of trios with 10x 
coverage dropped, the probability of mutation was multiplied by an adjustment factor in 
between 0.9 and 1. To determine the endpoints of the adjustment, we compared the 
ratio of the observed number of synonymous singletons to the overall probability of a 
synonymous mutation for a high confidence set of bases to sets of bases with fewer 
trios passing at 10x. The depth adjusted probabilities of synonymous mutation showed 
a significantly greater correlation to the number of synonymous singletons in the ESP 
data set when compared to gene length alone (0.891, p < 10-16). 
 
Divergence adjustment 
Divergence between humans and other primates is known to correlate with the 
relative number of SNPs in large regions24. We postulated that local divergence rates 
could be added to the model as a regional term that captured the local deviation from 
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the base mutation rate. We used human-macaque divergence information to determine 
the divergence score – defined as the number of divergent sites over screened sites for 
the region containing the gene as well as 1 MB upstream and downstream – for each 
gene. We used linear models to determine the best equation to adjust the per-gene 
probabilities of mutation to incorporate the divergence score. In the end, the probability 
of mutation is adjusted slightly for the divergence score. For genes with no divergence 
information, the average divergence score is used. This, however, lead to a global 
increase in the predicted rate of mutation, so all probabilities of mutation were modified 
so that the sum of all probabilities after divergence adjustment was equal to the sum of 
probabilities from before the adjustment. This adjustment of predictions significantly 
increased the correlation with the synonymous singletons in the ESP data (0.910, p < 
10-16). 
 
Replication timing adjustment 
Replication timing has also been associated with overall mutation rate, with later 
replicating DNA having a higher rate of mutation25. We used replication timing Z scores 
from Koren et al to create a replication timing score for each gene26. The replication 
timing score is defined as the average replication timing score across the length of the 
gene. The replication timing score was used in linear models. It did significantly add to 
the mutational model (p = 0.005), but had a very slight overall effect. Further 
investigation revealed that the model was predicting more synonymous changes as the 
average replication Z score increased, and thereby was already accounting for the 
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adjustments that the replication score was adding. We did not include the replication 
timing adjustment in any further analyses. 
 
Using rare variants instead of singletons 
To increase power for our definition of constrained genes, we extracted the 
number of rare (minor allele frequency < 0.01%) synonymous variants found in each 
gene in the ESP data set. The correlation between the number of rare synonymous 
variants and the gene length was 0.880; the probability of synonymous mutation as 
defined by our full model and the number of rare synonymous variants was 0.940. Due 
to the stochastic nature of small counts in the ESP data set, the maximum correlation 
we could achieve is 0.975, indicating that our model captured ~66% of the remaining 
correlation that we could achieve above gene length. 
 
Definition of constrained genes 
A traditional approach to identifying genes that appear to be under constraint is 
to compare the ratio of nonsynonymous to synonymous substitutions (known as the 
Ka/Ks or dN/ds). Given that the correlation between the probability of a synonymous 
mutation and the number of rare synonymous variants in a gene was high, we wanted 
to use our model to predict the number of rare missense variants as a way to evaluate 
genes under constraint in an approach similar to the Ka/Ks. We determined the expected 
number of variants by fitting a linear model based on the probability of mutation and the 
observed number of synonymous variants. The autosomes were fit separately from the 
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X chromosome. The equations were applied using the probability of a missense 
mutation to create an expected number of rare missense variants in the ESP dataset. 
For both synonymous and missense variants, we created a signed Z score of the chi-
squared deviation of observation from expectation. Negative values indicate more 
variants than expected, while positive values are tied to fewer variants observed than 
expected. 
In order to define the set of genes that appeared to be under excessive 
constraint, we used three filters: (1) the predicted number of rare synonymous variants 
should be 5 or greater, (2) the observed number of rare synonymous variants should 
not be significantly lower than expectation (p > 0.001), and (3) the observed number of 
missense singletons should be significantly lower than expectation (p < 0.001). The 
reason for restricting to genes with 5 or more expected synonymous singletons is so 
that true deviations from expectation can be separated from deviations caused by 
sampling problems. Using these filters, we identified 1,003 genes—which represent 
roughly 5% of the genes in the genome—that appeared to be under excessive 
constraint. 
The genes in the constrained gene list are enriched for entries in the OMIM 
database, especially for entries associated with mental retardation and retinitis 
pigmentosa. 31% of the top 86 constrained genes – for which the observed number of 
missense rare variants is significant at p < 10-6 – have entries in the Online Mendelian 
Inheritance in Man (OMIM) database with dominant or de novo inheritance patterns. 
None of them have recessive inheritance entries in OMIM. A comparison set was made 
to 111 genes for which the missense observations fell very closely around prediction    
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(-0.01 < Z < 0.01). This set of genes had 2 OMIM entries (1.8%) with dominant or de 
novo inheritance and 11 (10%) with recessive inheritance. 
 
Removing potential false positive constrained genes 
In order to identify genes that appeared to be significantly constrained, we used 
our probabilities of mutation to predict the expected amount of synonymous and 
nonsynonymous variation in the NHLBI’s ESP data. Those genes that had the expected 
amount of synonymous variation, but were significantly (p < 0.001) deficient for 
missense variation were labeled as constrained. To ensure that genes were not 
nominated as being constrained erroneously, we excluded from all analyses 134 genes 
where the observed synonymous and nonsynonymous rates were both significantly 
elevated or significantly depressed (both p < 0.001). Upon inspection, this list contained 
a number of genes that contained an internal duplication (e.g. FLG), a nearby 
pseudogene (e.g. AHNAK2), and a number of cases where recent duplications and/or 
annotation errors have led to the same sequence being assigned to two genes (e.g. 
SLX1A and SLX1B). These are all scenarios where standard exome processing 
pipelines systematically under-call variation – reads are unmapped due to uncertainty of 
which gene to assign them to – or overcall false variants owing to read misplacement. 
This further suggests that a byproduct of this analysis framework is the identification of 
a residual set of challenging genes for current exome sequencing pipelines. 
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Evaluating the global excesses of de novo variants 
To compare the observed rate of de novo variants by mutation type to the 
expected rate, we summed the total probability of the given type of mutation and 
adjusted for the number of individuals in the study. Poisson distribution probabilities 
were invoked to determine the significance of the observation. 
 
Number of genes with multiple de novo variants 
Even though there is a global excess in LoF variants in the ASD cases, the signal 
was spread over many genes, making it hard to determine which specific genes may be 
contributing to the etiology of ASD. One way to prioritize genes would be to focus on 
those genes that contain multiple de novo variants; we wanted to evaluate whether 
there was an excess of such genes. To do so, we simulated de novo events by 
extracting each gene’s probability of mutation and then randomly drew the expected 
number of de novo variants based on weight (the probability). Using these simulations, 
we could determine an empirical p-value for the observed number of genes with multiple 
de novo variants. Results are presented in Table 3.1b for the unaffected siblings and 
ASD cases, and in Table 3.4b for intellectual disability cases. The “LoF+missense” 
category uses the combined probability of a LoF and missense mutation to evaluate 
genes that show two or more de novo mutations that are LoF, missense, or both. The 
lowest possible p-value is 0.001 since 1,000 simulations were run. 
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Single genes with multiple de novo variants 
Since we generated a per-gene probability of de novo mutation, we can directly 
evaluate genes that contain multiple de novo variants for significance. To do so, each 
gene’s probability of mutation is extracted and the predicted number of de novo variants 
by mutation type is determined by adjusting for the number of individuals in the study. 
The observed and expected numbers of de novo variants are compared and the 
Poisson is invoked to determine significance. We perform two comparisons: the LoF 
mutations alone and the LoF and missense mutations together. The first comparison is 
only made for those genes that contain multiple LoF de novo mutations; the second is 
performed for genes that have a combination of missense and LoF de novo mutations. 
Here, we have set the significance threshold at 10-6 since it conservatively accounts for 
both the number of genes under study and the number of tests using the Bonferroni 
correction. 
 
Global de novo mutation rates separated by IQ group 
Due to the significant role of de novo variation in intellectual disability, we wanted 
to investigate the overall rates of mutations for those ASD cases without intellectual 
impairments. Several intelligence tests were used to assess proband IQ across testing 
sites. The IQ analyses presented here include individuals whose IQ was measured 
using one of four standardized, commonly used tests to evaluate intelligence in children: 
the WISC-IV27, the WASI28, the WPPSI-III (preschool and primary school age)29, and 
the DAS (early years and school age)30. These tests provide comparable assessments 
of full scale intelligence, using both verbal and nonverbal assessments31. Children who 
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did not complete one of these four tests (n = 95, 10.0%) were treated as missing without 
attempt. Probands who are missing IQ without attempt include those who were given an 
IQ test that does not assess intelligence comparably (n = 78, 8.2%), specifically the 
Mullen Scales of Early Learning or the Leiter International performance scale, which are 
strongly weighted towards nonverbal assessment32,33. 
We had access to phenotypic information for 954 of the sequenced probands. Of 
these, 859 had taken an IQ test that could be compared to other tests. We removed 
those individuals that had a 30-point or greater difference between their verbal and 
nonverbal IQs to avoid inclusion of excess measurement error or learning disabilities. 
Verbal and nonverbal IQ were correlated strongly with each other (r = 0.70, p < 0.0001) 
as well as with the full scale IQ score (verbal IQ: r = 0.89, p < 0.0001; nonverbal IQ: r = 
0.93, p < 0.0001). We separated the remaining 801 probands into those with and 
without measured IQs above statistical average. It is common for individuals affected 
with ASDs to be unable to complete or be scored on an IQ test; this was the case for 
14.3% (n = 115) of probands for whom a test was attempted in the Simons sample. In 
the Simons Simplex Collection, probands who attempted to complete an eligible IQ test, 
but did receive a score, had significantly lower scores on the Vineland Scales of 
Adaptive Behavior (IQ test scored mean = 76.0, IQ test not scored mean = 60.3; t = 
15.9, p < 0.0001). A Vineland composite standard score of 60 reflects adaptive behavior 
(overall functioning and self care skills) scores nearly three standard deviations below 
the mean, or approximately in the lowest 1% of the general population, controlling for 
age. As the inability to complete an IQ test is associated with case severity, we were 
specifically interested in estimating the de novo rate among individuals with both IQ 
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above the general population mean and the behavioral capability to complete an IQ 
test—both indicators of higher functioning ASDs. The observed and expected de novo 
variants per exome are listed in Table 3.5a-b. The individuals with full scale IQ ! 100 
matched expectation for de novo variants per exome. Those individuals without 
measured IQs over 100, on the other hand, showed a global excess in de novo LoF 
variants. The results were similar when verbal and nonverbal IQ were analyzed 
separately (Table 3.5c). There was no excess of de novo LOF mutation in individuals 
with verbal (p = 0.19) or nonverbal (p = 0.48) IQ greater than 100. 
 
Overlap between gene sets of interest and de novo containing genes 
A number of gene sets have been proposed as relevant to autism or descriptive 
of an ASD biochemical pathway. Given the global excess of de novo LoF variants, we 
wanted to evaluate whether or not the list of genes that contain such mutations overlap 
more than expected with several of the proposed gene sets. 
In order to determine the significance of any observed overlap between a gene 
set of interest and the list of genes that contain de novo variants, we first determine the 
total probability of mutation for all genes on the gene set of interest. The set total is 
compared to the total probability of mutation for all genes. This percentage becomes the 
expected overlap of de novo variants with the gene set. Using the expected overlap and 
the number of variants on the de novo list, we evaluate the observed overlap between 
the de novo list and the gene set of interest by invoking the binomial. All p-values are 
one-tailed. The de novo variant list is broken down by mutation type (LoF, missense, 
and synonymous), as are the probabilities of mutation for the gene set of interest. 
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We evaluated the overlap between three de novo lists and four separate gene 
sets of interest (Figure 3.2). The gene sets of interest are a set of genes reported as 
disrupted in individuals with ASD or autistic features (Betancur)12, the set of targets of 
FMRP identified by Darnell and colleagues (FMRP)13, the set of significantly constrained 
genes that we defined earlier (Constrained), and the set of FMRP targets that are also 
constrained (Constrained FMRP). Significance was conservatively set at 0.01.  
 
Phenotype of individuals with de novo LoF mutations in FMRP targets 
Across the 1,078 individuals with ASD, there were 35 de novo LoF variants in 
targets of FMRP spread across 34 individuals (referred to as FMRP-I here)13. For those 
individuals for which we had access to phenotypic information, we extracted IQ and sex. 
We found that the FMRP-I group had significantly fewer individuals with IQ ! 100 than 
the rest of the sample set (Table 3.6a, Fisher’s exact p = 4.01x10-4). As before, 
individuals who started an IQ test but were not given an IQ score due to being severely 
impaired are included in the IQ < 100 group. To ensure that the association was not 
driven by those probands with attempted but missing IQ values, we also tested the 
association using only those individuals with estimated full scale IQ scores (Table 3.6b, 
Fisher’s exact p = 0.0021). The FMRP-I group also had a reduced male bias. Where the 
whole set of individuals is ~80% male, the FMRP-I group is only ~59%, which is a 
significant difference (Table 3.7, Chi-square p = 0.02). 
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Comparing the power of our constraint method to that of NS:S ratio 
The ratio of nonsynonymous (NS) substitutions per NS site to synonymous (S) 
substitutions per S site in a gene has been often used to determine if that gene has 
evidence of selection acting on it. A high NS:S ratio would indicate positive selection, 
while a low NS:S ratio would be evidence for purifying selection. Theoretically, our 
method of comparing observed NS variants to expectation should achieve greater 
statistical power than the NS:S comparison. To support this claim, we used the number 
of NS and S rare variants (minor allele frequency < 0.1%) found in the NHLBI’s Exome 
Sequencing Project (ESP) dataset and determined each gene’s deviation in terms of 
their ratio of S to NS sites compared to the genome-wide average. 
We removed the 134 genes where the observed synonymous and 
nonsynonymous rates were both significantly elevated or significantly depressed from 
expectation as determined by our model (both p < 0.001). These poorly sequenced or 
mapped genes – as mentioned in the main text – were also removed from our analysis 
to define constrained genes. We then identified the remaining genes that were as 
deviant from the genome-wide average as the constrained genes we defined with our 
model were from expectation (p < 0.001). Compared to the 1,003 genes defined as 
constrained by our model, this approach only identified 377 genes that showed 
evidence of purifying selection, 237 (~63%) of which were also identified as constrained 
by our method. Included in the 766 genes considered constrained only by our metric 
were a number of genes – the top ten of which include RYR2, KMT2A (MLL), KMT2D 
(MLL2), and SYNGAP1 – that have already been established as causes of autosomal or 
X-linked dominant forms of Mendelian disease (OMIM enrichment p = 5 x 10-4). 
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Since our metric was able to identify more genes that showed evidence of 
selective constraint, and especially since some of those are known to be causes of 
Mendelian disease, we conclude that our method of identifying constrained genes adds 
substantial power to the traditional approach and is an appropriate metric. 
 
Comparison of constrained genes to the RVIS metric 
Recently, Petrovski et al published a similar method to search for genes that 
appeared to be intolerant of mutations8. Their method evaluates the shift in the allele 
frequency spectrum of variants identified in genes in the ESP dataset to identify genes 
that have more rare variation. Specifically, the number of common nonsynonymous 
variants found in each gene was regressed against the total number of variants to 
determine the intolerance score. Genes with an unusually high ratio of rare to common 
variation are more likely to be intolerant of mutations and are assigned a lower residual 
variation intolerance score (RVIS). This approach is orthogonal to our metric of 
constraint since we search for a deficiency of rare nonsynonymous variation. 
We took the intersection between the two datasets to compare our metric with 
the scores provided in Petrovski et al8. This process eliminated some of the genes 
considered constrained by our metric, leaving 827 genes. Their score yielded a similar 
number of constrained genes (n = 842), which were defined as those genes with a 
residual variation intolerance score in the top 5%. 231 genes were considered 
constrained by both metrics, which is far greater than expected (0.25%, ~41 genes). 
Using a Wilcoxon rank-sum test, we found that the genes defined as constrained by our 
metric had significantly lower (more intolerant) RVIS values (p < 10-16). Similarly, the 
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genes with the top 5% RVIS had significantly higher constraint scores (Wilcoxon rank-
sum, p < 10-16). We found a correlation of -0.35 between the two scores of constraint, 
which is illustrated in Figure 3.4. 
 
Confirming the association between constraint and de novo variants 
The power to determine if a gene is significantly constrained relies on gene size. 
As mentioned above, genes where we predicted fewer than 5 rare synonymous variants 
had to be removed. In order to confirm that the association we found between constraint 
and the de novo LoF variants identified in ASD patients, we first investigated the 
relationship between constraint and the de novo variants found in unaffected 
individuals. As depicted in Figure 3.2a, we found no enrichment of de novo LoF 
variants from unaffected individuals in constrained genes. Additionally, we included 
gene length as a covariate while performing regressions of ASD de novo LoF genes on 
constraint and found that the association remained. We also took the largest 10% of 
genes and performed the regression again; constraint was still significant, but the gene 
length – when included as a covariate – showed no association. 
Our method of determining constraint generates the number of rare missense 
variants that are expected to be in each gene. As an alternative metric to constraint, we 
also evaluated the fraction of missense variation that was not seen, a metric that is 
completely independent of gene size. We found that, in a linear regression, the fraction 
of missing missense variation was significantly able to predict whether a gene was 
haploinsufficient (p = 2.13x10-12). 
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For our final analyses to confirm that our enrichment analysis was not biased 
towards bigger genes, we created a list of the largest 5% of genes and queried the de 
novo loss-of-function variants identified in unaffected individuals. We expect that there 
should be no significant relationship between de novo LoF variants in unaffected 
individuals and these large genes. When we use a simple logistic regression to explain 
the de novo LoF genes in unaffected individuals, we find an odds ratio (OR) of about 
5.5, which describes a highly significant enrichment of big genes. Our method of 
determining enrichment, however, accounts for the expected mutation rate of each gene 
– thereby inherently incorporating gene size – and shows this set of mutations is not 
actually “enriched” at all (p = 0.425; fold enrichment/OR = 1.1). These de novo LoF 
mutations in unaffected individuals are occurring in exactly the chance proportion they 
should be in larger genes. We therefore conclude that the enrichment analysis central to 
our interpretation of ASD events is not affected by gene lists being non-random with 
respect to size. 
 
Comparison of three different metrics of constraint 
Our metric is one way of searching for genes that appear to be relatively 
intolerant of mutations in the human population. One approach is the residual variation 
intolerance score (RVIS) created by Petrovski and colleagues8, which evaluates the 
relative excess of rare variants to common ones in genes. Since Petrovski et al did not 
define a list of intolerant genes in their paper, we defined such a list by taking the top 
5.5% most intolerant genes according to their metric. 5.5% was selected since that is 
the percentage of genes that we define as constrained using our metric. An additional 
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alternative comes from Bustamante et al, who used both fixed and polymorphic 
synonymous and nonsynonymous sites to find genes that appear to be affected by 
selection, including 813 loci that appeared to be under negative selection16. 
We sought to compare both our constraint score and list of constrained genes 
with the results of these other approaches. To do this, we focused on the ability to 
predict known haploinsufficient genes (as defined in OMIM) and the enrichment of these 
genes with de novo LoF mutations identified in ASD patients. Our results are 
summarized in Table 3.8. For the quantitative metrics (our constraint score and the 
RVIS metric), we performed a linear regression between haploinsufficient genes and the 
score with gene size as a covariate. While both metrics have significant predictive 
ability, our constraint score outperforms RVIS slightly (t-value = 10.011 for constraint,    
-9.561 for RVIS). For the list-based comparison, we used a logistic regression with gene 
length as a covariate. In this comparison, the top 5.5% intolerant genes according to 
RVIS had an odds ratio (OR) of ~5.5, while the constrained gene set that we defined 
had an OR of 4.9, both of which were significant. The genes identified by Bustamante 
and colleagues showed no significance (Table 3.8a). 
We also evaluated the fraction of these different sets of constrained genes that 
contained a de novo LoF in ASD cases. Our method, as explained above, determines 
the fraction of constrained genes that are expected to contain a de novo mutation by 
chance. We then evaluate the observed fraction and can determine both the fold 
enrichment and significance. When we evaluated the three previously mentioned lists of 
genes – our constrained, top 5.5% intolerant genes using RVIS8, and the loci identified 
by Bustamante16 – we found that our list of constrained genes had the greatest fold 
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enrichment of genes that contained a de novo LoF in ASD cases (p = 3.58x10-6; Table 
3.11b). The top 5.5% of genes identified using RVIS also performed well (fold 
enrichment of 1.9, p = 5.36x10-5), but the loci from Bustamante et al showed no 
significant enrichment. 
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Chapter 4 
Leveraging large reference populations to identify functionally constrained genes 
 
 
 
 
Work presented in this chapter will be published as part of: 
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. 
Under review. 
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Abstract 
Large-scale exome sequencing efforts of reference populations have greatly 
improved both clinical and functional interpretation of genetic variation. We analyzed the 
variation identified in 60,706 individuals included in the Exome Aggregation Consortium 
(ExAC) dataset to identify genes under strong selective constraint. Of particular interest 
is the set of 3,230 genes that are significantly depleted of loss-of-function variation. 
These constrained genes are enriched for established haploinsufficient and dominant 
disease genes, and represent core biological processes (e.g. spliceosome and 
proteasome). However, only 28% have been associated with a human disease 
phenotype; those that have not yet been associated promise to be a fruitful set to further 
investigate both within the clinic and in functional studies. 
 
Introduction 
One of the major challenges within the field of human genetics is determining 
which variant, or set of variants, is associated to disease. High-throughput DNA 
sequencing technologies have aided this effort by allowing researchers to investigate 
nearly all single nucleotide and small insertion and deletion (indel) variants within an 
individual’s genome or exome (the 1% of the genome that codes for proteins). 
Unfortunately, each individual harbors tens of thousands of variants and examining 
each of these variants would be a long and laborious task. 
To make the task of associating variation to disease, it is critical to be able to 
prioritize variants and define a subset for further analysis. There are many variant-level 
prioritization tools1-3, but we have found that using gene’s intolerance of 
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nonsynonymous variation can also aid in variant interpretation4,5. Identifying these 
constrained genes depends on the availability of exome sequencing datasets of large 
reference populations. While both the 1000 Genomes Project6 and the National Heart, 
Lung and Blood Institute’s Exome Sequence Project7 publically released the protein-
coding variation from thousands of individuals (n = 2,504 and 6,503, respectively), the 
size of these datasets restricted researcher’s ability to identify genes that are intolerant 
of loss-of-function variation. 
Here, we describe using the Exome Aggregation Consortium (ExAC), which is an 
order of magnitude larger than previously released datasets (n = 60,706), to evaluate 
missense and loss-of-function constraint. 
 
Results 
The deep ascertainment of rare variation in the Exome Aggregation Consortium 
(ExAC) allows us to infer the extent of selection against variant categories on a per-
gene basis by examining the proportion of variation that is missing compared to 
expectations under random mutation. Conceptually similar approaches have been 
applied to smaller exome datasets4,5 but have been underpowered, particularly when 
analyzing the depletion of loss-of-function (LoF) variants. We compared the observed 
number of rare (minor allele frequency [MAF] < 0.1%) variants per gene to an expected 
number derived from a selection neutral, sequence-context based mutational model5 
(Chapter 3). The model performs well in predicting the number of synonymous variants, 
which should be under minimal selection, per gene (r = 0.98; Figure 4.1). 
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a) Synonymous     b) Missense 
 
 
c) Loss-of-function 
 
 
Figure 4.1. The correlation between observed and expected variant counts for 
synonymous (a), missense (b), and loss-of-function (c) variants. The line shows a 
perfect correlation (slope = 1). Axes have been trimmed to remove TTN. 
 
We quantified deviation from expectation with a Z score5, which for synonymous 
variants is centered at zero, but is significantly shifted towards higher values (greater 
constraint) for both missense and LoF (Wilcoxon p < 10-50 for both; Figure 4.2). The 
genes on the X chromosome are significantly more constrained than those on the 
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autosomes for missense (p < 10-7) and loss-of-function (p < 10-50). The high correlation 
between the observed and expected number of synonymous variants on the X 
chromosome (r = 0.97 versus 0.98 for autosomes) indicates that this difference in 
constraint is not due to a calibration issue. To reduce confounding by coding sequence 
length for LoFs, we developed an expectation-maximization algorithm (see Materials 
and Methods) using the observed and expected LoF counts within each gene to 
separate genes into three categories: null (tolerant of homozygous LoFs), recessive 
(tolerant only of heterozygous LoFs), and haploinsufficient (intolerant of homozygous 
LoFs). This metric – the probability of being loss-of-function intolerant (pLI) – separates 
genes of sufficient length into LoF intolerant (pLI ! 0.9, n = 3,230) or LoF tolerant (pLI # 
0.1, n = 10,374) categories. pLI is less correlated with coding sequence length (r = 0.17 
as compared to 0.57 for the LoF Z score), outperforms the LoF Z score as an 
intolerance metric (discussed more in Materials and Methods), and reveals the 
expected contrast between gene lists (Figure 4.3). 
Additionally, pLI is positively correlated with a gene product’s number of physical 
interaction partners (p < 10-41). The most constrained pathways (highest median pLI for 
the genes in the pathway) are core biological processes (spliceosome, ribosome, and 
proteasome components; Kolmogorov-Smirnov [KS] test p < 10-6 for all) while olfactory 
receptors are among the least constrained pathways (KS test p < 10-16), demonstrated 
in Figure 4.3 and consistent with previous work8-12. 
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Figure 4.2. The distribution of Z scores for synonymous (gray), missense (orange), and 
loss-of-function (red) for 18,225 genes. This measure of departure of number of variants 
from expectation is normally distributed for synonymous variants, but right-shifted 
(higher constraint) for missense and loss-of-function variants, indicating that more 
genes are intolerant to these classes of variation. 
 
Critically, we note that LoF-intolerant genes include virtually all known severe 
haploinsufficient human disease genes (Figure 4.3), but that 72% of these genes have 
not yet been assigned a human disease phenotype despite clear evidence for extreme 
selective constraint. Many of these genes (79%) specifically do not have a disease-
associated variant in ClinVar13 (a database that collects evidence for pathogenicity of 
variants). We note that this extreme constraint does not necessarily reflect a lethal 
disease, but is likely to point to genes where heterozygous loss-of-function confers 
some non-trivial survival or reproductive disadvantage. 
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Figure 4.3. The proportion of genes in gene sets that are very likely intolerant of loss-of-
function variation. pLI close to one indicates extreme intolerance to loss-of-function 
variation; we therefore take pLI ! 0.9 as the cut-off for extreme loss-of-function 
intolerance. The black error bars indicate a 95% confidence interval. olfactory = 
olfactory receptor genes (n = 371); recessive = recessive disease genes from Blekhman 
and Berg (n = 1,183); all (n = 18,225); dominant = dominant disease genes from 
Blekhman and Berg (n = 709); mouse hom = genes that are lethal in mice when both 
copies are knocked out (n = 2,760); essential = genes that are essential in cell culture 
as curated by Hart et al 2014 (n = 285); mouse het = genes that are lethal in mice when 
one copy is knocked out (n = 387); mild HI = haploinsufficient genes that cause a mild 
disease (n = 59); mouse cond = genes that are lethal in mice when conditionally 
knocked out in adult mice (n = 402); moderate HI = haploinsufficient genes that cause 
moderately severe disease (n = 77); severe HI = haploinsufficient genes that cause 
severe disease (n = 44). 
 
fraction of genes with pLI >= 0.9
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
olfactory
recessive
all
dominant
mouse hom
essential
mouse het
mild HI
mouse cond
moderate HI
severe HI
!! 93 
The most highly constrained missense (top 25% missense Z scores) and LoF 
(pLI !0.9) genes show higher expression levels and broader tissue expression than the 
least constrained genes14 (Figure 4.4). These most highly constrained genes are also 
depleted for eQTLs (p < 10-9 for missense and LoF; Figure 4.5a), yet are enriched 
within genome-wide significant trait-associated loci ($2 p < 10-14, Figure 4.5b). 
Intuitively, genes intolerant of LoF variation are dosage sensitive: natural selection does 
not tolerate a 50% deficit in expression due to the loss of single allele. Unsurprisingly, 
these genes are also depleted of common genetic variants that have a large enough 
effect on expression to be detected as eQTLs with current limited sample sizes. 
However, smaller changes in the expression of these genes, through weaker eQTLs or 
functional variants, are more likely to contribute to medically relevant phenotypes. 
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a) Median gene expression across all tissues for bins of constraint 
 
 
 
b) Number of tissues where the gene is expressed for bins of constraint 
 
 
 
Figure 4.4. Expression patterns of genes for bins of constraint. For synonymous and 
missense Z, the bins are: bottom quartile (< 25%), two middle quartiles grouped 
together, and top quartile (> 75%). For pLI: pLI # 0.1, 0.1 < pLI < 0.9, and pLI ! 0.9. 
Note pLI is the metric used for loss-of-function (LoF) intolerance. (a) The median gene 
expression, in log2(RPKM), across all tissues for bins of constraint. (b) The relationship 
between constraint and the number of tissues in which a gene is expressed at an RPKM 
> 0.1. Synonymous Z scores show no correlation with the number of tissues in which a 
gene is expressed, but the least missense- and LoF-constrained genes tend to be 
expressed in fewer tissues. Thick black bars indicate the first to third quartiles, with the 
white circle marking the median. 
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a) Enrichment of eQTLs    b) Enrichment of GWAS loci 
 
 
 
Figure 4.5. Signals of eQTL and GWAS loci enrichment for constraint bins. For 
synonymous and missense Z, the bins are: bottom quartile (< 25%), two middle 
quartiles grouped together, and top quartile (> 75%). For pLI: pLI # 0.1, 0.1 < pLI < 0.9, 
and pLI ! 0.9. (a) The proportion of eGenes (a gene with a significant eQTL at a false 
discovery rate [FDR] of 5%) found in whole blood samples from GTEx14 for each 
constraint bin. Highly missense- and LoF-constrained genes are less likely to have 
eQTLs as the average gene. No relationship between synonymous genes and eQTLs is 
observed. (b) Enriched of GWAS loci downloaded from the Catalog15 for each constraint 
bin. Highly missense- and LoF-constrained genes are more likely to be adjacent to 
GWAS signals than the average gene, but no relationship is seen for synonymous Z 
bins. Shaded regions around the lines indicate 95% confidence intervals. 
 
Discussion 
The large sample size of the ExAC dataset provided the opportunity to analyze 
the sensitivity of human genes to nonsynonymous variation. While previous sample 
sizes have been adequately powered for the assessment of gene-level intolerance to 
missense variation4,5, ExAC provides for the first time sufficient power to investigate 
genic intolerance to loss-of-function (LoF) variants. 
We created pLI—the probability of being loss-of-function intolerant—to identify 
highly LoF constrained genes and highlighted 3,230 that were significantly depleted of 
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LoF variation. Comparing pLI to the LoF Z score revealed that pLI was better able to 
predict haploinsufficient genes and had a greater enrichment of de novo LoFs identified 
in 3,982 cases with an autism spectrum disorder16,17. We also compared pLI to a 
previous metric developed to predict haploinsufficient genes called p(HI)18. Our metric 
was able to identify twice as many genes at same cut off as p(HI)—indicating increased 
sensitivity of our metric—but a larger proportion of the genes in the high p(HI) tail are 
considered likely haploinsufficient by both metrics. The subset of genes that are 
considered likely haploinsufficient (! 0.8) by both metrics shows the greatest enrichment 
of ClinGen haploinsufficient genes when compared to genes uniquely flagged by each 
metric. Therefore, there would be benefit in combining the two metrics in a future 
measure of haploinsufficiency. 
The 3,230 severely LoF constrained genes represent core biological processes 
and include many dominant and haploinsufficient disease genes. The established 
disease genes, however, do not explain the majority of the highly LoF-intolerant genes; 
only 28% of genes with a pLI ! 0.9 have a human disease phenotype listed in OMIM or 
ClinVar13. Further investigation will likely reveal genes that, when disrupted, cause 
embryonic lethality as well as additional disease genes that have yet to be tied to 
specific phenotypes. These results suggest that this set of genes will be able to aid in 
the interpretation of genetic variation identified in patients. 
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Materials and Methods 
Establishing the expected number of variants per gene 
Probabilities of a mutation 
Our metrics to evaluate a gene’s intolerance to variation—their level of 
constraint—rely on comparing the observed variant counts to an expectation. In order to 
determine the expected number of variants per gene, we modified a previous method 
described in detail in Chapter 3. We used the mutation rate table created for Samocha 
et al5 to determine the probability of mutation, split by mutational class (synonymous, 
missense, nonsense, and splice site), for each exon in the canonical transcript. As 
before, we adjusted the probabilities of mutation for regional divergence between 
humans and macaques. Two major changes were made between the previous version 
of the method and the one used in this paper: (1) we now used GENCODE v19 
annotations for transcripts instead of Refseq and (2) the expected number of variants, 
and not the probability of mutation, is adjusted for depth of sequencing coverage (see 
below). Here, we focused on the canonical transcript as defined by Ensembl v75 for 
each protein-coding gene and drop all transcripts that do not begin with a methionine, 
end with a stop codon, or whose length are not divisible by three. After all of these 
filters, there were 19,620 canonical transcripts that are used in all following analyses. 
 
Determining the depth of coverage correction 
We used the Exome Aggregation Consortium (ExAC; n = 60,706) dataset and 
extracted the number of rare (minor allele frequency < 0.1%) single nucleotide variants 
for every exon of the canonical transcripts. These variants were assigned functional 
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classes (synonymous, missense, nonsense, and splice site) based on the amino acid 
change or position in the splice site. We then needed a way to account for the depth of 
sequencing coverage since regions that are poorly sequenced will, by definition, have 
fewer variants than expected. To do this, we determined the median depth of coverage 
for each exon. Given that synonymous variants are most likely to be free of extreme 
negative selection, we focused on those variants. Using only those exons with a median 
depth ! 50, which we consider to be well sequenced, we regressed the number of rare 
synonymous variants on the probability of a synonymous mutation to determine the 
appropriate formula to predict the number of expected synonymous variants. This 
formula was applied to all exons (regardless of depth). To find the appropriate way to 
correct for sequencing coverage, we grouped exons by depth (bins of 2) and 
determined the sums of all observed and expected synonymous variants in these 
exons. The sum of observed synonymous variants divided by the sum of expected 
variants had a logarithmic relationship between depth bins of 0 and 50, where it then 
plateaued at ~1 (Figure 4.6). We fit the curve to determine the appropriate depth of 
coverage correction for exons with a median depth between 1 and 50. 
 !"#$!!!"#$%&'"!!"#$% ! ! !"#!$%!&!!"#$%!!"#$%&!!"#$!! ! !"!"#!$%!&!!"#$% ! !!!!"# ! !!!"# ! !" !"#$%&!!"#$! ! ! ! ! "#$%&!!"#$! ! !"!!!!"# ! !"#!$%!&!!"#$%!!"#$%&!!"#$! ! !  
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Figure 4.6. The relationship between the median depth of exons and the sum of all 
observed synonymous variants in those exons divided by the sum of all expected 
synonymous variants. 
 
Expected number of variants 
To determine the depth-corrected expected number of variants per exon, we 
used those exons with a median depth ! 50 and regressed the number of rare 
synonymous variants on the probability of a synonymous mutation. These regressions 
were done separately for the autosomes with the pseudo-autosomal regions (PAR) of 
the X chromosome, the non-PAR regions of the X chromosome, and the Y 
chromosome. The resulting formulas were used to predict the depth-uncorrected 
expected number of synonymous, missense, and loss-of-function variants (LoFs; 
nonsense and splice site) variants for all exons. The correlation between the observed 
and depth-uncorrected expected number of synonymous variants per exon was 0.8360. 
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We then corrected these expected numbers by the above equation and observed an 
increased correlation between observed and depth-corrected expected synonymous 
variants (r = 0.9283). Note that from this point forward, the expected number of variants 
always refers to the depth-corrected counts. 
 
Creation of the constraint metric 
Determining Z scores of the deviation of observation from expectation 
We created a signed Z score to establish the significance of the deviation of 
observed variant counts per gene from expectation as in Chapter 3 with minor 
modifications. To start, we sum all exon level variant counts across canonical 
transcripts. Here, the observed count is the number of unique variants with a VQSLOD 
! -2.632 and 123 or fewer alternative alleles (minor allele frequency cut off of ~0.1%). If 
an exon had a median depth < 1, the variant counts for that exon were not included in 
the total for the transcript. We then removed all transcripts where no variants were 
observed. For the remaining 18,466 transcripts, we calculated the chi-squared value for 
the deviation of observation from expectation for each mutational class: synonymous, 
missense, and loss-of-function (LoF). The square root of these values is multiplied by -1 
if the number of observed variants is greater than expectation (or 1 if observed counts 
are smaller than expected) to create the Z score. 
A critical next step is to correct the scores so that the synonymous Z scores 
followed an approximately normal distribution. For the synonymous Z scores, we used a 
subset of transcripts whose synonymous Z scores fell in between -5 and 5. All 
synonymous Z scores were divided by the standard deviation of this outlier-removed 
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subset to create the corrected Z scores. A slightly different approach was used for 
missense and LoF Z scores. We took all transcripts with a missense Z score between -5 
and 0 and combined them with those same Z scores multiplied by -1 (to create a 
mirrored distribution). All missense Z scores were divided by the standard deviation of 
the mirrored distribution to create the corrected missense Z scores. The same 
procedure was applied to the LoF Z scores. 
 
Removing outliers 
We then used these corrected Z scores to define outlier transcripts—specifically 
those with significantly elevated synonymous and missense counts or significantly 
depleted synonymous and missense counts. These outliers were defined as transcripts 
with a synonymous Z < -3.71 and a missense Z < -3.09 or transcripts with a 
synonymous Z > 3.71 and a missense Z > 3.09. These filters removed a total of 241 
transcripts, leaving 18,225 for all further analyses. The distribution of the synonymous, 
missense, and LoF Z scores are depicted in Figure 4.2. Note that a Z score of ~3.09 is 
equivalent to a p-value of 10-3 and is considered the significance threshold when 
splitting transcripts into constrained and unconstrained classes. 
 
Correlation of observed and expected counts 
For the set of 18,225 cleaned transcripts, the correlation between the number of 
observed rare (minor allele frequency < 0.1%) synonymous variants and the expected 
number of variants given the above model is 0.9776. This correlation is higher than 
simply regressing the observed synonymous variants against number of coding bases 
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in the gene (r = 0.9201), or the probability of a synonymous mutation (r = 0.9349). This 
relationship between observed and expected mutation counts can be seen for 
synonymous, missense, and LoF variants in Figure 4.1. 
 
Power of the Z score analyses 
To achieve a Z score of 3.09 (a p-value equivalent of 10-3), the number of 
expected variants would need to be a minimum of 10. Following this criterion, 99.5% of 
transcripts could be evaluated for missense constraint. However, only 11,437 transcripts 
(62.8%) were mutable enough to have 10 or more expected LoFs in the ExAC dataset 
(see below). 
 
Z score distributions for gene lists 
We next investigated the synonymous, missense, and LoF Z score distributions 
for the following gene lists: autosomal recessive19,20, autosomal dominant19,20, essential 
in cell culture21, ClinGen haploinsufficient, FMRP interactors22, and olfactory 
receptors23. For the synonymous Z scores (Figure 4.7), most gene lists match the 
distribution of the full set of canonical transcripts (median Z = 0.05). The only notable 
exception is the list of olfactory receptors, which show 118% of the expected 
synonymous variation (Wilcoxon p < 10-46). 
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Figure 4.7. Distribution of synonymous Z scores for gene sets. Wilcoxon p-value for 
difference from the full distribution, the number of genes in the set, and the percentage 
of expected variation observed are reported on the right. 
 
Across all canonical transcripts, ~89% of all missense variation is observed and 
the median missense Z score is 0.51. As a note, higher (more positive) Z scores 
indicate increased selective constraint, while negative Z scores are given for transcripts 
where more variation was seen than expected. All of the gene sets tested significantly 
differ from the overall distribution (Figure 4.8) with the recessive genes and olfactory 
receptors showing slightly lower missense Z scores. The rest of the gene sets have 
significantly higher missense Z scores (Wilcoxon p < 10-28). 
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Figure 4.8. Distribution of missense Z scores for gene sets. Wilcoxon p-value for 
difference from the full distribution, the number of genes in the set, and the percentage 
of expected variation observed are reported on the right. 
 
The LoF Z scores have the most skewed distributions (Figure 4.9). Overall, only 
39% of the expected loss-of-function variation is observed, giving the full set of 
canonical transcripts a median LoF Z score of 1.97. The Z scores for the autosomal 
recessive genes match the overall distribution fairly closely (Wilcoxon p = 0.02, median 
= 2.09). The olfactory receptors, as before, have significantly lower LoF Z scores 
(Wilcoxon p < 10-50, median = 0.16), but unlike with synonymous and missense do not 
have more loss-of-function variation than expected (95% observed). 
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Figure 4.9. Distribution of loss-of-function Z scores for gene sets. Wilcoxon p-value for 
difference from the full distribution, the number of genes in the set, and the percentage 
of expected variation observed are reported on the right. 
 
Creation of a new loss-of-function constraint score 
The LoF Z score is correlated with gene length 
The Z scores were created to evaluate the significance of the deviation of 
observed counts from expectation. Given this, it is sensitive to differences in power. For 
example, a gene with 0 observed variants would require ~10-11 expected variants to 
pass a significance threshold of 10-3 (Z score of 3.09). The expected number of variants 
per gene is based on the length and mutability of the transcript. Since the probability of 
having a loss-of-function mutation is small (roughly an order of magnitude less than the 
probability of a missense mutation), only 63% of the canonical transcripts are expected 
to have 10 or more LoFs in the ExAC dataset (59% if expecting 11 LoFs). 
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Due to this reliance on mutability, it is unsurprising that the LoF Z score is 
correlated with the coding length of the transcript (r = 0.5697; Figure 4.10a). This 
correlation is not seen for the missense Z score (r = 0.0566; Figure 4.10b). Therefore, 
larger transcripts will have more significant LoF deviations (and Z scores) than smaller 
transcripts and some transcripts that are truly intolerant of loss-of-function variation will 
be too small to achieve statistical significance. These results motivated the search for a 
better metric to capture LoF constraint (discussed below). 
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a) Loss-of-function 
 
 
b) Missense 
 
 
 
Figure 4.10. The correlation between the length of the gene and the Z score. (a) The 
correlation for the loss-of-function Z score. The Pearson’s r between the two is 0.5697. 
(b) The correlation for the missense Z score. The Pearson’s r between the two is 
0.0566. The black line shows the linear relationship. Axes have been trimmed to 
remove TTN. 
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Evaluating the ratio of missing loss-of-function variation 
A natural metric to evaluate intolerance to loss-of-function variation is the amount 
of expected variation that was not observed. Truly intolerant transcripts should be 
missing most of the expected variation, which is independent of the length of the 
transcript. We defined the ratio of missing variation as one minus the quotient of the 
observed counts divided by the expected counts. 
The correlation between the length of the transcript and the ratio of missing loss-
of-function variation is 0.1561 (Figure 4.11). The distributions of the ratio of missing 
synonymous, missense, and loss-of-function variation are depicted in Figure 4.12a. The 
majority of transcripts fall between 0 and 1 for the ratio of missing LoF variation, where 
1 means the transcript is completely devoid of LoF variation. Both the synonymous and 
missense distributions shift towards transcripts having more of their expected variation. 
 
 
 
Figure 4.11. The relationship between gene length and the ratio of missing loss-of-
function variation. The Pearson’s r between the two is 0.1561. The x-axis was trimmed 
to remove TTN and the y-axis was cut at -1.5 (out of -4) to show pattern of the data. 
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a) Distribution of the ratio of missing expected variation for synonymous, missense, and 
loss-of-function 
 
 
 
b) The ratio of missing loss-of-function variation for gene lists 
 
 
 
Figure 4.12. Distributions of the ratio of missing variation. Note that 1 means there were 
no variants observed and negative values indicate more variation observed than 
expected. (a) The distribution of the ratio of missing expected variation for synonymous, 
missense, and loss-of-function. The x-axis has been trimmed at -8 (out of -18) to 
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Figure 4.12 (Continued) highlight the patterns of the data. (b) The ratio of missing loss-
of-function variation for gene sets. The median ratio of missing loss-of-function variation 
for all genes is indicated by the dashed red line. The x-axis has been trimmed at -2 (out 
of -5) to highlight the patterns of the data. 
 
The ratio of missing LoF variation is depicted for the gene lists used above in 
Figure 4.12b. All gene sets are significantly different from the set of all canonical 
transcripts (referred to as “All genes” in the figure; Wilcoxon p < 10-10 for all). Autosomal 
recessive genes and olfactory receptors have slightly more of their expected LoF 
variation than the set of all transcripts. The rest of the gene sets are significantly more 
depleted for the expected LoF variation than the full set of transcripts. The most striking 
signal comes from the haploinsufficient genes, none of which have more LoF variation 
than expected. 
 
Creation of pLI 
One of the main goals of this work was to identify genes that are intolerant of 
loss-of-function variation. Given the continuous nature of the ratio of missing loss-of-
function variation, it is slightly challenging to do this. To address this challenge, we 
estimated the probability of being loss-of-function intolerant (pLI) using the expectation-
maximization (EM) algorithm. 
The underlying premise of this analysis is to assign genes to one of three natural 
categories with respect to sensitivity to loss-of-function variation: null (where loss-of-
function variation – heterozygous or homozygous - is completely tolerated by natural 
selection), recessive (where heterozygous LoFs are tolerated but homozygous LoFs are 
not), and haploinsufficient (where heterozygous LoFs are not tolerated). We assume 
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tolerant (null) genes would have the expected amount of LoF variation and then took the 
empirical mean observed/expected rate of LoF variation for recessive disease genes 
(0.463) and severe haploinsufficient genes (0.089) to represent the average outcome of 
the homozygous and heterozygous intolerant scenarios respectively. These values (1.0, 
0.463, 0.089) are then used as a three-state model to which we fit the 
observed/expected LoF variant rate of each gene via the following analysis. 
Let ! !! !!!"## !!!"# !!!"! represent the proportion of all genes that fall into each 
of the three proposed categories: null, recessive, and haploinsufficient. 
Let *+,--, *.$/, and *01 denote the expected amount of loss-of-function depletion in 
each of the three categories. Based on the observed depletion of LoF variation in the 
autosomal recessive19,20 and ClinGen dosage sensitivity gene sets, we use: 
! "#$%%!9!(!! "&'(!9!)"*&$!! ")*!9!)"),+!
For each gene 2, we model the observed data (LoF counts) as a function of the 
unobserved class labels (32) as follows: ! !! !!!!! !!"#!!!"## !!!"# !!!"!!! !"#! !!!!! ! !!"#$!!!!!!!
Here, 4'52 represents the observed number of LoFs in gene 2 and + is sample 
size, such that !!!! is the expected number of loss-of-function variants in a gene 
belonging to class 32 in the ExAC data. Our goal is to find the maximum-likelihood 
estimate (MLE) for 6 (the mixing weights of the three gene classes), and to use this 
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estimate to obtain an Empirical Bayes maximum a posteriori (MAP) estimate for 32 – the 
probability of gene assignment to each category – for all genes 2789:.  
We use an expectation-maximization (EM) algorithm to find the MLE for 6 and 32, 
treating 6 as the parameters and the 32 as the latent variables. We initialize the EM 
algorithm by setting !! ! !! ! ! ! ! ! ! !!. 
In the E-step, we evaluate the distribution of the latent variables (32) given the 
values of the parameters (6) from the previous iteration. The E-step is 
! !! !!!!! ! !"#! ! !"#$ !"#! ! ! !!!!!!!"#$ !"#! ! ! !!!!!!! !!
where !"#$ denotes the Poisson likelihood. In the M-step, we update the parameters 6 
with a new expectation taken under the distribution of the latent variables (32) computed 
in the M step. The update is !!"# !! ! ! !! !!!!"#!!!!"# !!"#$#%!  
We repeat these steps until the convergence criteria are met (!!" changes by 
less than 0.001 from one iteration to the next). 
When the EM has converged, the final mixing weights are used to determine 
each gene’s probability of belonging to each of the categories (null, recessive, 
haploinsufficient). ! !!! "## ! !"#$ !"#! ! ! "!"##!!! !!! "# ! !"#$ !"#! ! !"!"#!!! !!! " ! !"#$ !"#! ! ! "!"!!
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The final metric, pLI (the probability of being loss-of-function intolerant): 
!"# ! !!! "!! !
The closer pLI is to 1, the more likely the transcript is loss-of-function intolerant. 
The overall distribution of pLI is fairly bimodal, with most genes looking either tolerant or 
intolerant of loss-of-function variation (Figure 4.13a, right panel). Additionally, pLI is only 
modestly correlated with transcript length (r = 0.1668; Figure 4.13b). However, we find 
that the most highly LoF-intolerant genes (pLI ! 0.9) are significantly longer than all 
genes (Wilcoxon p < 10-50; Figure 4.14a). The least intolerant genes are also 
significantly—but to a lesser extent—larger than all genes (Wilcoxon p < 10-3; Figure 
4.14b). 
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a) Distributions of pNull, pRec, and pLI 
 
 
 
b) Relationship between transcript coding length and pLI 
 
 
 
Figure 4.13. Properties of pNull, pRec, and pLI. (a) The distribution of pNull, pRec, and 
pLI across all transcripts. The distribution is roughly bimodal for each. (b) The 
relationship between pLI and the number of coding bases in each gene. The Pearson’s 
r is 0.1668. 
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a) Highly loss-of-function intolerant genes (pLI ! 0.9) 
 
 
 
b) Least loss-of-function intolerant genes (pLI # 0.1) 
 
 
 
Figure 4.14. The distribution of gene length (bp) for all genes and those genes with high 
and low pLI values versus all genes. (a) The highly LoF intolerant genes (pLI ! 0.9) are 
significantly longer than all genes (Wilcoxon p < 10-50). (b) The least LoF intolerant 
genes (pLI # 0.1) are slightly significantly longer than all genes (Wilcoxon p = 5 x 10-4). 
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In order to additionally confirm that the pLI metric was free of confounding with 
gene length, we compare the gene size distribution of genes with a pLI ! 0.99 versus 
genes that had the pLI equivalent for falling into the recessive category (pRec) ! 0.99. 
pRec is determined by the equation below: 
!"#$ ! !!! "#!! !
We find no significant difference in the distribution of gene length between genes 
with pLI ! 0.99 (n = 1,803) and genes with pRec ! 0.99 (n = 1,145; p = 0.3032; depicted 
in Figure 4.15). 
 
 
 
Figure 4.15.  The distribution of gene length for high pLI and pRec genes. There is no 
significant difference between gene length (in base pairs [bp]) for genes with pLI ! 0.99 
or pRec ! 0.99 (p = 0.3032). 
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We also show that longer genes are, in general, more depleted of LoF variation 
(observed/expected), which can explain the enrichment of long genes in the set of 
genes with pLI ! 0.9. There is a relationship between deciles of gene length (bins of 
increasing gene length) and the observed depletion of LoFs in that bin: longer genes 
(deciles closer to 1) have a significantly lower rate of observed/expected (p < 10-50; 
Figure 4.16). 
 
 
 
Figure 4.16. The relationship between deciles of gene length and the amount of 
expected variation observed. Longer genes (higher decile numbers) have a significantly 
lower rate of observed/expected loss-of-function (LoF) variation (p < 10-50). 
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= 4.43x10-8; loss-of-function p = 2.50x10-75). The high correlation between the observed 
and expected number of synonymous variants on the X chromosome (r = 0.9677 vs 
0.9777 for autosomes) indicates that this difference in constraint is not due to a 
calibration issue. 
We find that 3,230 (17.7%) of genes are confidently considered extremely loss-
of-function intolerant since their pLI is 0.9 or greater. Similarly, there are 3,463 (19.0%) 
and 1,226 (6.7%) genes with pRec or pNull ! 0.9, respectively. pRec and pNull also 
show fairly bimodal distributions (Figure 4.13, middle and left panels, respectively). As 
a warning, while we consider pLI to be a valuable metric to identify genes that appear 
haploinsufficient, we caution against using pRec as a similar metric for recessive 
disease genes. An appropriate recessive disease gene metric would benefit from 
including information about the site frequency spectrum of variants observed in the 
gene, among other properties. 
 
Comparison to a previous haploinsufficiency metric: p(HI) 
Our metric to evaluate loss-of-function intolerance was designed to identify 
genes that are intolerant of heterozygous loss-of-function variants, which would mean 
that these genes are likely acting via haploinsufficiency. Previously, Huang et al (2010) 
designed p(HI)—the probability of being haploinsufficient18—to determine how likely 
each gene was to be haploinsufficient. Huang and colleagues made this metric by using 
properties of established haploinsufficient and haplosufficient genes to train a predictive 
model. The properties included in the final model were “dN/dS between human and 
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macaque, promoter sequence, embryonic expression and network proximity to known 
HI [haploinsufficient] genes”18. 
In order to compare pLI and Huang’s p(HI), we took the 18,064 genes that had 
values for both metrics. Since p(HI) was trained on a set of haploinsufficient genes, we 
removed 64 genes that were part of their training data set and considered to be 
haploinsufficient by ClinGen’s Dosage Sensitivity Map, which left 18,000 genes for 
analysis. While there are 3,175 genes in this set with pLI ! 0.9, there are only 613 with 
p(HI) ! 0.9. For this reason, we dropped the cut-off to 0.8, giving 3,878 genes for pLI 
and 1,061 for p(HI). 
Within the 18,000 genes, 148 are considered haploinsufficient by ClinGen, 109 of 
which have a pLI ! 0.8. By contrast, only 51 of the 148 haploinsufficient genes have a 
p(HI) ! 0.8, and 80% of those (n = 41) also have pLI ! 0.8. Our metric identifies twice as 
many genes at the same cut off, but a larger proportion of the genes in the high p(HI) 
tail are considered likely haploinsufficient by both metrics. 
Table 4.1a and b depict the breakdown of all genes and ClinGen 
haploinsufficient genes, respectively, by their pLI and p(HI) values. We took those data 
and found the enrichment of ClinGen haploinsufficient genes in the high pLI and p(HI) 
tails by setting as baseline the fraction of ClinGen haploinsufficient genes with pLI and 
p(HI) < 0.8 compared to all genes in that category (n = 29 and 13,681, respectively). 
The fraction of each other category was compared to this baseline to determine the 
enrichment of genes that fall into each of the other categories (pLI < 0.8 and p(HI) ! 0.8, 
etc.) and is shown in Table 4.1c.  Genes uniquely flagged by both metrics have similar 
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enrichments (10 for pLI versus 10.8 for p(HI)). The real enrichment, however, is found in 
the subset of genes that are considered likely haploinsufficient (! 0.8) by both metrics. 
 
Table 4.1. Probability of Loss of Function (pLI) and Probability of Haploinsufficient ( 
p(HI)) counts for all genes and ClinGen. The breakdown of all genes (a) and ClinGen 
haploinsufficient genes (b) by their pLI and p(HI) values. (c) The enrichment of ClinGen 
haploinsufficient genes that fall into the high pLI and p(HI) tails when taking the fraction 
of ClinGen genes with pLI and p(HI) < 0.8 compared to all genes. 
 
a) Breakdown of all genes (n = 18,000) by their pLI and p(HI) values 
 
 p(HI) < 0.8 p(HI) ! 0.8 
pLI < 0.8 13681 441 
pLI ! 0.8 3258 620 
 
b. Breakdown of ClinGen haploinsufficient genes (n = 148) by their pLI and p(HI) values 
 
 p(HI) < 0.8 p(HI) ! 0.8 
pLI < 0.8 29 10 
pLI ! 0.8 68 41 
 
c. Enrichment of ClinGen haploinsufficient genes in each pLI and p(HI) category 
 
 p(HI) < 0.8 p(HI) ! 0.8 
pLI < 0.8 1.0 10.8 
pLI ! 0.8 10.0 31.6 
 
Evaluating loss-of-function constraint metrics 
To determine which of the three protein-truncating constraint metrics (LoF Z, ratio 
of missing LoF variation, and pLI) is the most useful to use as a general LoF intolerance 
measure, we perform two tests: (1) the ability to predict known haploinsufficient genes 
and (2) enrichment of de novo LoFs found in autism spectrum disorder cases. 
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We perform a logistic regression using the three LoF constraint metrics to predict 
inclusion in the ClinGen haploinsufficient gene list. For all regressions, transcript length 
is included as a covariate. pLI has the highest Z-value (14.314), reflecting a more 
significant ability to predict haploinsufficient genes. The Z-value for LoF Z is 11.307 and 
is 12.164 for the ratio of missing protein-truncating variation. 
For the enrichment of de novo LoFs, we use the published de novo variants from 
3,982 cases with autism and 2,078 controls16,17 and a previously described method that 
controls for the mutability of each gene (see Chapter 3)5. In brief, the probability of 
mutation (for a specific mutation type) is summed across all genes in a gene set and 
compared to the total probability of mutation (of the same type) for all genes. That 
fraction becomes the expected fraction of genes in the gene set that should harbor a de 
novo variant of the same type. We evaluate the observed overlap between the de novo 
list and the gene set of interest by invoking the binomial. 
Since this method requires an established gene set, we took genes with pLI ! 0.9 
(n = 3,230) and matched the set size using the genes with the highest LoF Z scores and 
ratio of missing LoF variation. While the fold enrichment is greatest for the ratio of 
missing LoF variation (enrichment = 1.9, p < 10-21), pLI still outperforms the LoF Z score 
(Table 4.2). No significant enrichments are seen when using the control de novo LoFs 
(fold enrichments between 0.81 and 0.91). 
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Table 4.2. The enrichment of de novo loss-of-function variants (LoFs) from autism 
cases with the top loss-of-function intolerant genes as defined by LoF Z, the ratio of 
missing LoF variation, and pLI. 
 
 LoF Z > 3.891 
(n = 3,230) 
Ratio missing LoFs  > 0.9061 
(n = 3,230) 
pLI ! 0.9 
(n = 3,230) 
LoF fold enrichment 1.3656 1.9224 1.6290 
p-value 5.07x10-12 5.12x10-22 8.31x10-20 
 
Applications of pLI 
Given pLI’s superior performance in predicting haploinsufficient genes and 
clearer interpretability than the ratio of missing LoF variation, we chose to use pLI as 
our main metric of LoF intolerance. 
Established haploinsufficient genes are enriched in the high pLI tail (pLI ! 0.9, $2 
p < 10-50; Figure 4.3). Of note, the enrichment in pLI stratifies with the severity of the 
disease caused by the haploinsufficient genes with increasingly severe phenotypes 
showing increased enrichment in the highly LoF-intolerant genes (manually curated 
from the ClinGen dosage sensitivity list). Critically, we note that LoF-intolerant genes 
include virtually all known severe haploinsufficient human disease genes (Figure 4.3), 
but that 79% of these genes do not have a disease-associated variant listed in ClinVar13 
despite the clear evidence for extreme selective constraint. 
The targets of FMRP22 are also strongly enriched in the high pLI tail (pLI ! 0.9, $2 
p < 10-50; Figure 4.3). Dominant disease genes19,20 and those essential in cell culture21, 
however, are more evenly split between the two categories, but still enriched for pLI ! 
0.9 ($2 p < 10-30 and p < 10-23, respectively). Olfactory receptors23 and recessive 
disease genes19,20 have low pLI scores overall, indicating that these sets are not likely 
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haploinsufficient. These results do not mean that recessive genes are not important to 
disease, but that they can on average tolerate a heterozygous LoF. 
We also studied three gene lists that correspond to genes found in mice: those 
genes that are lethal as homozygous knock outs, genes that are lethal as heterozygous 
knock outs, and genes that are lethal when conditionally knocked out in adult mice 
(mouse gene lists were provided by Joanne Berghout from JAX). As depicted in Figure 
4.3, the conditional lethal genes are the most enriched in the most LoF-intolerant genes, 
followed by the heterozygous lethal, and then the homozygous lethal genes. 
 
Gene expression and eQTLs 
To further understand the characteristics of constrained genes we investigate the 
association of the synonymous Z score, missense Z score, and pLI with various gene 
expression and regulation metrics utilizing the multi-tissue gene expression data from 
the Genotype-Tissue Expression (GTEx) project14 (GTEx Analysis V4, dbGaP 
Accession phs000424.v4.p1) spanning 53 tissue types sampled from 212 post-mortem 
donors downloaded from the GTEx portal (http://www.gtexportal.org) on July 29, 2015. 
The medians of log2-transformed RPKM values for each tissue are correlated 
with the constraint scores after excluding sex chromosomal transcripts and transcripts 
not expressed in the given tissue (i.e. median RPKM = 0). Given the high correlation in 
gene expression between the various brain regions sampled in GTEx, a composite 
measure for brain expression is created by taking the median expression values for 
each gene across these eleven brain tissue types (only one of the duplicate 
measurements for each cerebellum and cortex was included). This composite brain 
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expression measure is used instead of the individual brain regions when the per-gene 
median and maximum expression values across all tissues are calculated and similarly 
when the total number of tissues a given gene is expressed in is determined, therefore 
giving 41 as the maximum number of tissues in which a gene can be detected. 
Consistently in each tissue, gene expression level is strongly and positively 
correlated with missense Z score and pLI, a result that is further strengthened after 
accounting for gene coding sequence length. The association with synonymous Z 
score, however, is non-significant or considerably subtler. Similar patterns of 
association are observed for the median and maximum gene expression across tissues 
(median gene expression is depicted in Figure 4.4a). Also, the total number of tissues a 
gene is expressed in is positively correlated with missense Z score and pLI at different 
RPKM cutoffs (Figure 4.4b; Figure 4.17). 
 
 
 
Figure 4.17. The relationship between constraint and tissue expression at different 
RPKM cutoffs for constraint bins. For synonymous and missense Z, the bins are: bottom 
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Figure 4.17 (Continued) quartile (< 25%), two middle quartiles grouped together, and 
top quartile (> 75%). For pLI: pLI # 0.1, 0.1 < pLI < 0.9, and pLI ! 0.9. 
 
The relationship between the constraint scores and gene regulatory variation 
detected in the GTEx dataset is investigated in the 13 tissues with the largest sample 
sizes (expression and genotype data available for >60 individuals) that were included in 
the GTEx V4 eQTL analyses (Adipose – Subcutaneous, Artery - Aorta, Artery – Tibial, 
Esophagus - Mucosa, Esophagus - Muscularis, Heart - Left Ventricle, Lung, Muscle – 
Skeletal, Nerve – Tibial, Skin - Sun Exposed (Lower leg), Stomach, Thyroid and Whole 
Blood). The eQTL analysis follows the steps described in detail in the GTEx pilot phase 
manuscript14. 
Dividing the analyzed transcripts into three subsets based on their constraint 
scores (for Z: bottom quartile (<25%), the two middle quartiles grouped, top quartile 
(>75%); for pLI: pLI # 0.1, 0.1 < pLI < 0.9, pLI !0.9), we calculate the proportion of 
eGenes, i.e. a gene with a significant eQTL (FDR 5%), out of all genes included in the 
eQTL analysis (expressed in at least ten individuals at >0.1 RPKM) in each of the 
constraint subsets for each of the 13 tissues and for synonymous, missense and LoF 
constraint scores separately. The power for eQTL discovery varies widely from tissue to 
tissue given the sample sizes per tissue, which range from 74 (Artery - Aorta) to 168 
(Whole Blood). Independent of the total number of eGenes discovered, in each tissue, 
the most missense and loss-of-function constrained group of genes are significantly 
depleted of eGenes compared to the least constrained group (e.g. in skeletal muscle, p 
< 10-24 for pLI ). Such pattern is not seen when grouping the genes based on their 
constraint for synonymous variation. To have a metric comparable between tissues, we 
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further normalize these eGene proportions by the total number of eGenes discovered in 
each tissue. Figure 4.5a shows the average proportion of eGenes in whole blood 
clearly demonstrating both the depletion (59.57% of the average for pLI) of eGenes 
among the most and enrichment (125.11% of the average for pLI) among the least 
missense and loss-of-function constrained genes. 
 
Enrichment of GWAS signals 
Next we investigate the same synonymous Z score, missense Z score, and pLI in 
the Genome-wide Association Studies (GWAS) Catalog15 for the closest gene to signal; 
see Gene List table below) [Hindorff et al, Accessed 02/04/2015]. We filter results to 
include only those GWAS signals that had been reported with a p < 5.0x10-8. In order to 
categorize GWAS results by ontologies, we only include those signals that have been 
mapped in the “Experimental Factor Ontology” (EFO, http://www.ebi.ac.uk/efo). We find 
2,792 unique genes that have been listed in the Catalog and for which we have Z 
scores and pLI.   
As performed in previous analyses, we divide variants by functional categories: 
synonymous, missense and loss-of-function, and each category was further divided in 
three constraint groups: Lowest (0 - 25% quantile for Z; pLI # 0.1), Middle (25 – 75% 
quantile for Z; 0.1 < pLI < 0.9) and Highest (75 – 100% quantile for Z; pLI ! 0.9). Then 
we estimate the enrichment of genes in the GWAS catalogue as: 
  !! ! !!! ! ! 
 !! ! !!"#$! !"#$ 
 ! ! !! !"#$ 
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where: !; is the proportion of GWAS genes in the quantile " 
and < is a scaling factor (number of evaluated genes divided by number of GWAS hits) 
The standard error for the proportions are similarly scaled: 
  !" ! ! !! !!!!!!! ! !! 
 
We estimate the significance of the difference in the number of GWAS loci of 
highest versus the lowest constraint scores using a !2 test. 
While only the loss-of-function category shows a clear and significant difference 
between the highest and the lowest constraint scores, we note a pattern in the 
missense category where the less constrained genes have higher, albeit not significant, 
proportion of GWAS hits than the middle category (Figure 4.5b).  
To better characterize this pattern we divide the GWAS hits by major EFO 
categories: Cancer, Cardiovascular, Digestive, Immune, Metabolic, Nervous, Response 
to drug, Body measure and Others, and compare the least constrained genes versus 
the middle category as well as the most constrained genes versus the middle category 
(Figure 4.18). Again, we see that on average, GWAS hits are enriched in the most LoF 
constrained genes and depleted in the least constrained. In this sub-analysis we also 
identify an enrichment of Cardiovascular, Metabolic, and body measurement GWAS hits 
in the most missense constrained genes, while these categories with enrichments were 
non-significant in least missense constraint genes. 
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Figure 4.18. The odds ratio of being a GWAS hit for each Experimental Factor Ontology 
trait for the most constrained genes versus the middle bin. For synonymous and 
missense Z, the bins are: bottom quartile (< 25%), two middle quartiles grouped 
together, and top quartile (> 75%). For pLI: pLI # 0.1, 0.1 < pLI < 0.9, and pLI ! 0.9. 
 
Networks and pathway analysis 
To better understand the set of genes considered intolerant of loss-of-function 
variation, we use the STRING database24 to obtain a network of experimentally 
Synonymous
OR
0.4 0.8 1.2 1.6 2.0
Cancer
Cardiovascular
Digestive
Immune
Metabolic
Nervous
Response to drug
.Body measure
.Other
ALL
Missense
OR
1.0 1.5 2.0
LoF
OR
1.0 1.5 2.0 2.5
!! 129 
supported protein-protein physical interactions. The network consists of 14,160 genes 
(nodes) and 712,137 physical interactions (edges). For each gene, we compute the 
number of neighbors it has in the network (degree of the node), which corresponds to 
the number of interaction partners its encoded protein has. We run a linear regression 
between the pLI score of a gene and its number of interaction partners and find that 
genes with more partners are more likely to have high pLI scores (t-test p < 10-41). A 
weaker positive correlation is found between the number of interaction partners and the 
missense Z score of a gene (t-test p < 10-8). A weak negative correlation is observed 
between the number of partners and the synonymous Z score (t-test p < 10-6).  
The list of 186 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
were obtained from Broad Institute GSEA. Each pathway is represented by the list of 
pLI scores for each of the genes in the pathway. For each pathway, we compute the 
Kolmogorov-Smirnov (KS) statistic between its list of pLI scores and the pLI scores of all 
the genes to quantify the enrichment or depletion of pLI for this pathway. Fifty-eight 
pathways show significant deviations in pLI from the rest of the genes at multiple-testing 
adjusted p-value of 10-7 (Table 4.3). 
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Table 4.3. 58 KEGG pathways that show significant deviations in pLI. 
 
Pathway name p-value Median pLI 
Number 
of 
genes 
Fraction of 
genes with 
duplication 
KEGG_ACUTE_MYELOID_LEUKEMIA 1.13E-12 0.966868135 55 0.090909091 
KEGG_SPLICEOSOME 3.22E-24 0.962186023 119 0.042016807 
KEGG_ADHERENS_JUNCTION 9.98E-16 0.954642795 72 0.041666667 
KEGG_PROSTATE_CANCER 4.65E-17 0.953884196 88 0.045454545 
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 2.39E-12 0.953566812 74 0.067567568 
KEGG_ENDOMETRIAL_CANCER 2.22E-09 0.945932366 50 0.04 
KEGG_PROTEASOME 4.46E-07 0.939368296 44 0.068181818 
KEGG_NON_SMALL_CELL_LUNG_CANCER 6.81E-11 0.937024402 53 0.056603774 
KEGG_LONG_TERM_POTENTIATION 1.38E-09 0.934189798 69 0.115942029 
KEGG_RENAL_CELL_CARCINOMA 9.26E-15 0.934189798 69 0.043478261 
KEGG_CHRONIC_MYELOID_LEUKEMIA 8.58E-16 0.927847096 72 0.069444444 
KEGG_PANCREATIC_CANCER 1.93E-12 0.914702778 69 0.057971014 
KEGG_GLIOMA 3.49E-14 0.912772901 65 0.107692308 
KEGG_SMALL_CELL_LUNG_CANCER 1.95E-10 0.912222953 83 0.108433735 
KEGG_THYROID_CANCER 4.84E-06 0.907173398 28 0.035714286 
KEGG_MTOR_SIGNALING_PATHWAY 1.08E-06 0.898304164 51 0.019607843 
KEGG_WNT_SIGNALING_PATHWAY 5.43E-20 0.894082823 142 0.077464789 
KEGG_AXON_GUIDANCE 3.44E-15 0.889436552 125 0.168 
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 4.10E-17 0.879812545 132 0.060606061 
KEGG_MELANOMA 2.06E-10 0.86533156 69 0.057971014 
KEGG_ERBB_SIGNALING_PATHWAY 1.54E-12 0.855133233 86 0.046511628 
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 4.18E-18 0.833673302 124 0.10483871 
KEGG_GAP_JUNCTION 1.50E-07 0.832476903 86 0.174418605 
KEGG_COLORECTAL_CANCER 1.96E-11 0.82592172 60 0.033333333 
KEGG_PATHWAYS_IN_CANCER 4.59E-31 0.817693684 315 0.082539683 
KEGG_RIBOSOME 3.00E-22 0.791160924 86 0.046511628 
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 2.49E-10 0.787536053 94 0.106382979 
KEGG_TGF_BETA_SIGNALING_PATHWAY 3.23E-09 0.774529936 83 0.120481928 
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 5.22E-11 0.774064994 106 0.075471698 
KEGG_MAPK_SIGNALING_PATHWAY 1.11E-20 0.726173344 257 0.062256809 
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 2.92E-14 0.702854984 209 0.081339713 
KEGG_HEDGEHOG_SIGNALING_PATHWAY 6.08E-06 0.68038415 55 0.163636364 
KEGG_BASAL_CELL_CARCINOMA 3.18E-06 0.68038415 51 0.117647059 
KEGG_PROGESTERONE_MEDIATED_OOCYTE 
_MATURATION 1.04E-08 0.657005772 84 0.107142857 
KEGG_ENDOCYTOSIS 3.16E-11 0.656574472 175 0.08 
KEGG_ALDOSTERONE_REGULATED_SODIUM 
_REABSORPTION 5.41E-06 0.641391597 41 0.146341463 
KEGG_OOCYTE_MEIOSIS 6.30E-10 0.634553384 110 0.045454545 
KEGG_FOCAL_ADHESION 1.84E-12 0.629287802 196 0.12755102 
KEGG_CELL_CYCLE 1.18E-10 0.618667023 122 0.024590164 
KEGG_MELANOGENESIS 5.89E-07 0.596680215 97 0.18556701 
KEGG_CHEMOKINE_SIGNALING_PATHWAY 3.53E-14 0.42745098 185 0.210810811 
KEGG_CARDIAC_MUSCLE_CONTRACTION 9.89E-06 0.324238693 71 0.070422535 
KEGG_HUNTINGTONS_DISEASE 2.45E-07 0.301784519 170 0.070588235 
KEGG_ALZHEIMERS_DISEASE 1.36E-06 0.218440721 155 0.096774194 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR 
_INTERACTION 8.60E-06 0.09785415 257 0.249027237 
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Table 4.3 (Continued)"!!
pathway name p-value median pLI 
number 
of 
genes 
fraction of 
genes with 
duplication 
KEGG_OLFACTORY_TRANSDUCTION 4.42E-17 0.005113489 376 0.909574468 
KEGG_ARACHIDONIC_ACID_METABOLISM 2.04E-06 2.36E-05 58 0.431034483 
KEGG_STEROID_HORMONE_BIOSYNTHESIS 3.81E-07 3.67E-06 54 0.685185185 
KEGG_METABOLISM_OF_XENOBIOTICS_BY 
_CYTOCHROME_P450 9.30E-10 3.49E-06 69 0.753623188 
KEGG_PENTOSE_AND_GLUCURONATE 
_INTERCONVERSIONS 7.42E-09 2.34E-06 27 0.703703704 
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 1.64E-09 9.11E-07 71 0.774647887 
KEGG_RETINOL_METABOLISM 9.25E-12 2.93E-07 63 0.714285714 
KEGG_DRUG_METABOLISM_OTHER_ENZYMES 2.12E-09 2.93E-07 51 0.588235294 
KEGG_LINOLEIC_ACID_METABOLISM 1.37E-06 2.82E-07 29 0.586206897 
KEGG_OTHER_GLYCAN_DEGRADATION 8.57E-06 2.77E-07 16 0 
KEGG_ABC_TRANSPORTERS 1.65E-07 4.44E-08 44 0.272727273 
KEGG_ASCORBATE_AND_ALDARATE 
_METABOLISM 1.51E-08 3.50E-08 25 0.8 
KEGG_STARCH_AND_SUCROSE_METABOLISM 4.60E-09 3.06E-08 50 0.52 
 
 
For each pathway, we quantify the degree of its redundancy by computing the 
fraction of its genes with a duplication in the human genome25. Among the highly 
constrained pathways (highest median pLI for the genes in the pathway) are core 
biological processes (spliceosome, ribosome, and proteasome components; KS test p < 
10-6 for all) while olfactory receptors are among the least constrained pathways (KS test 
p < 10-16). More surprisingly, we identify multiple metabolic pathways, such as starch 
and sucrose metabolism (KS test p < 10-9), as being highly unconstrained. Members of 
these pathways are also likely to have paralogous genes in the human genome. 
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Chapter 5 
Investigating patterns of regional missense constraint within genes 
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Abstract 
The identification of constrained genes has already proven useful when 
analyzing genetic variation, particularly within a clinical context. Treating the whole gene 
as a unit does not take advantage of the known function of elements within the gene, 
but was necessary when using smaller exome sequencing datasets. The size of the 
recently released Exome Aggregation Consortium (ExAC; n = 60,706 individuals) now 
permits the evaluation of constraint of regions within genes. Loss-of-function variants 
typically have the same effect no matter where they occur in the gene, but the 
deleteriousness of missense variants varies depending both on the location of the 
variant in the gene and the specific amino acid substitution. In this work, we use the 
ExAC dataset to identify patterns of regional missense constraint within genes and 
show that these constrained regions are enriched for both established pathogenic 
variants and de novo missense variants found in patients with a neurodevelopmental 
disorder. We additionally created a metric—which includes information about local 
missense depletion and amino acid substitution deleteriousness among other 
features—to aid in the prioritization of missense variants. Compared to multiple other 
metrics, it is the best predictor of missense variant pathogenicity and will ultimately 
improve variant interpretation of clinical exomes. 
 
Introduction 
The availability of large-scale exome sequencing datasets has provided the 
opportunity to better understand patterns and rates of variation within the human 
population. These resources permit the identification of genetic sequences that are 
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intolerant of nonsynonymous variation (constrained) and therefore more likely to be 
associated to disease. One signature of strong selective constraint is the depletion of 
nonsynonymous variation within reference populations of individuals. There is also a 
shift in the allele frequency spectrum of the remaining variants to increasingly rare 
variation. Both signatures have previously been evaluated in a set of 6,503 individuals 
from the National Heart, Lung and Blood Institute’s Exome Sequencing Project (ESP)1 
to identify genes that are significantly missense constrained (Chapter 3)2,3. More 
recently, similar methods have been applied to the Exome Aggregation Consortium 
dataset (n = 60,706) and found genes intolerant of loss-of-function variation (Chapter 4). 
The constrained genes identified in all studies were enriched for known disease genes 
and harbored significantly more de novo loss-of-function variants identified in cases with 
severe neurodevelopmental disorders, establishing their medical relevance. 
Identifying constrained genes has already proven to be useful in the 
interpretation of patient variation4. However, it is well known that missense variants can 
have dramatically different effects, depending on where they occur in the gene and the 
specific amino acid substitution. While the ESP dataset was not well powered to 
evaluate missense intolerance of sub-genic regions, the ExAC dataset permits such 
investigations. Determining a domain’s intolerance to variation would highlight the 
functional components that are most sensitive to perturbation. Unfortunately, protein 
domain information is not known for all genes. We therefore use the exon as a basis to 
evaluate regional patterns of missense constraint within genes so that the method may 
be applied globally. In this work, we describe a method to perform this analysis and find 
that 15% of genes show evidence of variability in missense constraint. 
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We also sought to use the depletion of missense variation in the region where a 
variant resides to aid in variant interpretation. There are many tools to predict the 
deleteriousness of missense variants5-7 and to evaluate specific amino acid 
substitutions8,9. We create a score that measures the increased deleteriousness of 
amino acid substitutions when they occur in missense-constrained regions. We then 
combine information from orthogonal deleteriousness into one metric (MPC), which 
outperforms all other metrics at separating pathogenic and benign missense variants. 
To evaluate the usefulness of our metric outside of established disease-
associated variants, we study newly arising (de novo) missense variants identified in 
cases with a neurodevelopmental disorder. Over the last 5 years, there have been 
many large-scale sequencing projects of parent-child trios to evaluate the role of de 
novo variation and identify genes and pathways relevant to disease etiology. These 
studies have focused primarily on neurodevelopmental disorders, such as intellectual 
disability10,11, developmental delay12, and epileptic encephalopathy13. These studies 
have established an important, but modest, role of de novo variation in these diseases. 
The largest excesses were seen for de novo loss-of-function variation, which have 
become the main focus for follow up research. However, there is also a significant 
enrichment of de novo missense variants in these patients, but it is modest (1.2 fold), 
indicating that a subset of the variants are disease-related but the majority are not. We 
find that the most missense constrained genes and regions contain nearly all of the 
excess of de novo missense variation in the neurodevelopmental cases and additionally 
show that MPC promises to be a powerful way to prioritize missense variants. 
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Results 
Searching for regional missense constraint within transcripts 
We used a set of 18,225 transcripts (see Materials and Methods for transcript 
filtering) and, for every exon, extracted rare (minor allele frequency [MAF] < 0.1%) 
missense variants from the Exome Aggregation Consortium (ExAC; n = 60,706) dataset 
and predicted the expected number as described previously (Chapters 3 and 4)3. 
To define regions within transcripts that were specifically missense constrained, 
we applied a likelihood ratio test to determine the break in between neighboring exons 
that most significantly (by $2) splits the transcript into two regions with varying levels of 
missense depletion. If the largest (most significant) $2 was above our significance 
threshold (! 10.8; p < 10-3), we then similarly searched for a way to continue to split the 
transcript into regions until the best $2 fell below our significance threshold. If the 
transcript did not have strong enough evidence to be split into two regions, we tested 
two breaks at a time to recover transcripts that have a depleted region in the middle. We 
only accepted the two-break model if the $2 was 13.8 (p < 10-4) or larger. The method is 
depicted in Figure 5.1. 
Applying this method to 18,225 transcripts, we found evidence of regional 
differences in missense depletion in 2,671 transcripts (14.7%) with 1,700 having one 
significant break (being split into 2 segments), 919 with 3 breaks, and 52 with three or 
more breaks (Table 5.1). 
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Figure 5.1. Visual of the method to find regional constraint within transcripts. The 
example transcript has four exons. First, all possible breaks in between exons are 
tested and the $2 are collected. If the largest $2 ! 10.8 (p < ~10-3), the method searches 
for a second significant break while keeping the first break set (here, the break between 
exons B and C). This process continues until the largest $2 obtained is less than 10.8 
and, at that point, the last significant model is kept. If a transcript does not have 
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Figure 5.1 (Continued) evidence of a significant single break, the method searches for 
two breaks at a time. If the largest $2 ! 13.8 (p < ~10-4), then that two break model is 
kept as the result. Otherwise, the transcript is considered to have no evidence of 
regional missense constraint. 
 
Table 5.1. Distribution of significant breaks for all canonical transcripts. 
 
Number of breaks Number of transcripts Percentage of transcripts 
0 15,554 85.3 
1 1,700 9.3 
2 919 5.0 
3 35 0.2 
4 14 0.1 
5 2 < 0.1 
6 1 < 0.1 
 
 We plotted the fraction of expected variation observed (%) for all full transcripts 
and the regions of transcripts that were split by our method (Figure 5.2). While most 
transcripts and regions of transcripts have the expected amount of missense variation, 
there is an excess of missense-depleted regions, particularly when % < 0.8. All coding 
sequence above 0.8 does not appear to be missense constrained, so we focus our 
future analyses on those transcripts and regions with % < 0.8. Within the missense 
constrained transcripts and regions, we further subdivided into four quartiles: [0-0.2], 
(0.2-0.4], (0.4-0.6], and (0.6-0.8]. 
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Figure 5.2. The distribution of the fraction of expected missense variation observed 
(observed/expected, also referred to as %) for all transcripts and regions of transcripts. 
The dashed black line represents the mirror of the distribution above one. The solid red 
line indicates the threshold between likely missense constrained regions (% # 0.8) and 
regions that show no evidence of regional missense constraint (% > 0.8). The dashed 
gray lines demarcate the % quartiles used in later analyses: [0-0.2], (0.2-0.4], (0.4-0.6], 
and (0.6-0.8]. 
 
ClinVar variants and regional depletion 
Given that the transcripts and regions with % # 0.8 are depleted of missense 
variation, we hypothesized that they would be enriched of disease-associated missense 
variants. We therefore extracted pathogenic variants from ClinVar14 to evaluate any 
potential enrichments. Since our method is focused on finding regions that are intolerant 
of heterozygous missense variants, we selected only those variants that disrupt 
haploinsufficient genes known to cause severe disease (n = 440 variants). 
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While the missense-constrained regions (% # 0.8) represent about a third of all 
coding bases, they contain the great majority of the pathogenic ClinVar variants (2.7 
fold enriched; p < 10-50; Table 5.2). However, almost all of this enrichment is found in 
those transcripts and regions that have % # 0.6: 82.7% of ClinVar variants vs 15.6% of 
coding bases (5.3 fold enriched; p < 10-50). These data indicate that the transcripts and 
regions in between 0.6 and 0.8 have a similar signature as the missense unconstrained 
transcripts and regions and are therefore less likely to harbor pathogenic variation that 
causes severe disease when disrupted. 
 
Table 5.2. Shown for each bin of missense depletion is the count (N) and percentage 
(%) of coding base pairs (in megabase pairs [Mbp]), pathogenic or likely pathogenic 
variants from ClinVar14 in haploinsufficient genes that cause severe disease (ClinVar). 
The range of missense depletion (fraction of expected missense variation observed) is 
provided in the first column (%). 
 
" (obs/exp) N Mbp % Mbp N ClinVar % ClinVar 
[0, 0.2] 0.7 2.21% 25 5.68% 
(0.2, 0.4] 1.4 4.34 141 32.05 
(0.4, 0.6] 2.9 9.06 198 45.00 
(0.6, 0.8] 5.1 15.97 8 1.82 
> 0.8 22.0 68.42 68 15.45 
 
Of the 44 severe haploinsufficient genes, 24 (55%) have evidence of regional 
variability in missense constraint, and of this subset 18 (75%) contain both 
unconstrained and constrained regions. As an example, the first 9 exons of CDKL5 
have only 25% of their expected variation ($2 = 52.5), but the last 11 have 81% ($2 = 
6.4). ClinVar lists 43 pathogenic or likely pathogenic missense variants in CDKL5, 39 
(91%) of which are found in the constrained regions (Figure 5.3). Three of the 
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remaining variants are in the first 50 base pairs (bp) of exon 10 and lie in the kinase 
domain that extends 66 bp into that exon. 
 
 
 
Figure 5.3. Distribution of ClinVar14 pathogenic and likely pathogenic variants in 
CDKL5. Variants are indicated with a star. 91% of the variants (39/43) fall into the first 9 
exons, which are significantly constrained (gamma = 0.25, $2 = 52.5). The constrained 
region is marked with a bar. 
 
Using regional constraint to interpret de novo variation 
The ClinVar variants have been established as pathogenic, but we wanted to test 
if our regional missense depletion results of the regions could aid in prioritization of 
variants identified in patients. We chose to study de novo missense variants from cases 
with a neurodevelopmental disorder (n = 1,640)10-13 due to the significant, but modest, 
excess of de novo missense variants in these cases (1.2 fold enriched; p = 2.3x10-11; 
Table 5.3). The de novo missense variants from 2,078 unaffected siblings of autism 
cases were used as controls15,16. 
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Table 5.3. Counts, fold enrichment, and significance of de novo variants. The observed 
counts (Obs), expected counts (Exp), fold enrichment (Fold), and p-value for 
synonymous (Syn), missense (Mis), and loss-of-function (LoF; nonsense, essential 
splice site, and frameshift) variants are presented for control trios15,16, developmental 
delay (DDD)12, intellectual disability (ID)10,11, epileptic encephalopathy (EE)13, and all 
neurodevelopmental cases (a combination of DDD, ID, and EE; all neuro). 
 
  Control DDD ID EE All neuro 
 N trios 2078 1133 151 356 1640 
Sy
n 
Obs 506 263 28 89 380 
Exp 582.68 317.70 42.34 99.82 459.87 
Fold 0.8684 0.8278 0.6613 0.8916 0.8263 
p-value 0.0013 0.0018 0.0254 0.3007 0.0001 
M
is
 Obs 1215 868 106 278 1252 Exp 1308.86 713.64 95.11 224.23 1032.98 
Fold 0.9283 1.2163 1.1145 1.2398 1.2120 
p-value 0.0046 1.23x10-8 0.1437 0.0003 2.30x10-11 
Lo
F 
Obs 184 233 36 59 328 
Exp 181.71 99.07 13.20 31.13 143.41 
Fold 1.0126 2.3518 2.7265 1.8953 2.2872 
p-value 0.5868 1.91x10-30 1.69x10-7 5.57x10-6 8.05x10-40 
 
As depicted in Figure 5.4, the distribution of control de novo missense variants 
between bins of missense depletion follows the distribution seen for coding base pairs. 
For example, 71.4% of the control variants are in regions with % > 0.8, which represent 
68.4% of all coding bases. By contrast, the de novo missense variants identified in 
patients with a neurodevelopmental disorder are enriched in the most missense-
depleted regions. This is seen most strongly, as for the ClinVar variants, in regions with 
% # 0.6 (2 fold enriched, p < 10-17). 
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Figure 5.4. Fraction of base pairs and variants for each constraint bin. Shown for each 
bin of missense depletion (e.g. % > 0.8) is the fraction of coding base pairs (base pairs), 
de novo missense variants from 2,078 control trios (control dn mis)15,16, de novo 
missense variants from 1,640 cases with a neurodevelopmental disorder (neurodev dn 
mis)10-13, and pathogenic or likely pathogenic missense variants from ClinVar14 in 
haploinsufficient genes that cause severe disease (severe HI variants). Lighter blues 
indicate greater missense depletion. 
 
We then compared the rate of de novo missense variants in cases to the rate in 
controls across missense constraint bins. If a region or transcript is tolerant of missense 
variation, we expect it to have the same rate of de novo variation in cases as in controls, 
reflecting the background rate of mutation (1:1). However, if the region is intolerant of 
missense variation—and therefore more likely to be associated to disease—we expect 
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to find a higher rate of de novo variants found in cases compared to the rate in controls 
(>1:1). As expected, the least missense-constrained bin (% > 0.8) is indistinguishable 
from one (Figure 5.5; Table 5.4). While the most depleted two bins (% # 0.4) show a 
much higher rate of de novo missense variants in cases than in controls (OR > 4.5), 
there is no difference in the fourth bin (0.6 < % # 0.8). Regions and genes with more 
modest missense depletion (0.4 < % # 0.6) have an intermediate OR of 2.3, supporting 
that there is power is using the quantitative depletion of missense variation and not 
solely a threshold. 
 
 
 
Figure 5.5. Comparison of the rate of case de novo missense variants to control de 
novo missense variants by bins of missense depletion. The case variants come from 
1,640 trios with a neurodevelopmental disorder10-13 and the control variants were 
identified in 2,078 control trios15,16. The dashed gray line indicates a ratio of one. 95% 
confidence intervals are depicted around each point estimate. 
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Table 5.4. Shown for each bin of missense depletion is the count (N) and percentage 
(%) of coding base pairs (in megabase pairs [Mbp]) for de novo missense variants 
found in 1,640 trios with a neurodevelopmental disorder (case dn)10-13 and those from 
2,078 control trios (control dn)15,16. The last column (C:C dn rate) provides the ratio of 
the neurodevelopmental case to control de novo missense rate. The first column lists 
the range of missense depletion (fraction of expected missense variation observed; !). 
 
" (obs/exp) N Mbp % bp N case dn 
% case 
dn 
N control 
dn 
% control 
dn 
C:C 
dn rate 
(0, 0.2] 0.7 2.21% 52 4.33% 14 1.19% 4.5877 
(0.2, 0.4] 1.4 4.34 146 12.16 38 3.23 4.8215 
(0.4, 0.6] 2.9 9.06 170 14.15 94 7.99 2.2861 
(0.6, 0.8] 5.1 15.97 163 13.57 190 16.16 1.0875 
> 0.8 22.0 68.42 670 55.79 840 71.43 1.0179 
 
Combining the three most depleted bins together (% # 0.6), there are 0.21 de 
novo missense variants per case exome and only 0.05 per control exome. However, 
this enrichment disappears when % > 0.6 (0.51 events per case exome versus 0.50 in 
controls). It is important to note, however, that a majority (56%) of the de novo variants 
found in cases are in transcripts and regions are not considered missense constrained 
(% > 0.8). These analyses have refined the signal of de novo variant enrichment and 
have shrunk the number of candidate pathogenic variants from 1,201 to 368. 
Taken together, these analyses indicate that the signal for both established 
pathogenic variants as well as the excess of de novo missense variants in cases with a 
neurodevelopmental disorder can be found in those transcripts and regions with 60% or 
less of their expected missense variation. 
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Measuring the increased deleteriousness of amino acid substitutions 
While the gene or region disrupted by a missense variant is important to 
consider, it is also critical to consider the specific type of amino acid substitution that 
occurred. Major changes in the physiochemical properties of the side chain are 
expected to have larger effects on the protein than more subtle changes. The 
deleteriousness of these changes has been quantified in a variety of metrics, the two 
most common of which are BLOSUM9 and Grantham8. Here, we postulated that there 
may be specific amino acid substitutions that are preferentially eliminated when they 
occur in the most missense depleted regions of the exome. 
To measure the increased deleteriousness of amino acid substitutions when they 
occur in the constrained regions of the exome, we tabulated all possible amino acid-to-
amino acid substitutions that could occur in the exome via a single nucleotide mutation 
as well as the number observed in ExAC (with MAF < 0.1%). The rate of possible 
substitutions observed was determined for constrained (% # 0.8) and unconstrained (% > 
0.8) regions separately; in almost all instances, we observed a higher rate in the 
unconstrained regions, including for synonymous variants. The fold difference between 
the rate in the unconstrained and constrained regions clusters for synonymous changes 
around one and is in the 2.5-3 range for nonsense, with missense values falling 
primarily in between the two (Figure 5.6). 
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Figure 5.6. The fold difference between the rate of possible amino acid substitutions 
observed in unconstrained versus constrained regions. All possible amino acid 
substitutions that could be created by a single nucleotide mutation were tallied for 
unconstrained (% > 0.8) and constrained (% # 0.8) regions of the exome. The observed 
rate of the possible substitutions was calculated and the fold difference between that 
observed in the unconstrained regions versus the constrained regions is plotted. 
Synonymous substitutions are in gray; missense in orange; and nonsense in red. The 
dashed lines indicate the median of the fold differences for all synonymous substitutions 
(gray) and nonsense substitutions (red). 
 
We used the normalized fold difference of missense substitutions (“missense 
badness”) as a measure of the increased deleteriousness of amino acid substitutions 
when they occur in constrained genes and regions. As expected, this score has a high 
correlation with BLOSUM and Grantham scores (r = -0.6327 and 0.5255, respectively; 
Figure 5.7). Interestingly, we find that leucine to isoleucine substitutions are not among 
the most tolerant amino acid substitutions based on missense badness (missense 
badness = 0.42) even though the two are isoforms of each other. By contrast, both the 
BLOSUM and Grantham scores for this substitution indicate tolerance of the substitution 
(BLOSUM = 2; Grantham = 5). On the other side, serine to leucine substitutions—which 
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is a change from a hydrophilic to a hydrophobic side chain—are considered deleterious 
by BLOSUM (-2) and Grantham (145), but not by missense badness (0.20). Further 
investigation into these differences may reveal properties of the constrained transcripts 
and regions. 
 
a) BLOSUM      b) Grantham scores 
  
Figure 5.7. The correlations between missense badness and other metrics of amino 
acid substitution deleteriousness. Missense badness shows a high correlation to both 
BLOSUM (r = -0.6327, a) and Grantham scores (r = 0.5255, b). 
 
Combining variant level deleteriousness scores 
We wanted to determine which variant deleteriousness metric, or combination of 
metrics, was best at differentiating benign from pathogenic missense variants. We 
selected missense variants with a MAF > 1% in ExAC as our benign set (n = 93,238 
variants) and used the ClinVar missense variants found in haploinsufficient genes that 
cause severe disease as our set of pathogenic variants (n = 1,674). The metrics we 
compared were: missense depletion of the region in which the variant was found (%), 
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missense badness, Polyphen25, BLOSUM9, and Grantham scores8. Using logistic 
regressions, we found that the best predictor of missense deleteriousness was the 
missense depletion (%) of the region in which the variant was located (Table 5.5). 
 
Table 5.5. Comparing the ability of various metrics to differentiate between benign and 
pathogenic variants. Logistic regressions were performed to determine which score 
could best separate benign from pathogenic missense variants. Missense variants in 
ExAC with a MAF > 1% were considered benign (n = 93,238). Pathogenic variants were 
those missense variants in ClinVar that were found in haploinsufficient genes that cause 
severe disease (n = 1,674). Lower AIC indicates a better predictor. 
 
Score AIC 
Missense depletion (%) 13967.06 
Polyphen2 14615.62 
Missense badness 15218.00 
Grantham 15233.18 
BLOSUM 15239.38 
 
The metrics can provide complementary information, so we sought to create a 
composite predictor. Given that % was by far the best score, we tested nested models 
and found that both missense badness and Polyphen2 significantly added to the 
composite predictor, but that neither BLOSUM nor Grantham did. Therefore, the best 
model included %, missense badness, and Polyphen2 (Table 5.6), and we take the 
predictions as our final score, known as MPC. 
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Table 5.6. The models tested combining missense depletion (obs_exp), missense 
badness (mis_badndess), and Polyphen2 (polyphen2). Note that when BLOSUM is 
added back, the predictor works less well. 
 
Model AIC 
obs_exp + mis_badness + polyphen2 13286 
obs_exp * mis_badness * polyphen2 13174 
obs_exp + mis_badness + obs_exp:mis_badness + polyphen2 + 
obs_exp:polyphen2 
13172 
obs_exp + mis_badness + obs_exp:mis_badness + polyphen2 + 
obs_exp:polyphen2 + blosum 
13176 
 
 
Using MPC to evaluate the deleteriousness of de novo variants 
We tested the usefulness of MPC by analyzing the de novo variants from cases 
with a neurodevelopmental disorder10-13 and from controls15,16. The number of benign 
variants limits the range of MPC from 0 to 5, with increasing large numbers indicating 
increased deleteriousness. The distribution of MPC for the control de novo variants is 
made primarily of scores below 1 (Figure 5.8a). The MPC distribution for the de novo 
missense variants identified in cases with a neurodevelopmental disorder, on the other 
hand, appears to be made of two distributions: one following the distribution of the 
control de novo variants and the other with a peak at an MPC of 2 (Figure 5.8b), 
reinforcing that these variants are a mix of signal and noise. 
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a) MPC distribution for control de novo missense variants 
 
 
 
b) MPC distribution for de novo missense variants found in cases 
 
 
 
Figure 5.8. The MPC distributions for de novo variants in cases and controls. The MPC 
scores for the 1,254 de novo missense variants identified in control trios (a) and the 
MPC scores for the 1,234 de novo missense variants found in cases with a 
neurodevelopmental disorder (b). 
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Discussion 
We have developed a method to locate regions within genes that are specifically 
intolerant of missense variation. Across all genes, 15% have evidence of regional 
variability in missense constraint, most of which are only split into two regions. We find 
that the genes and regions that have 60% of less of their expected missense variation—
while only representing a small fraction of all coding sequence—contain 85% of 
pathogenic variants14 in haploinsufficient genes known to cause severe disease. These 
genes and regions also contain nearly all of the excess of de novo missense variation 
that is seen in cases with a neurodevelopmental disorder10-13. 
Ideally, constraint would be calculated per base, but even the ExAC dataset is 
not large enough to provide sufficient power to do this. We therefore need to aggregate 
variant counts. While there are many options, we chose to aggregate counts across 
exons. Aggregating across protein domains would potentially be more informative 
functionally, but domain information is unfortunately unavailable for many genes. Since 
exons are natural biological units transferred between transcripts and are available for 
all genes, we believe they are currently the best option. 
Moving forward, it will be important to not only include protein domain information 
but to consider non-linear sequences. Binding pockets are critical aspects of proteins, 
but are made up of amino acids scattered across the gene. Other 3D structural aspects 
of the protein (internal versus external residues, etc.) would also be important to 
consider when evaluating variant deleteriousness. Therefore, future work would greatly 
benefit from being able to evaluate disparate amino acids. 
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Since the missense constrained regions are depleted of variation due to selective 
pressures, we proposed that including information about the local missense depletion 
could improve variant deleteriousness metrics. We first created a measure of the 
increased deleteriousness of amino acid substitutions when they occur in missense 
constrained genes and regions, which outperformed similar amino acid substitution 
matrices (BLOSUM9 and Grantham8) at separating pathogenic14 from benign variants. 
The best predictor of variant deleteriousness, however, was the combination of regional 
missense constraint, the amino acid substitution score we developed (missense 
badness), and Polyphen25. The MPC scores—the joint metric—for the de novo 
missense variants from neurodevelopmental cases10-13 appeared to be a mixture of two 
distributions (benign and pathogenic), which matches what would be expected given the 
modest enrichment of such variants in the cases. 
We predict that MPC will be most informative for those variants that are found in 
regions with intermediate missense depletion (40-60% of expected variation) since this 
set of variants has a lower signal to noise ratio than the variants found in the more 
missense depleted genes and regions. We also hope to test MPC on the de novo 
missense variants from 3,982 cases with an autism spectrum disorder (ASD)15,16. We 
previously found a relationship between the IQ of an ASD case and the rate of de novo 
loss-of-function variants, with lower IQ individuals having a higher rate3,17. We recently 
discovered a similar relationship with IQ for de novo missense variants that were 
predicted to be damaging by Polyphen25 and fell into one of the 1,003 missense 
constrained genes discussed in Chapter 318.  
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As the number of sequenced individuals increases in reference datasets such as 
ExAC, we will be able to further refine our analyses of regional constraint. Additionally, 
the aggregation of whole genome sequencing data from reference populations will allow 
similar analyses of noncoding regions and promises to empirically highlight genetic 
regions intolerant of variation. The knowledge gained from our work and similar studies 
will continue to improve our ability to interpret genetic variation and, therefore, 
understanding of the genetic basis of disease. 
 
!"#$%&"'()"*+)!$#,-+()
Transcript and exon definitions 
In order to have one representative transcript for each gene, we used the 
canonical GENCODE (v19) transcript as defined by Ensembl 75, for protein-coding 
genes. We removed transcripts that lacked a methionine at the start of the coding 
sequence, a stop codon at the end of coding sequence, or were indivisible by three, 
which left 19,621 transcripts. Additionally, 795 transcripts that had zero observed 
variants—when dropping counts in exons with a median depth < 1 (explained below)—
were removed, leaving 18,466 transcripts for analysis. The exon boundaries were 
defined by UCSC’s annotation for GENCODE v19 (downloaded on June 16th, 2014). 
 
Observed variant counts 
We consider intolerance to loss-of-function variation to primarily be a property of 
a gene. We therefore searched for regional constraint to missense variation alone. To 
obtain the observed number of missense variants per exon, we extracted variants from 
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the Exome Aggregation Consortium’s dataset (ExAC; n = 60,706) that met the following 
criteria: 
(1) Defined as a missense change by the predicted amino acid substitution. 
Variants that would be considered “initiator_codon_variants” and “stop_lost” 
by annotation programs such as VEP19 are therefore included in the total. 
(2) Caused by a single nucleotide change. 
(3) Had an adjusted allele count # 123, corresponding to a minor allele frequency 
(MAF) < 0.1%. The adjusted allele count only includes individuals with a 
depth (DP) ! 10 and a genotype quality (GQ) ! 20. 
(4) Had a VQSLOD ! -2.632. 
Due to the VQSLOD threshold, variants were not required to have a PASS in their 
FILTER column. The observed counts represent the unique number of qualifying 
variants and not the aggregate allele count of all qualifying variants within the exon. 
 
Expected variant counts 
Expected missense variant counts were determined as described in Chapter 4. 
Briefly, we used a model of mutation based on sequence context and corrected for 
regional divergence between humans and macaques to define the probability of a 
mutation per exon in all canonical transcripts (as discussed in Chapters 3 and 4)3. We 
used exons with a median depth ! 50 and regressed the number of rare, synonymous 
variants on the probability of a synonymous mutation. Note that regressions were run 
separately for the autosomes with the pseudo-autosomal regions (PAR) of the X 
chromosome, the non-PAR regions of the X chromosome, and the Y chromosome. The 
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expectations produced by these regressions were then corrected for the median depth 
of coverage of the exon using the following equation: 
!"#$!!!"#$%&'"!!"#$% ! ! !"#!$%!&!!"#$%!!"#$%&!!"#$!! ! !"!"#!$%!&!!"#$% ! !!!!"# ! !!!"# ! !" !"#$%&!!"#$! ! ! ! ! "#$%&!!"#$! ! !"!!!!"# ! !"#!$%!&!!"#$%!!"#$%&!!"#$! ! !  
As mentioned above, for exons with a median depth < 1, we set both the observed and 
expected counts to 0. 
 
Likelihood ratio tests to define regional constraint 
Using the observed and expected counts for the 18,466 canonical transcripts, we 
searched for significant breaks between exons that would split the transcript into two or 
more regions with varying levels of missense depletion. We chose to use exons in these 
analyses for three main reasons: (1) the size of ExAC does not allow for base pair 
resolution so we must aggregate variant counts; (2) exons are a natural biological unit 
which are transferred between transcripts; (3) protein domain information, while ideal, is 
missing for many genes and we wanted an approach that would be applicable to all 
genes. 
We assume that observed counts should follow a Poisson distribution around the 
expected number. We defined the null model—no regional variability in missense 
depletion—as the model where the overall fraction of expected missense variation 
observed (!) for the transcript is used as the expectation for all segments. We then 
employed a likelihood ratio test to compare the null model with an alternative model 
where expectation was ! for each specific segment. Given that the alternative model 
should always have a better fit than the null, we require a $2 above a given threshold to 
establish significance. 
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We used the following general formula to determine the significance of a break 
that would split a transcript into segments A and B: !! ! !"#$ !"#!! !"#! ! ! ! !"#$!!"#! ! !"#! ! !! !! ! !"#$ !"#!! !"#! ! !! ! !"#$!!"#! ! !"#! ! !!! !! ! !!!"#!!!!! !"#!!!!!! 
Where ! is the fraction of expected variation observed across all segments in the 
transcript; !"#! is the observed number of missense variants in segment A; !"#! is the 
expected number of variants in segment A; !! is the fraction of expected variation 
observed only for segment A; !"#! is the observed number of missense variants in 
segment B; !"#! is the expected number of variants in segment B; !! is the fraction of 
expected variation observed only for segment B; and !"#$ denotes the Poisson 
likelihood. 
For the purposes of this method, all exons or sections with more observed 
variants than expected were assigned ! ! ! since we were looking for variation in 
missense depletion. In addition, exons or sections with zero observed variants were 
considered to have one variant to prevent ! ! !. 
We first searched for a single break in between exons that would significantly ($2 
! 10.8, p < ~10-3) better model the transcript’s data than the null model. If multiple 
significant breaks between exons were found, we took the best break as defined by the 
$2 value. If a significant break was found, we searched for a second break. This process 
was repeated until the best break between exons did not significantly improve on the 
model ($2 < 10.8). If a transcript had no significant single break, we searched for two 
breaks at a time, requiring a $2 ! 13.8 (p < ~10-4) to indicate significance. Those 
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transcripts with $2 < 13.8 were considered to show no evidence of regional variability in 
missense depletion, and were left intact. The general process is depicted in Figure 5.1. 
 
Excess of missense depleted coding sequence 
For all coding segments (both full transcripts and the regions of transcripts), we 
plotted the fraction of expected variation observed (%; Figure 5.2). There is a peak at 
one, indicating that most transcripts and regions have the expected amount of missense 
variation. We expect that natural stochasticity in counts will lead to a distribution of % 
around 1. Even given this, we see an excess of transcripts and regions that are 
depleted of missense variation. To aid in visualization, we took the distribution of 
transcripts and regions above one and mirrored it (displayed as a dashed line). The 
excess of transcripts and regions with low % over the mirrored distribution occurs when % 
< 0.8, particularly below 0.6. We therefore took 0.8 as an arbitrary cut-off between 
regions that are likely missense constrained (% # 0.8) and those that have no evidence 
of missense constraint (% > 0.8). Within the missense constrained regions and 
transcripts, we further subdivided into four quartiles: [0-0.2], (0.2-0.4], (0.4-0.6], and 
(0.6-0.8]. 
 
ClinVar pathogenic variants 
To test if the genes and regions we identified as missense constrained were 
enriched for established disease-associated variants, we extracted variants from the 
July 9, 2015 release of ClinVar14 that were labeled as “pathogenic” and “likely 
pathogenic”. We specifically focus on those missense variants that fell into a set of 44 
haploinsufficient genes that cause severe disease (n = 440 variants). The 
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haploinsufficient genes were those with sufficient evidence for dosage pathogenicity 
(level 3) as determined by the ClinGen Dosage Sensitivity Map 
(www.ncbi.nlm.nih.gov/projects/dbvar/clingen/; downloaded on May 5, 2015); the 
severity of disease caused by variants in the genes was manually curated. 
 
De novo variants from cases with a neurodevelopmental 
Over the last five years, there have been a large number of exome sequencing 
studies, particularly of neurodevelopmental disorders. We collected the de novo variants 
found in 151 trios with intellectual disability10,11, 1,133 with developmental delay12, and 
356 with an epileptic encephalopathy13. In these studies, there is a large excess of de 
novo loss-of-function variants (> 2 fold enriched; Table 5.3) but also a significant, but 
more modest, excess of de novo missense variants (1.1-1.3 fold enriched). The modest 
enrichment indicates that there is a set of variants contributing to disease (signal), but 
many neutral variants (noise). De novo variants from the unaffected siblings of autism 
cases were used as controls (n = 2,078)15,16. 
 
Confidence intervals around the ratio of case:control de novo variant rates 
 We compared the rate of de novo missense variants in cases compared to the 
rate in controls for the five constraint bins. To determine confidence intervals around the 
point estimates of the ratio of de novo variant rates, we took the natural logarithm of the 
point estimate 
! ! ! !! !!!! !!!!!! 
and found the standard error 
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!" !"#!! ! ! !!! ! !!! !!!! ! !!! ! !!! !!!!  
using the delta method. The upper and lower bounds are then transformed back to 
obtain the 95% confidence interval ! !"# !!!!"!" !"# ! !!!! 
where !! is the number of case de novo variants; !! is the number of case trios; !! is 
the number of control de novo variants; and !!is the number of control trios. 
 
Creation of missense badness 
We created a metric (missense badness) of the increased deleteriousness of 
specific amino acid substitutions when they occur in constrained regions to identify 
those substitutions that are preferentially eliminated when they occur in missense 
depleted sequence. We identified all possible amino acid-to-amino acid substitutions 
that could occur via a single nucleotide mutation and then tallied the number of these 
substitutions in ExAC with a MAF < 0.1%. The observed and possible were then split by 
whether they occurred in a gene or regions with % # 0.8 (constrained) or % > 0.8 
(unconstrained) and we determined the rate of possible substitutions observed for both 
groups. While we observed a higher rate of possible substitutions observed in the 
unconstrained regions, we noticed that synonymous changes in isoleucine and those in 
phenylalanine did not follow this pattern. 
We used the median fold difference of all synonymous substitutions as a floor 
(set to 0) and the median of all nonsense substitutions as a ceiling (set to 1) and 
normalized the missense fold differences to create missense badness. We find a high 
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correlation between missense badness and other amino acid substitution matrices (r = -
0.6327 for BLOSUM and 0.5255 for Grantham scores (Figure 5.7). 
 
Creation of MPC, a composite missense deleteriousness score 
We used logistic regressions to determine which of five deleteriousness metrics 
was best at separating benign from pathogenic missense variants. The metrics we 
compared were the missense depletion of the region in which the variant was found (%), 
missense badness, Polyphen25, BLOSUM9, and Grantham scores8. Our benign variants 
were missense variants with a MAF > 1% in ExAC (n = 93,238 variants). The 
pathogenic variants were ClinVar14 missense variants found in haploinsufficient genes 
that cause severe disease (n = 1,674). The best single predictor of missense 
deleteriousness was the missense depletion (%) of the region in which the variant was 
located (Table 5.5). 
As the metrics provide complementary information, we used nested models to 
determine the best composite score starting with missense depletion (%). Missense 
badness and Polyphen2 significantly added to the composite predictor, but BLOSUM 
and Grantham did not. We therefore tested the combination of the three significant 
metrics and all possible interactions between them. The best model included all three 
scores and the interaction between % and missense badness as well as the interaction 
between % and Polyphen2 (Table 5.6). 
We used the best regression to predict scores for all benign and pathogenic 
variants. In order to make more easily interpretable numbers, we transformed the raw 
score (RS) 
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!!"#!" !!"#$%# ! !!"!!"#$%# !!!! 
where !!"#$%# is the number of benign variants with a raw score less than RS and !!"#$%# is the total number of benign variants. We refer to the final composite score as 
MPC. Since there are ~91k benign variants that had information for all three metrics, the 
highest MPC is ~5. 
MPC contains three mostly orthogonal pieces of information for each missense 
variant: the missense depletion (%) of the region in which the variant is found; the 
deleteriousness of the specific amino acid substitution; and the Polyphen2 score, which 
incorporates multiple lines of evidence (phylogenetic, structural, etc.) to determine 
deleteriousness of the variant. 
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Chapter 6 
Discussion 
 
  
!! 169 
The main goal of this thesis was to develop methods and tools to better 
understand rare protein-coding variation, especially within the context of interpreting 
such variation in disease. To that aim, we built a pipeline to robustly identify de novo 
variants from sequencing data; created a sequence-context based model of mutation; 
identified genes that were intolerant of missense and loss-of-function variation; and 
found regions of missense intolerance within genes. 
 
Summary of results 
Identifying de novo variation 
In the study of de novo variation, it is especially important to be confident in the 
genotype calls of all members of the parent-child trio. As described in Chapter 2, we 
determined a set of key parameters to consider when identifying de novo variation: (1) 
the genotype likelihoods provided by the genotyping software, (2) the relative number of 
reference and non-reference sequencing reads, and (3) the depth of sequencing 
coverage. The second parameter was particularly critical as we found that the most 
likely explanation for a falsely called “de novo” variant was missing a heterozygous 
genotype in one of the parents. 
As an additional improvement to our de novo identification pipeline, we used the 
allele frequency in a reference population of a potential de novo variant to compare the 
probability that the variant was truly de novo versus the probability of missing a 
heterozygous genotype in one of the parents. The probability of being a true de novo 
variant, in combination with the aforementioned parameters, was used to separate 
variants into three categories in terms of the likelihood of validating as de novo. We 
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found that the class with the strongest evidence of being de novo had a high rate of 
molecular validation (97.3% for single nucleotide changes and 92.3% for indels1; Table 
2.3). Our final workflow is a sensitive and specific method to identify de novo variation 
from sequencing data of trios. 
 
Creating a mutational model 
We created a sequence-context based mutational model in order to rigorously 
evaluate the observed burden of de novo variants within cases with an autism spectrum 
disorder (ASD; Chapter 3). We first created a mutation rate table using intergenic single 
nucleotide polymorphisms (SNPs) from the 1000 Genomes Project2 and applied it to the 
coding region of the genome to create a per gene probability of mutation, which we split 
by mutational class. The raw probabilities of mutation were corrected for only two 
factors: the depth of coverage at the site and the regional divergence between humans 
and macaques. The final probabilities of mutation formed the basis of a statistical 
framework to evaluate de novo variant burden globally, for sets of genes, and on a per-
gene basis. 
 We also used the mutational model to predict the expected number of rare (minor 
allele frequency (MAF) < 0.1%) variants in the National Heart, Lung and Blood 
Institute’s Exome Sequencing Project (ESP; n = 6,503)3. The high correlation between 
the observed and expected number of rare synonymous variants per gene (r = 0.940) 
supported that predictions of both missense and loss-of-function variants would also be 
accurate. We created a signed Z score to evaluate any deviation of observed from 
expected counts. While we were underpowered to analyze loss-of-function variation, we 
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found 1,003 genes that were significantly depleted of the expected amount of missense 
variation (missense Z score > 3.09). Given that the model is selection neutral, these 
deficits are consistent with evolutionary constraint. These constrained genes were 
enriched for established dominant and haploinsufficient disease genes. 
We then used the statistical framework to analyze the de novo variants identified 
in 1,078 trios where the child had an autism spectrum disorder (ASD)4-8. We found both 
a global excess of de novo loss-of-function variants (1.57 fold enriched; p = 2.1x10-7; 
Table 3.1a) and far more transcripts harboring loss-of-function variants than expected 
(p < 0.001). An important aspect of our model was to determine the significance of 
burden within single genes: in this dataset, we found two genes (DYRK1A and SCN2A) 
had more de novo loss-of-function variants than expected at a significance threshold of 
10-6 (Table 3.2). The targets of FMRP9 and the missense constrained genes defined 
above were two gene sets that were significantly enriched for de novo loss-of-function 
variation in ASD cases (>2 fold; p < 10-4 for both). By contrast, the de novo variants 
from 343 unaffected siblings had no significant enrichments in any category. 
All analyses were repeated using the de novo variants found in 151 trios with 
intellectual disability10,11. The global enrichment of de novo loss-of-function variants was 
greater for intellectual disability (0.24 de novo loss-of-function events per exome; p = 
6.5x10-7; Table 3.4a) and, even though there were fewer cases, there were three genes 
with a significant burden of de novo loss-of-function and missense variants (Table 
3.4c). Given these results, we separated the ASD samples with IQ ! 100 from the rest 
of the cases. All of the significant signals in ASD—global enrichment of de novo loss-of-
function variants, excess of genes with multiple such variants, and the enrichment of 
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such variants in the targets of FMRP and constrained genes—were not observed for the 
ASD cases with IQ ! 100, indicating that the genetic architecture of ASD varies between 
low and high IQ cases. 
Finally, we found that the distributions of missense Z scores of genes harboring a 
de novo loss-of-function variant in ASD or intellectual disability cases were significantly 
shifted towards higher constraint (Wilcoxon p < 10-6 for both; Figure 3.3). The 
distribution for genes with a de novo loss-of-function variant in an unaffected individual 
was no different from the overall distribution of missense Z scores. Together, these 
results indicated a significant role of de novo loss-of-function variation in ASD etiology, 
and that the constrained genes we identified were medically relevant. 
 
Identifying genes intolerant of loss-of-function variation 
The Exome Aggregation Consortium (ExAC) dataset, which contains protein-
coding variation for 60,706 reference individuals, provided us the opportunity to 
investigate loss-of-function constraint (Chapter 4) and intolerance to missense variation 
within transcripts (Chapter 5). To identify constrained genes using the ExAC dataset, we 
slightly modified the mutational model to incorporate an empirically defined, and ExAC-
specific, depth of coverage adjustment. While the Z score was well powered for 
studying missense constraint, the loss-of-function Z score was highly correlated with the 
number of coding bases in a transcript (r = 0.5697; Figure 4.10a). We therefore created 
pLI—the probability of being loss-of-function intolerant—which identified 3,230 genes 
that are extremely depleted of loss-of-function variation (pLI ! 0.9). Established 
haploinsufficient disease genes are enriched in the high pLI tail, as are dominant 
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disease genes12,13, and genes found to be essential in cell culture14 ($2 p < 10-50, 10-30, 
and 10-23, respectively; Figure 4.3). 
The most loss-of-function intolerant genes compromise core biological 
processes, such as members of the spliceosome and proteasome complexes. The 
missense Z score and pLI also show a relationship with the number of protein-protein 
interaction partners associated with the gene: those genes with many protein-protein 
interaction partners are more likely to be constrained (t-test p < 10-8 for missense Z and 
p < 10-41 for pLI). Additionally, we found that the most highly constrained missense and 
loss-of-function genes are expressed at higher levels and in more tissues, are depleted 
of eQTLs15, and are enriched for GWAS loci16. 
 
Searching for patterns of missense constraint within genes 
The size of the ExAC dataset also allowed us to investigate patterns of regional 
missense constraint within genes given the large expected number of missense variants 
per genes (average 170; median 127). We used the observed and expected missense 
variant counts per exon and applied a nested likelihood ratio test to identify significant 
breaks in between exons that split the gene into regions with varying levels of missense 
depletion. Overall, 2,738 genes (14.8%) had evidence of regional missense constraint 
with the majority of these being split into only two regions (Table 5.1). 
Across all genes and regions of genes, those with 60% of less of their expected 
missense variation contained the majority (85%) of the ClinVar17 pathogenic variants in 
severe haploinsufficient disease genes. These regions were also enriched for de novo 
missense variants in cases with a neurodevelopmental disorder10,11,18,19, but not for de 
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novo variants found in control individuals1,20 (Figure 5.4). The importance of these 
regions was further supported by the fact that the rate of de novo missense variants in 
cases with a neurodevelopmental is significantly higher than the rate seen in controls 
(2-4 fold enriched; Figure 5.5). Overall, we find 0.22 de novo missense variants per 
case exome and 0.07 per control exome in these missense-depleted regions. By 
contrast, all other regions show no difference in the number of events per exome (0.51 
for cases compared to 0.50 in controls). 
We used the total number of observed and possible amino acid substitutions in 
constrained and unconstrained regions to create missense badness, a measure of the 
increased deleteriousness of specific amino acid substitutions when they occur in the 
constrained regions of the exome. Missense badness is correlated with both BLOSUM21 
and Grantham22 scores (r = -0.6327 and 0.5255, respectively; Figure 5.7) and was able 
to separate pathogenic variants from ClinVar17 from benign variants (MAF > 1% in 
ExAC) better than the two other metrics. 
The most accurate single predictor of whether a variant was pathogenic or 
benign, however, was the missense depletion of the region. Given that missense 
badness and missense depletion are capturing orthogonal pieces of information, we 
chose to find the best combination of a number of scores. The best joint metric included 
missense depletion, Polyphen2 score23, and missense badness. MPC worked better 
than all other single metrics or combinations at separating pathogenic and benign 
missense variants. 
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Improvements and future directions 
Better processing of challenging variants 
Our de novo variant identification workflow has proven to be both sensitive and 
specific, but it currently does not process sites with more than three alleles (one 
reference and two non-reference). As more individuals are sequenced and included in 
the same datasets, the number of multi-allelic sites will increase and therefore the script 
should be updated. We are also limited by the quality of variants provided by the 
genotyping software. In particular, variant calls on the Y chromosome as well as indels 
could be much improved. Therefore, our de novo results are less reliable for both 
chromosome Y variants and indels. 
 
Accounting for indels and methylation status of CpG sites 
Our inability to reliably identify indels in sequencing data has also limited the 
field’s ability to model indel mutation rates. A major limitation of the mutational model 
used throughout this thesis is that it lacks the ability to predict the expected number of 
indels—specifically frameshift variants—per gene. In order to study frameshift variants 
in our de novo data, we estimated the rate based on the rate of nonsense variants. 
While this estimate was useful for the de novo variant studies, we knew it was not 
accurate enough to predict the expected number of frameshift variants in reference 
populations such as ExAC, and thus we had to exclude all frameshift variants from our 
calculations of loss-of-function constraint. 
While our mutational model accurately predicts the number of rare synonymous 
variants per transcript in ExAC (r = 0.9776), we are also aware that there are other 
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improvements that could be made to the mutational model itself. Two other factors that 
could influence mutation rate that we did not incorporate into the mutational model are 
the methylation status of CpG sites in the male germline and the effects of transcription-
coupled repair (TCR). Cytosines in CpG dinucleotides are sometimes methylated and 
can then deaminate, leading to a C>T (G>A) transition. Transitions at methylated CpGs 
occur at a much higher rate than all other mutations, including transitions at 
unmethylated CpGs. Our model of mutation could therefore be improved by splitting 
CpGs by their methylation status in the male germline (where de novo variants are most 
likely to arise) and using separate mutation rates for the two types. 
Another potential improvement to the model would be accounting for TCR, which 
is a DNA damage repair mechanism that corrects mutations on the template strand of 
transcribed genes via nucleotide excision. A signature of TCR is strand asymmetry for 
mutations, which is especially prominent when studying transitions that result from CpG 
methylation and then deamination24. Our early investigations into TCR indicated that it 
did not have a large influence on the predictions of our model, but strand asymmetry 
has been seen in de novo variants from whole genome sequencing25, indicating that it 
may be important to revisit. 
 
Probabilities of mutation for further split by mutational class 
It would be useful to have the probabilities of mutation per gene split by more 
than simply mutation type. As an example, we could split the probability of a missense 
mutation by the three Polyphen223 categories (benign, possibly damaging, and probably 
damaging). We would specifically like to have the breakdown of high confidence versus 
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low confidence loss-of-function variants, as defined by LOFTEE 
(http://www.github.com/konradjk/loftee). This work is currently underway and will 
hopefully be released with the second release of the ExAC dataset. 
 
Incorporating allele frequency information for loss-of-function constraint 
The next wave of the ExAC dataset is predicted to have nearly 100,000 
individuals as part of the reference population (D.G. MacArthur, personal 
communication) and would provide greatly increased power to detect constrained 
genes. For pLI, there are 4,621 (25%) transcripts that have a pLI between 0.1 and 0.9 
that we consider to be uninterpretable due to their low expected loss-of-function counts 
(mean of 11.47; median of 8.25). Incorporating information from LOFTEE and removing 
low confidence variants, such as those that occur in the last 5% of a transcript, would 
also improve our loss-of-function constraint analyses. Additionally, a few of our high pLI 
genes have common (MAF > 0.1%) loss-of-function variants. A future improvement to 
the method may also include the combined allele frequency of all loss-of-function 
variants in the transcript. The largest drawback of this potential addition would be 
adding in common variants that appear to be loss-of-function, but do not have the 
predicted effect on the protein. This issue may be mitigated, in part, by only using high 
confidence LOFTEE variants. 
 
Moving regional constraint beyond exon boundaries 
We have many more analyses planned for the regional missense constraint 
work. We know that our method to search for regional constraint is limited by exon 
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boundaries. As depicted in Figure 5.3, 39 of the 43 pathogenic missense variants from 
ClinVar17 in CDKL5 are found in exons 1-9, which we considered constrained. While 
one of the remaining variants falls in the middle of the unconstrained exons (10-20), 
there are three pathogenic variants that lie within 50 base pairs of the beginning of exon 
10, which is part of the unconstrained region in CDKL5, and are all within the kinase 
domain that extends 66 base pairs into that exon. We will be updating our method to 
detect regional constraint so that, once it finds a significant break in between two exons, 
we search amino acid by amino acid in the two nearby exons to find the best way to 
split the gene. 
We are also working on a way to search for constraint of non-linear sequences. 
The current sample size of ExAC does not permit the evaluation of constraint on single 
bases and would require many to be combined to achieve the necessary power. 
However, the non-linear approach would allow us to interrogate constraint of 3D 
structural features of the protein, such as the amino acids in binding pockets. 
 
Continued testing of MPC 
Finally, our score of missense deleteriousness, MPC, that accounts for regional 
missense depletion, Polyphen223, and missense badness still needs to be tested 
against other variant prioritization tools, such as CADD26. We would also like to test how 
well it separates pathogenic from benign variants specifically in regions that have 40-
60% of their expected missense variation. This is an interesting set of coding 
sequences to investigate since it contains a lower signal to noise ratio than sequence 
with < 40% of its expected missense variation. 
!! 179 
Final thoughts 
Throughout this thesis, we have sought to understand the rate and distribution of 
rare protein-coding variants. Our sequence-context based mutational model proved 
useful both to analyze the burden of de novo variation in trio sequencing studies and to 
identify genes and regions within genes that are intolerant of nonsynonymous variation. 
Overall, we have established methods to prioritize medically relevant variation with the 
goal of separating it from the vast amounts of relatively neutral variants also identified in 
sequencing studies. 
The tools and metrics we created have become widely adopted within the field. 
The de novo identification pipeline and framework to rigorously evaluate de novo 
variation have been used in studies of schizophrenia, congenital heart disease27, and in 
the children of testicular cancer survivors28, among others. Beyond de novo studies, the 
probabilities of mutation we generated are being used outside of the context of de novo 
variation29,30 and the missense Z scores created from the ESP dataset are being 
applied as a metric of genic intolerance to variation31-33. Finally, the constraint and pLI 
scores are available on the ExAC web browser (http://www.exac.broadinstitute.org) and 
for free download in order to aid the community in variant prioritization. 
  
!! 180 
Bibliography 
1. De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in 
autism. Nature 515, 209-15 (2014). 
2. Genomes Project, C. et al. A global reference for human genetic variation. 
Nature 526, 68-74 (2015). 
3. Fu, W. et al. Analysis of 6,515 exomes reveals the recent origin of most human 
protein-coding variants. Nature 493, 216-20 (2013). 
4. Iossifov, I. et al. De Novo Gene Disruptions in Children on the Autistic Spectrum. 
Neuron 74, 285-299 (2012). 
5. Neale, B.M. et al. Patterns and rates of exonic de novo mutations in autism 
spectrum disorders. Nature 485, 242-245 (2012). 
6. O'Roak, B.J. et al. Exome sequencing in sporadic autism spectrum disorders 
identifies severe de novo mutations. Nature genetics 43, 585-9 (2011). 
7. O'Roak, B.J. et al. Sporadic autism exomes reveal a highly interconnected 
protein network of de novo mutations. Nature 485, 246-250 (2012). 
8. Sanders, S.J. et al. De novo mutations revealed by whole-exome sequencing are 
strongly associated with autism. Nature 485, 237-241 (2012). 
9. Darnell, J.C. et al. FMRP Stalls Ribosomal Translocation on mRNAs Linked to 
Synaptic Function and Autism. Cell 146, 247-261 (2011). 
10. de Ligt, J. et al. Diagnostic Exome Sequencing in Persons with Severe 
Intellectual Disability. New England Journal of Medicine 367, 1921-1929 (2012). 
11. Rauch, A. et al. Range of genetic mutations associated with severe non-
syndromic sporadic intellectual disability: an exome sequencing study. The 
Lancet 380, 1674-1682 (2012). 
12. Berg, J.S. et al. An informatics approach to analyzing the incidentalome. Genet 
Med 15, 36-44 (2013). 
13. Blekhman, R. et al. Natural selection on genes that underlie human disease 
susceptibility. Curr Biol 18, 883-9 (2008). 
14. Hart, T., Brown, K.R., Sircoulomb, F., Rottapel, R. & Moffat, J. Measuring error 
rates in genomic perturbation screens: gold standards for human functional 
genomics. Mol Syst Biol 10, 733 (2014). 
!! 181 
15. Consortium, G.T. Human genomics. The Genotype-Tissue Expression (GTEx) 
pilot analysis: multitissue gene regulation in humans. Science 348, 648-60 
(2015). 
16. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic Acids Res 42, D1001-6 (2014). 
17. Landrum, M.J. et al. ClinVar: public archive of relationships among sequence 
variation and human phenotype. Nucleic Acids Res 42, D980-5 (2014). 
18. Deciphering Developmental Disorders, S. Large-scale discovery of novel genetic 
causes of developmental disorders. Nature 519, 223-8 (2015). 
19. Epi, K.C. & Epilepsy Phenome/Genome, P. De novo mutations in epileptic 
encephalopathies. Nature 501, 217-221 (2013). 
20. Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum 
disorder. Nature 515, 216-21 (2014). 
21. Henikoff, S. & Henikoff, J.G. Amino acid substitution matrices from protein 
blocks. Proc Natl Acad Sci U S A 89, 10915-9 (1992). 
22. Grantham, R. Amino acid difference formula to help explain protein evolution. 
Science 185, 862-4 (1974). 
23. Adzhubei, I.A. et al. A method and server for predicting damaging missense 
mutations. Nature methods 7, 248-9 (2010). 
24. Green, P. et al. Transcription-associated mutational asymmetry in mammalian 
evolution. Nat Genet 33, 514-7 (2003). 
25. Francioli, L.C. et al. Genome-wide patterns and properties of de novo mutations 
in humans. Nat Genet 47, 822-6 (2015). 
26. Kircher, M. et al. A general framework for estimating the relative pathogenicity of 
human genetic variants. Nat Genet 46, 310-5 (2014). 
27. Homsy, J. et al. De novo mutations in congenital heart disease with 
neurodevelopmental and other congenital anomalies. Science 350, 1262-6 
(2015). 
28. Kryukov, G.V. et al. Genetic Effect of Chemotherapy Exposure in Children of 
Testicular Cancer Survivors. Clin Cancer Res (2015). 
29. Loveday, C. et al. Mutations in the PP2A regulatory subunit B family genes 
PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth. Hum Mol Genet 
24, 4775-9 (2015). 
!! 182 
30. Hinshaw, S.M., Makrantoni, V., Kerr, A., Marston, A.L. & Harrison, S.C. Structural 
evidence for Scc4-dependent localization of cohesin loading. Elife 4, e06057 
(2015). 
31. Coutelier, M. et al. A Recurrent Mutation in CACNA1G Alters Cav3.1 T-Type 
Calcium-Channel Conduction and Causes Autosomal-Dominant Cerebellar 
Ataxia. Am J Hum Genet 97, 726-37 (2015). 
32. Kumar, R. et al. THOC2 Mutations Implicate mRNA-Export Pathway in X-Linked 
Intellectual Disability. Am J Hum Genet 97, 302-10 (2015). 
33. O'Rawe, J.A. et al. TAF1 Variants Are Associated with Dysmorphic Features, 
Intellectual Disability, and Neurological Manifestations. Am J Hum Genet 97, 
922-32 (2015). 
 
Appendix 
!! 184 
Explanation of the appendix 
Given that work presented in Chapters 2 and 3 have already been published, I 
have included the final versions of the main articles in this appendix. Their respective 
supplements can be found online. 
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